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ABSTRACT
RNA-SEQUENCING APPLICATIONS: GENE EXPRESSION QUANTIFICATION AND
METHYLATOR PHENOTYPE IDENTIFICATION
Publication No.________
Guoshuai Cai, M.S.
Supervisory Professor: Shoudan Liang, Ph.D.

My dissertation focuses on two aspects of RNA sequencing technology. The first is the
methodology for modeling the overdispersion inherent in RNA-seq data for differential expression
analysis. This aspect is addressed in three sections: (1) Investigation of the relationship between
overdispersion and sequencing depth on the gene level and modeling for differential expression
analysis. (2) Investigation of the relationship between overdispersion and sequencing depth on the
position level and modeling for differential expression analysis. (3) Investigation of the hidden bias
on the measurement of spike-in transcripts and modeling to correct this bias. The second aspect of
sequencing technology is the application of RNA-seq data to identify the CpG island methylator
phenotype (CIMP) by integrating datasets of mRNA expression level and DNA methylation status.
Section 1: The cost of DNA sequencing has reduced dramatically in the past decade.
Consequently, genomic research increasingly depends on sequencing technology. To measure gene
expression, RNA-seq, sequencing mRNA-converted cDNA, is becoming a widely used method. As
it remains elusive how the sequencing capacity influences the accuracy of mRNA expression
measurement, an investigation of that relationship is required. First, we empirically calculate the
accuracy of the RNA-seq measurement from repeated experiments and identify the source of error to
be mainly library preparation procedures. Second, we observe that accuracy improves along with the
increasing sequencing depth. However, compared with the accuracy predicted from the binomial
distribution, the rate of improvement as a function of sequence reads is globally slower, which
indicates that overdispersion exists and is related to sequencing depth. To model the overdispersion,
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we therefore use the beta-binomial distribution with a new parameter indicating the dependency
between overdispersion and sequencing depth. Our modified beta-binomial model performs better
than the binomial or the pure beta-binomial model with a lower false discovery rate.
Section 2: Although a number of methods have been proposed to handle these biases and
spurious effects in order to accurately analyze differential RNA expression on the gene level,
modeling on the base pair level is required to precisely estimate the mean and variance by taking the
non-uniformity of RNA-seq into account. We show in Chapter 1 that the overdispersion rate
decreases as the sequencing depth increases on the gene level. Here, we find that the overdispersion
rate decreases as the sequencing depth increases on the base pair level, in agreement with what we
previously reported for the gene level. Investigating the impact of the sequencing depth and local
primer sequence on the overdispersion rate, we observe that the local primer sequence no longer
significantly influences the overdispersion rate after stratification by the sequencing depth. Also, we
propose four models and compare them with each other and with the DESeq model based on the
likelihood value, Akaike information criterion, goodness-of-fit

test, false discovery rate and the

area under the curve. As expected, our beta binomial model with a dynamic overdispersion rate is
shown to be superior. Furthermore, this model has many advantages that make it more desirable than
DESeq.
Section 3: We investigate biases in RNA-seq by exploring the measurement of the external
control, spike-in RNA. This study is based on two datasets with spike-in controls obtained from a
recent study. In the ENCODE dataset, 51 replicates of human samples were measured, and in the
modENCODE dataset, 6 fly samples from difference scenarios were sequenced. By comparing the
patterns of the reads and correlations among samples, we observe an undiscovered bias in the
measurement of the spike-in transcripts that arises from the influence of the sample transcripts in
RNA-seq. Also, we find that this influence is related to the local sequence of the random hexamer
that is used in priming. We suggest a model of the inequality between samples and to correct this
type of bias. After corrections, the Pearson correlation coefficient increases by 0.1.
vi

Section 4: The expression of a gene can be turned off when its promoter is highly methylated.
Several studies have reported that a clear threshold effect exists in gene silencing that is mediated by
DNA methylation. As the transcriptional regulatory system is complicated and has many
components, it is reasonable to assume the thresholds are specific for each gene. It is also intriguing
to investigate genes that are largely controlled by DNA methylation, as their methylation possibly
plays an important role in cancer oncogenesis by significantly inhibiting transcription. These genes
are called “L-shaped” genes because they form an “L” shape when plotting mRNA expression level
against DNA methylation status. We develop a method to determine the DNA methylation threshold
using 997 samples across 7 cancer types from TCGA datasets. Then, from 285 tumor samples and 21
normal samples of breast tissue, we select 128 “L-shaped” genes according to our criteria and
identify the CIMP using biclustering and hierarchical clustering. We identify a new CIMP of BRCA
with 11 markers and observe significant correlation between the CIMP+ subtype and the wild-type
TP53 mutation, ER+/PR+ status, higher age at initial pathologic diagnosis, better treatment response
and the possibility of a longer survival time. The 11 CIMP markers are shown to be associated with
TP53 directly or indirectly, and enriched in cancer and other disease networks. Also, we find that 7
epigenetic genes are strongly correlated with both the new CIMP and TP53 mutation. Based on our
findings, we propose a model of the TP53-mediated regulatory network with two components:
“guidance” genes and “ustainer” genes.
In conclusion, we provide a detailed understanding of the relationship between the
overdispersion rate and sequencing depth, which will aid in the analysis of RNA-seq data for
detecting and exploring biological problems. Additionally, we demonstrate a novel property of
overdispersion in that it improves with sequencing depth. We propose a beta-binomial model with
dynamic overdispersion on the position level. We demonstrate that our model provides a better fit for
the data. We reveal a new bias in RNA-seq and provide a detailed understanding of the relationship
between this new bias and the local sequence, which will aid in understanding RNA-seq technology
and in correcting for this bias in the analysis of RNA-seq data. We develop a powerful method to
vii

dichotomize methylation status and consequently we identify a new CIMP of breast cancer with a
distinct classification of molecular characteristics and clinical features. Our results suggest that
methylation may play an important role in resisting tumor development and that “guidance” genes
and genetic modifiers BMI1, IDH1 and TET1 are potential new therapeutic targets.
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CHAPTER 1
Introduction

1.1 Biases and Spurious Effects in RNA-seq Technology
RNA-seq is becoming a common technique for surveying RNA expression. Because the cost of
next-generation sequencing is dropping dramatically, RNA-seq may soon replace microarray
analysis in genome-wide surveys of gene expression [1]. Because of the complexity of RNA-seq
technology, many inherent biases and unwanted effects exist that make it difficult to develop
accurate methods for analyzing RNA-seq data. The various biases and effects that have been
identified include a base calling bias, GC content bias, hexamer priming bias, length bias, library
effect, and batch effect [2,3,4,5,6,7,8].
Base calling has been reported to be biased. The errors in base calling have been found to
increase from the start to the end of the reads. It is known that we can compensate for this error rate
by increasing the sequencing depth. Dohm et al. showed that the error rate will shrink to close to 0
when the sequencing depth reaches 20X [9]. Bravo and Irizarry demonstrated that the error rate
varies for different nucleotide compositions [7].
The GC content bias arises from the generation of a greater number of reads in regions that are
enriched in G-C bases. Thus, sequencing reads have been reported to be differently distributed,
over-representing genes with more GC-enriched regions [7,9]. Also hexamer priming introduces bias
according to its local sequence by PCR amplification. Li et al. showed non-uniformity in RNA-seq
data [4], demonstrating that the number of sequencing reads per nucleotide can vary by 100-fold
across the same gene. However, the patterns of reads are highly conserved across tissues. Local
sequencing bias has been reported to be a major source of bias in the hybridization step for both
microarray and sequencing technologies [3,4,10,11]. On microarrays, probe signals depend on the
probe sequence. Li et.al investigated this influence and developed a model of binding interactions
that improves the measurement of gene expression. Furthermore, probes may cross-hybridize to off1

target transcripts that have sequences similar to those of the target transcripts. Many studies have
been reported on detecting and modeling cross-hybridization events [10,12,13]. The use of a random
hexamer primer has been shown to cause bias because of the specific hybridization affinity of its
sequence. Both Hansen et al. and Li et al. confirmed that random hexamer priming causes biases in
the nucleotide composition at the beginning of the transcriptome sequencing reads [3,4].
Length bias occurs in differential expression analysis of RNA-seq data. For genes with similar
expressions, the total sequencing reads on them would correlate with their length such that more
reads are observed on longer genes, and more power would be obtained in statistical testing in the
differential expression analysis. Oshlack et al. validated that more differential expressions were
detected on longer genes using several widely used statistical methods [14].
Furthermore, the sequencing measurement has been found to be influenced systematically by
external factors such as the time when the measurement is made, the specific technician performing
the measurements, and the specific library preparation procedure. Leek et.al showed a distinct
pattern produced by the batch effect on DNA sequencing measurements from the 1000 Genome
project [15]. Because of the extra noise introduced by biases or spurious effects, measurements on
the same gene often show a level of dispersion that is larger than that given by a Poisson distribution.
A comparison of different samples often shows a dispersion that is larger than that given by a
binomial distribution. This phenomenon has been termed overdispersion [4].

1.2 Current Methods to Correct Biases and Spurious Effects
These biases and spurious effects have been investigated in several studies and researchers have
suggested methods to control or correct them. Several methods have been developed to reduce the
error rate of base calling and control the quality of the reads. The use of spike-in transcripts has been
suggested as a means of providing quality control and as a standard for normalization. In addition,
many statistical methods have been developed to correct for the biases and undesirable effects and to
take them into account in the downstream analysis.
2

1.2.1 Reads Quality Control
Because higher error rates have been found at the end of sequencing reads, some studies have
suggested cutting several base pairs from the end of sequencing reads. Ensuring a high sequencing
depth is one way to efficiently reduce the error rate. Alternative base calling methods have been
developed to decrease the error rate of sequencing reads [16,17,18], and other methods have been
developed to enhance the quality of sequencing reads after base calling [19,20,21,22].

1.2.2 Spike-in Transcripts
In order to achieve quality control of measurements, the use of spike-in transcripts was first
designed for microarray technology. Spike-in external controls are RNA strands synthesized in vitro
that are designed to be fairly different from the genome being studied. Several spike-in sets have
been developed, including the GeneChip eukaryotic poly(A) RNA control kit, External RNA
Controls Consortium (ERCC) spike-in controls, Agilent Technologies spike-in set and others. The
ERCC aims to establish 100 platform-independent controls for evaluating the quality of
measurements [23]. Recently, Jiang et al. synthesized ERCC RNAs as a standard for next-generation
sequencing as well. The ERCC RNA was synthesized from DNA derived from the deep-sea vent
microbe M. jannaschii or the B. subtilis genome or by in vitro transcription of de novo DNA
sequences [24]. The researchers used ERCC RNA to measure the biases produced by the GC content
bias, transcript length bias, and measurements correlated with the local sequence of the priming
hexamer. The measurement of spike-in controls can be used to measure the performance of data
normalization and approaches to differential expression analysis [23,25].

1.2.3 Statistical Methods
Several statistical methods have been suggested to correct for the biases and spurious effects of
RNA-seq technology. In order to correct for the uniformity of measurement on the same gene, Li et
3

al. proposed a statistical method that is based on a linear model with the nucleotide composition at
the beginning of the transcriptome sequencing reads as the predicative factor [4]. Li et al. were able
to explain more than 50% of the variations and observed better estimations of gene expression on
data from both Illumina and Applied Biosystems. Also, Zheng et al. proposed a generalized linear
model based on the principal components transformed from dinucleotide compositions and gene
length. Their method corrected for the biases on the gene level and could be used for meta-analysis
on multiplatform data in terms of gene expression levels [8].
Aiming to take overdispersion into account, the analysis of large datasets produced by RNA-seq
requires compatible models and methods. Among those analyses, differential expression (DE) testing
is foremost as an essential step [26]. Several methods for DE testing have been proposed, including
reads per kilobase of gene length per million mapped reads (RPKM), a 2-stage Poisson model [27], a
Bayesian method for calling DE [28], edgeR [29], DESeq [30], and others [26]. Compared with the
methods based on Poisson and binomial models, methods based on a quasi-Poisson model and
negative binomial model perform better by taking overdispersion into account. Auer and Doerge
proposed the 2-stage Poisson model (TSPM) for differential expression analysis. TSPM first tests
whether the gene is overdispersed and chooses the Poisson model or quasi-Poisson model
automatically for the analysis of genes that are not overdispersed and which are overdispersed,
respectively [27]. Further, the generalized linear model could be used to estimate parameters
efficiently based on log transformation of the Poisson or quasi-Poisson model. The methods edgeR,
DESeq and baySeq were based on a negative binomial model. The method edgeR estimates the
variance for each gene specifically by borrowing information from all genes. An empirical Bayeslike approach was used to achieve this aim [29]. Also, DESeq estimates specific dispersions from the
local regression from the dispersions and means [30]. Using the negative binomial distribution as the
priority distribution, baySeq employs an empirical Bayes method to estimate the specific posterior
probability of a DE model for each gene. In addition, methods based on a Bayesian hierarchical
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model have been proposed for DE analysis [28]. Oshlack et al. provided a critical review of the
methods commonly used for DE analysis [31].
To correct for length bias, Oshlack suggested performing the DE analysis within a fixed-length
window on all genes. However, much information would be lost using that approach. Later, Gao et.al
proposed two methods to adjust for the length bias in DE analysis based on a Poisson model [2].
The best way to deal with batch effects is to avoid them by using a careful research protocol. A
surrogate variable analysis can also be used to correct for batch effects through coefficient estimation
in a linear model [32]. Also, methods such as fRMA have been developed to capture batch-to-batch
variations for multiarray analysis [33,34].

1.3 Sequencing Analysis is Still Young and Our Research Hypothesis
RNA-seq analysis methods are relatively new, and the biases and spurious effects inherent to
RNA-seq technology are still not known clearly. Although many studies have investigated these
biases and spurious effects and several statistical methods have been suggested for correcting or
modeling them [4,27,29,35], the overdispersion properties of this technology remain elusive.
Investigations of the properties of overdispersion will benefit the understanding of sequencing
technology and the accuracy of downstream analyses.

1.3.1 The Dependence of Overdispersion and Sequencing Depth
As discussed above, by accounting for overdispersion, the negative binomial and quasi-Poisson
models showed much better performance than the former models based on binomial or Poisson
distributions. And models with dynamic overdispersion rates were superior to models with constant
overdispersion rates [27,29,35]. The constant overdispersion rate is good for describing a genetic
difference. However, for genes with no genetic variations, a constant overdispersion rate is
inappropriate, based on the intuition that along with increasing sequencing depth the accuracy of the
measurement should improve. Therefore, knowing the properties of overdispersion will be crucial
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for accurate down streaming analysis, especially for DE analysis. Because the relationship between
overdispersion and sequencing depth had not been illustrated, to our knowledge, in this study we first
investigated this intuitive notion of dependency.

1.3.2 Modeling on Base Pairs Rather than Genes
Two important and related findings on RNA-seq have been reported. First, Li et al. showed
non-uniformity in RNA-seq data [4], including that the number of sequencing reads per nucleotide
can vary by 100-fold across the same gene. However, they found that the patterns of reads are highly
conserved across tissues. Second, both Hansen et al. and Li et al. confirmed that random hexamer
priming causes biases in the nucleotide composition at the beginning of transcriptome sequencing
reads [3,4]. These findings indicate that the measurement on each base pair of a gene has a specific
mean and variance. Therefore, it is more reasonable to model the measurement based on a base pair
rather than a gene. Also, in Chapter 1.3.1, we assumed that the main source of the variance is in the
library preparation steps prior to DNA sequencing and showed that the overdispersion rate decreases
as the sequencing depth increases on the gene level from the above hypothesis. On the basis of these
findings, we developed three corresponding hypotheses. (1) Where there is no difference between
two samples, the ratio of the measurements of each base pair on a gene from two samples is a
constant across the whole gene. With this assumption, the beta-binomial model is appropriate for
comparing samples in two conditions, as modeling on proportion will transform the distribution of
reads mapped to base pairs from non-uniformity to uniformity. (2) The overdispersion rate is
influenced by random hexamer priming. (3) On the base pair level, as we found on the gene level,
the overdispersion rate decreases as the sequencing depth increases. To test these hypotheses, we
developed two beta-binomial models. One was a full model based on all three hypotheses, and the
other was a reduced model based on hypotheses 1 and 3.

1.3.3 Study of Biases from Spike-in Transcripts
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As reviewed above, the local sequence has been reported to influence the measurement from
RNA-seq for both microarray and sequencing technologies. Measurement signals in microarrays can
be influenced by the affinity of the probe sequence with the target transcript. And cross-hybridization
is a well-known cause of bias in microarray technology; therefore, probes could target spike-in
transcripts through cross-hybridization [13]. In RNA-seq, the interaction between spike-in and target
transcripts remains elusive, although the spike-in transcripts were designed to be quite different from
the target transcripts. Also, as a stable quantitative source, spike-in transcripts will offer new insights
in understanding biases in RNA-seq.
In this study, aiming to identify potential sources of bias in RNA-seq and develop statistic
models to correct for such bias, we investigated the potential biases from the measurement of spikein transcripts.

1.4 Beta-binomial Distribution and Overdispersion
For RNA-seq analysis, a fundamental question is the relationship between the accuracy of the
measurement and the increasing depth of sequencing [36]. The sequencing depth was represented by
the total number of mapped reads for each position of a gene, which can be accumulated from
multiple lanes for the same sample. Aiming to compare mRNA expression from two samples, we
usually assume a binomial distribution. In the binomial model, the uncertainty is
number of mapped reads on the gene and the uncertainty will shrink to 0 when

√

, where

is the

is large. It has been

shown that the ratio of read counts from two samples follows a binomial distribution [35,37].
However, as discussed above, biological differences and biases introduce extra noise. A distribution
with a larger dispersion than that observed from the binomial distribution has been shown by
comparing the measurements of different samples [3,4]. A beta-binomial distribution can be used to
capture this overdispersion appropriately. Beta-binomial distributions have been used for differential
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expression analysis on SAGE data [38], and on peptide counts from label-free tandem mass
spectrometry-based proteomics [39]. The probability mass function of a beta-binomial distribution is
( |
This is the probability of obtaining

)

( )

observations from

(

)
(

)

.

sample pools. Parameters

and

were

inherited from the beta distribution, followed by the probability of the observation. After
reparameterization by

,

, the variance from the beta-binomial distribution can

expressed as

( )

(

)

.

Form the equation, the dispersion contains two parts: the first part is from the binomial distribution,
which shrinks to 0 when

is large, and when n is large, the second part is a constant. Although using

a constant for all genes is appropriate to capture the genetic variant; it may not be correct for genes
without genetic variations.

1.5 DNA Methylation and Its Significance in Cancer
It has been shown that DNA methylation is related to cancer through the hypermethylation of
cancer suppression genes and hypomethylation of oncogenes. This research on DNA methylation has
focused on the methylation status of CpG island promoters. The reason for this focus is that CpG
island promoter methylation has been demonstrated to silence genes permanently in mammalian
cells. Recent studies have shown that global epigenomic alterations cause silencing in cancer with
the altered pathways involved in stem cell growth and differentiation [40].

1.5.1 DNA Methylation and Cancer
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It is known that a gene may gain or lose its function through mutation, amplification, or
deletion of the genomic neighborhood of the gene. It is also increasingly appreciated that, in cancer,
a gene may also lose its function through epigenetic changes—particularly by DNA methylation of
its promoter [41,42]. Since DNA methylation as a “silencing” epigenetic change was proposed in
1975, many of its properties have been identified. About 80% of CpG pairs in the human genome are
chemically modified by the attachment of a methyl group to the cytosine ring. CpG methylation
represses transcription and is thought to be a mechanism to control the transposable elements. The
only location where CpG pairs tend not to be methylated is near the transcription start sites, in CpGrich regions called CpG islands. CpG methylation is epigenetic, i.e., the methylation pattern is
preserved mitotically. A genome-wide survey of DNA methylation has shown that the pattern of
DNA methylation changes drastically in cancer: there is massive hypomethylation genome-wide, but
hypermethylation in CpG island promoters. The hypermethylation of CpG island promoters results in
the silencing of a large number of genes. By some estimate, the number of genes silenced by DNA
methylation is about ten times the number of mutated genes [43,44], therefore the number of genes
silenced by DNA methylation is much larger than the number of mutations.

1.5.2 CpG Island Methylator Phenotype (CIMP)
CIMP was first discovered in colorectal cancer [45] as tumor-specific CpG island
hypermethylation of a subset of genes in a subset of tumors. This was confirmed later [46] and has
also been found recently in glioma [47]. Previously, several aberrant methylations of genes were
reported in breast cancer [48,49,50,51,52,53], and DNA methylation patterns have been claimed to
be associated with histological tumor grade [49,54], tumor growth [55,56,57], hormone receptor
status, Her2 expression [56,58,59,60], and breast cancer subtypes [61,62,63]. Only a few studies
have claimed CIMP with hypermethylated genes for breast cancer [64]. Others have argued that
more studies are required in order to confidently state that CIMP exists for breast cancer [51].
However, very recently, TCGA identified methylation clusters that significantly correlate with
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mRNA subtypes, and mutations of TP53, PIK3CA, MAP3K1 and MAP2K4 [65]. In order to
investigate CIMPs with the new insight of dichotomizing methylation status, the present study
focused on breast cancer.

1.5.3 DNA Methylation and mRNA Expression
The expression of a gene can be turned off when its promoter is highly methylated. The exact
amount of methylation that will trigger gene silencing depends on the gene as well as the relative
position of the CpG site to the transcription start site (TSS). Several studies have reported that a clear
threshold effect exists in the gene silencing mediated by DNA methylation, and that significant
transcription inhibition occurs only when the methylated CpG islands reach a certain level [66,67].
We also verified this threshold effect genome-wide in this study. The transcription regulatory system
is well known as an extremely complicated system with many components, including gene-gene
interaction, microRNA regulation, and DNA methylation. Also, the hybridization properties of the
probe affect the signal strength for C/T nucleotides and introduce an additional variable from the
measured beta value to the gene expression status. Therefore, the threshold of DNA methylation
should be gene-specific. To determine whether a gene is turned off by DNA methylation, we
therefore must determine a probe-specific threshold in order to dichotomize the methylation status.
As we have discussed, the DNA methylation threshold is a stable indicator of whether a gene has lost
function. There are several potential benefits, including a better definition of the CIMP. A good way
to find the CIMP is by biclustering, in which we search for a sub-cluster of genes and tumors that
have the same methylation status. Dichotomizing methylation makes the task of biclustering easier
[68,69]. The measurement of DNA methylation can be represented by a

value for each tag, which

is the proportion of methylated signals among all signals.
,
where for the -th tag,

is the methylation signal and
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is the unmethylation signal.

1.6 Reduced Representation Bisulfite Sequencing (RRBS)
DNA methylation can be determined genome-wide using reduced representation bisulfite
sequencing (RRBS). Bisulfite treatment of DNA converts cytosine to uracil but leaves methylated C
unchanged. DNA sequencing of the whole genome and comparing the sequence at CG with the
reference therefore allows the methylation status to be determined genome-wide [70,71]. Wholegenome sequencing is expensive. RRBS is cheaper but it is difficult to control the coverage. Most of
the genome-wide data on cancer are obtained by reading C/T polymorphism using well-established
SNP arrays. Illumina Infinium is an assay specially designed to measure methylation in the
promoters of annotated genes. It has on average four probes per gene and therefore measures the
methylation of four CpG sites per gene. This is far less expensive and is at present the most costeffective method of measuring methylation systematically.

1.7 Challenges and Our Hypothesis on DNA Methylation
Many studies have been developed on DNA methylation and many findings have been reported.
Several properties of CpG island (CGI) methylation have been classified from studies [72]. We list
six such properties here: (1) at a transcription start site (TSS), most CpG islands are hypo
methylated; (2) long-term silencing is associated with CGI methylation; (3) sometimes a tissuespecific pattern can be identified in CGIs in gene bodies; (4) compared with that of CGIs, the
methylation status of non-CGIs is more tissue-specific and more dynamic; (5) rather than elongation,
methylation blocks the start of transcription; and (6) cancer-causing mutations can be the
consequence of methylation in gene bodies. However, it is still a big challenge to clarify the
mechanisms underlying DNA methylation and its function regarding RNA expression. We sought to
investigate genes that are largely regulated by DNA methylation.
Aiming to identify the genes of interest and determine the DNA methylation threshold for the
inhibition of mRNA expression as discussed above, in this study we took advantage of computing
conditional mutual information scores, which will be robust in determining the methylation threshold
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specific to one site on a particular gene. The novelty of this new method is that it relates gene
silencing by DNA methylation of promoter CpG islands to gene expression in several tissues, and
increases the accuracy of the determination of mRNA methylation status and expression status.
Fortunately, some consortia such as TCGA have made efforts to profile a large collection of patients’
samples for mRNA expression, miRNA expression, DNA copy number, and methylation status,
which makes our study feasible. Based on the genes identified to have large contributions from DNA
methylation on transcription regulation, we intended to find a new CIMP of breast cancer in this
study.

RNA sequencing technology is complicated and is characterized by many inherent biases and
spurious effects. Statistical methods are still limited for accurately estimating overdispersion in DE
analysis. Studies have shown that the sequencing reads are not uniformly distributed on genes and
are correlated with the nucleotide composition of the hexamer primer local sequence. Also, with the
intuition that added increments of sequencing depth will improve the accuracy of the measurement,
we investigated the relationship of the overdispersion rate and sequencing depth. We suggested
methods based on a beta-binomial model to estimate the overdispersion rate for DE analysis on both
the gene level and the position level. Also, inspired by the cross-hybridization issue inherent in
microarray technology, we investigated the measurement of spike-in transcripts from RNA-seq,
aiming to identify hidden biases. In addition, in order to identify cancer-related genes in terms of
methylation status, we developed a method to identify genes for which expression was highly
regulated by DNA methylation. From these genes, we identified a new CIMP with correlations
between the molecular signature and clinical features.
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CHAPTER 2
Accuracy of RNA-seq and Its Dependence on Sequencing Depth

In the past decade, the cost of DNA sequencing has been rapidly and dramatically decreasing.
Consequently, sequencing technologies are widely used for genomic research today. Many
sequencing platforms have been developed for specific aims, among those, RNA-seq is a key
technique to measure gene expression. Sequencing technology is complicated, and many of its
properties remain elusive even though numerous studies have been devoted to it. Based on the
intuition that increasing the sequencing depth could improve the accuracy of the measurement, we
sought to investigate this relationship in order to benefit downstream analyses such as differential
expression analysis.
Toward this aim, we empirically evaluated the variance in three RNA-seq datasets. Based on
our observation, we concluded that the error of RNA-seq measurements was mainly from the library
preparation steps prior to sequencing. And we observed that increasing the sequencing depth indeed
improves accuracy. However, in general, with an incremental increase in the depth of the sequencing
reads, the overall dispersion decreases more slowly than predicted by the binomial distribution. This
indicates that overdispersion exists and decreases along with increments in the sequencing depth.
Applying this property, we developed a method based on the beta-binomial distribution with a new
parameter to model the relationship between overdispersion and the sequencing depth. We borrowed
the information from all genes of replicates to capture this relationship. Then, we estimated the mean
and dispersion of each gene specifically according to this relationship. By indicating the specific
overdispersion for each gene, our method showed a better performance than the methods based
directly on binomial and pure beta-binomial distributions.
We demonstrated a novel property of overdispersion in that it improves with increments in the
sequencing depth. Also, we proposed a new form of overdispersion in the beta-binomial model to
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borrow the information from all genes to estimate specific parameters for each individual gene. We
demonstrated that this new form fits the data better.

2.1 Methods
2.1.1 Peak of Histogram of Proportion Normalization
The normalization procedure using the peak of the histogram of proportion assumes that
most genes remain unchanged in the two conditions being compared. In this normalization
procedure, we fit the highest peak in the histogram of proportion to a beta function. The
maximum of the beta function determines the normalization proportion .
In RPKM normalization, we first count the total number of tags mapped to any gene in
the RNA-seq experiment. The number of tags mapped to a particular gene is divided by the
total number of tags sequenced (the unit is millions of tags), and then divided by the number
of nucleotides in the gene (the unit is thousands). [73]
2.1.2 Datasets Used
The three datasets we used are listed in Table 2.1.
Table 2.1 Three datasets [73]
Data Sets

A

B

Caltech

Normal Blood

Embryonic Stem Cells

Rep1Gm12878CellLongpolyaBow0981x32

PairedRep1H1hescCellPapErng32aR2x75

Rep2Gm12878CellLongpolyaBow0981x32

PairedRep2H1hescCellPapErng32aR2x75

PairedRep1Gm12878CellLongpolyaBb12x75

PairedRep3H1hescCellPapErng32aR2x75

PairedRep2Gm12878CellLongpolyaBb12x75

PairedRep4H1hescCellPapErng32aR2x75

Knock-out of TDP-43

Wild Type

GSM546932 A sorted

GSM546935 B sorted

GSM546933 D sorted

GSM546936 C sorted

Chiang

GSM546934 E sorted
Bullard

Brain

UHR library A

UHR library B

SRR037457

SRR037466

SRR037470

SRR037458

SRR037467

SRR037471

SRR037468

SRR037472

SRR037469
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The Chiang dataset consisted of five independent libraries of the deleted TDP-43 gene
in the mouse. The data were derived from three independent clones of TDP-43 knockout
embryonic stem (ES) cells and two independent clones of control ES cells. Raw reads were
mapped to the University of California Santa Cruz mm9 genome library by efficient largescale alignment of nucleotide databases. One gene deletion is an ideal case for testing
normalization procedures with the assumption that most genes do not change.
The Caltech dataset consisted of two cells lines: GM12878 (normal blood) and H1hESC
(embryonic stem cells), each with four libraries made independently from the same
biological sample. The process involved raw Illumina reads on 2x75 datasets (RawData files
on the download page, fasta format), which were run through Bowtie, version 0.9.8.1, with
up to 2 mismatches. The resulting mappings were stored (RawData2 files, Bowtie format)
for up to ten matches per read to the genome, spiked controls and UCSC knownGene splice
junctions.
The Bullard dataset consisted of human brain reference RNA and human universal
reference RNA as two library preparations. We used Bowtie, version 0.12.7, to align the
reads to the genome (H. sapiens, NCBI 37.1 assembly). The Bowtie command we used to
implement this mapping strategy was ./bowtie -a -v 2 -t -m 1 --best -strata
h\_sapiens\_37\_asm. [73]

2.1.3 Maximum-likelihood Estimation (MLE)
Let
and
be the tags mapped to the -th gene and -pair of experiment and
control, respectively. The likelihood function according to the beta-binomial distribution is
(
where

and

)

∏

)∏

(
∏

(

(

)
)

,

are two parameters of the beta-binomial distribution. This is equivalent to

using instead the parameters

and

. It can be shown analytically

that the proportion that maximizes the likelihood function is given by
will further assume that
parameters

and :

likelihood

is independent of
(

)

; we reparameterize

. We
in terms of

. The parameters were determined by maximizing the

∑

( ) [73]

2.1.4 Likelihood Ratio Test
According to the likelihood ratio test,

( )
)
)

((

follows a

distribution, where

is

the proportion for gene and
is the normalized proportion corresponding to no change in
gene expression. This is the most convenient way to compute the -value. [73]
2.1.5 FDR and ROC
To determine the false discovery rate (FDR), we assumed that any gene deemed to be
significantly differentially expressed at a given -value was false when comparing two
replicates sequenced from the same biological sample. We computed the FDR by dividing
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the number of falsely discovered genes at a given -value by the number of significantly
differentially expressed genes, and comparing the sample to the control at the same -value.
To determine the receiver operating characteristic (ROC), we first established a gold
standard. Approximately 1,000 genes in the Bullard dataset were previously assayed by RTPCR in four independent experiments [74]. Differentially expressed genes were determined
by t-test by Bullard et al. [37]. We used their results to draw an ROC curve when
comparing the binomial and beta-binomial distributions for the Bullard dataset. For the
Caltech and Chiang datasets, we assumed that the t-test provided a gold standard. In order to
reduce errors for small tag counts, we required a gene to have more than 20 mapped tags.
For the Caltech data, the Benjamini & Hochberg adjustment was applied to the -value
calculated by the t-test, using a cutoff of 0.05 [75]. We could not use the FDR -value
adjustment on the Bullard dataset, as much fewer genes had differential expression levels
detected from the wild/knockout samples. Therefore, we applied a cutoff of 0.05 to the value from the t-test and required a fold change larger than two. [73]
2.1.6 Computing the Fold Change
We related the fold change in the gene expression level
to the optimized ratio and
obtained, by definition,
. This ratio has to be calibrated against the normalization
of the entire experiment. We defined
(
values of

), where

as no change. Therefore,

(

)

( )

is the normalized ratio as determined over the entire dataset. Infinite

can be avoided by adding a pseudo-count to

and

so that

. [73]

2.2 Results
2.2.1 Normalization by Proportion
The use of a proportion is a convenient way to compare two samples. Let
the number of tags mapped to gene . The proportion is defined as

and
be
. It is

convenient to use a proportion because differences in proportion give rise to -values using
established statistics such as binomial and beta-binomial distributions. A proportion is also a
convenient component of a normalization procedure.
In order to detect differential expression in two samples, we must determine the ratio of
the counts in the two samples that corresponds to the same expression. One method, adapted
in calculating the RPKM, assumes that the total number of tags sequenced, and equivalently
the total amount of RNA, is a constant. The problem with RPKM normalization is that the
number is dominated by a few genes that receive the highest number of sequence reads.
These genes may or may not remain constant under the two experimental conditions. One
could also use housekeeping genes such as POLR2A (polymerase II) or GAPDH in a
normalization procedure. The problem with relying on a housekeeping gene is that the
normalization depends on the choice of genes. Since the number of housekeeping genes is
small, this normalization procedure is subject to fluctuation due to relatively small tag counts
on these genes. Bullard et al. have shown good results with an upper-quartile normalization
method [37].
The most conservative normalization procedure assumes that the maximum number of
genes remains unchanged in the two experimental conditions. This corresponds to the
maximum in the histogram ratio of tag counts . The tag count proportion is more
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convenient to use. The maximum in a histogram of that corresponds to the neutral ratio
, where the expression levels are assumed to be equal in the two samples. This maximum
can be determined from fitting a Gaussian (or beta function) to the peak of the histogram
(Figure 2.1). In this formulation, the RPKM normalization corresponds to choosing
, where and are the total number of tags to genes in the experiment and control.
This peak of histogram normalization is expected to be the most reasonable procedure
for the Chiang dataset [76], which consists of the wild-type and knockout versions of the
TDP-43 gene (see Data and Methods for details). For this dataset, we expect the perturbation
to the global gene expressions to be smaller than when comparing two different types of
cells. Indeed, our peak for the histogram normalization procedure resulted in a median of
base-2 logarithm of expression difference ratio between the wild-type and knockout gene of
0.014, which is to be compared to 0.025 for the median under the RPKM normalization
procedure. This showed that peak normalization was comparable to and perhaps slightly
better than RPKM normalization.
Normalization is performed according to the assumption that most of the genes do not
change expression in the two experimental conditions. Although this convenient assumption
is probably true in most cases, it has no ironclad biological justification. [73]

Figure 2.1 Histogram of proportions and peak of histogram of proportion normalization. The
peak in the histogram corresponds to the largest density of genes. To determine the peak
maximum, the histogram was fitted to a beta function. The blue curve shows the best fit with
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the maximum at
RPKM normalization,

. This is to be compared to the proportion corresponding to
. [73]

2.2.2 Binomial Distribution Fits the Variance from the Same Library but not from Different
Libraries
We empirically studied errors in RNA-seq experiments by examining the variance from
replicated measurements. We first examined the fluctuation in reads mapped to a gene from
duplicate experiments based on the same biological sample. The -values of the differences
were computed according to a binomial distribution by comparing to a neutral ratio
as
determined by peak normalization. For the same sample and the same library preparation
sequenced in different lanes of the Illumina sequencer, the histogram of the -values is flat
(Figure 2.2 a). This indicates that the errors in different lanes containing samples from the
same library are consistent with the binomial distribution. In contrast, the histogram of values according to the binomial distribution for two independent library preparations
showed clear overabundance of small p-values (Figure 2.2 b). This demonstrated that the
binomial distribution does not adequately describe the data---the dispersion of the random
fluctuation is stronger than that given by the binomial distribution. We use the term library
preparation to refer to an independent extraction of RNA, conversion to DNA and PCR
amplification of DNA. Since the experiment and the control must be in separate library
preparations, it is important to capture this overdispersion. The overabundance of small values for different libraries was also true when we used Fisher's exact test (data not shown).
When we used the beta-binomial distribution to compute the -values for the different
libraries, the histogram was flat. This shows that the overdispersion is accounted for by the
beta-binomial distribution. A Q-Q plot against either a binomial or beta-binomial
distribution (data not shown) also indicated that the beta-binomial distribution better fit the
data. [73]
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Figure 2.2 Histogram of -values of gene expression differences from duplicate experiments
on the same biological sample. (a) Duplicate experiments were from the same DNA library
sequenced in different lanes. The -values were calculated from the binomial distribution.
(Two datasets compared: Bullard SRR037457 vs SRR037458.) (b) When the binomial
distribution is applied to the same biological sample prepared in two different libraries, more
genes than expected had small probability, which erroneously predicted the existence of
significantly differentially expressed genes when there should not be any. (Two datasets
compared: Bullard SRR037467 vs SRR037471.) (c) When the same two libraries are
compared using the beta-binomial distribution, there is no longer a high density at small values. Peak of proportion normalization was used in these calculations. These histograms
were drawn using R package Bum-class. [77] [73]
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2.2.3 Errors Decreased with Sequencing Depth
We first addressed the uncertainty in the RNA-seq measurement and how uncertainty
was related to the sequencing depth empirically from repeated measurements. Specifically,
from replicates of the biological sample, we calculated the standard deviation of the
proportion. If the proportion satisfied the binomial distribution, we expected (
)
(
)
, where and
are tags mapped to gene in two duplicate experiments of the
(

)

sample (possibly from different libraries),
Figure 2.3 shows a plot of

(

)
(

and

is the normalization proportion.

, averaged over pairs of duplicate experiments (Table

)

2.1), as a function of the mean
for the three sets of experimental data. These figures
show that the variance of the proportion continued to decrease at large
and there
was no sign of saturation. However, the rates of decrease with the tag counts depended on
the dataset and were slower than that given by the binomial distribution. [73]
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Figure 2.3 The variance of proportion versus the mean tag counts in base-10 log scale. The
variances of proportion were computed from replicates of the same biological samples. (a)
Caltech dataset; (b) Chiang dataset; (c) Bullard dataset. Each point represents a gene
averaged over replicates (see Table 2.1 for the number of replicates for each dataset). The
red line has a slope of -1. The black line is fit to the data for a mean (x-axis) larger than 2
(count greater than 100). [73]
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2.2.4 Modified Beta Binomial Distribution
We used a beta-binomial distribution to describe the overdispersion in the data, as shown
in Figure 2.2 b. However, in the beta-binomial distribution, the standard error approaches a
constant as the mean tag counts become very large, whereas empirically, the standard error
follows a decreasing trend at large tag counts (Figure 2.3). We therefore made the following
assumption about the form of the parameter in the beta-binomial distribution (see Method
for details). Let and
be the number of tags mapped to gene . We make depend
explicitly on the tag counts.
( )
(
)
Under this assumption, for
, the asymptotic form of the variance of the proportion
at large tag count
according to the beta-binomial distribution is
.
Therefore the variance of the proportion of the modified beta-binomial distribution does
approach zero at large , but at a slower rate than in the binomial distribution. [73]
2.2.5 Determining the Parameters

and

Although can be estimated from the slope and intercept, in the log scale of variance
versus the mean tag count (Figure 2.3), it required multiple experiments and had low
accuracy due to data scattering. For a better estimation of the parameters $\gamma$ and
in Eq.2, we used maximum-likelihood estimation (MLE). In this approach, the likelihood
was derived from the beta-binomial distribution of tag counts
and
for gene , and
summed over all the genes and over all the pairs of duplicate experiments. The
overdispersion parameters were given by Eq.2 and the parameter and parameters
for
each gene were chosen to maximize the likelihood. The plots in (Figure 2.4) were obtained
by performing a full optimization of likelihood Eq.1 (see Methods) with respect to
for
each , and plotting the optimized likelihood values against . Table 2.2 compares the
from two estimates. The estimated depended on the data. We computed for three sets of
data. The values ranged from 0.2 to 1.0 (Figure 2.4). These estimates were consistent with
those from the standard error (Figure 2.3). [73]
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Figure 2.4 Beta-binomial likelihood as a function of the parameter (a) Caltech dataset; (b)
Chiang dataset; (c) Bullard dataset. The vertical lines marked the position of maximum. [73]
Table 2.2 Two estimations of
Pairs of Experiments
used in calculation
Caltech
6a
Chiang
3b
Bullard
12c
1obtained from slope in Figure 2.4
Data Set
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from three datasets [73]
Standard Error1
0.26
0.40
0.76

MLE2
0.2
0.2
1.0

2 from maximizing likelihood Eq.(1)
a from four libraries of same biological sample
b from three knockout replicates and two wild type replicates
c by comparing two di_erent libraries having four and three replicates

2.2.6 Comparison of Beta-binomial and Binomial Distributions
Figure 2.5 shows a comparison of the false discovery rates (FDRs) [75] and receiver
operating characteristics (ROCs) [78] for genes deemed to be differentially expressed by the
binomial and beta-binomial distributions. For the Bullard dataset, the results were
comparable for the two distributions. For the Caltech and Chiang datasets, the beta-binomial
distribution was superior (for dataset details, see Methods).
We took the top 300 genes deemed most significantly differentially expressed by a t-test,
and by binomial and beta-binomial distributions, and overlaid them in a plot of the fold
change versus the average tag counts (see Figure 2.6 and Figure 2.7). We note that the genes
identified as significantly differentially expressed by the binomial distribution tended to have
large tag counts; whereas many genes identified as significantly differentially expressed
from the t-test had small tag counts. Some genes identified as significantly differentially
expressed by the binomial distribution (marked by a triangle only) were not identified as
significantly differentially expressed by the beta-binomial distribution, even though they had
higher fold changes than other genes at similar tag counts. The large fluctuations in the
assessment of these genes are evident because they were also not called significantly
differentially expressed by the t-test. [73]
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Figure 2.5 False discovery rate (FDR) and receiver operating characteristic (ROC) for three
datasets. (a) and (b) Caltech dataset; (c) and (d) Chiang dataset; (e) and (f) Bullard dataset.
Three panels on the left indicate the FDR. FDR (on y-axis) is plotted against the number of
most significantly differentially expressed genes (on x-axis). Three panels on the right
indicate the ROC. Bi denotes binomial distribution; BB denotes beta-binomial distribution.
The line for BB
was obtained by setting
and optimizing . It corresponds to
the normal beta-binomial distribution. In (b), the line for BB
overlaps with the line for
BB
.3. [73]
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Figure 2.6 Gene expression fold change in the TDP-43 deletion vs wild-type genes (Chiang
dataset). Gene expression fold change is plotted against the average tag counts (x-axis in
base-10 log; y-axis in base-2 log). The 300 most significantly differentially expressed genes
by -values are depicted by squares (t-test), diamonds (beta-binomial distribution), and
triangles (binomial distribution). Black circles represent genes not among the top 300 in any
methods. The green and purple boxes and lines indicate the median for RPKM and peak of
proportional normalization. The data were from the average of three deletion and two wildtype experiments. [73]
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Figure 2.7 Venn diagram comparison. The overlap of top 300 genes identified by betabinomial (bb) binomial (bi), and the t-test (t) is shown. The number in the lower right of the
rectangle indicates the total number of transcripts detected. [73]
2.3 Discussion
In this study, we investigated the error of the gene expression measurement from replicated
RNA-seq experiments. We observed that a binomial distribution fit the comparison of the
sequencing reads from different sequencing lanes of the same sample, but not from the different
preparations of the same biological sample. This observation indicated that a binomial or Poisson
distribution fit the nature of the sequencing technology but larger variations could be introduced by
the library preparation steps prior to obtaining replicates of the same biological sample. Also we
observed that the accuracy of measurement from RNA-seq improved along with increments in
sequencing depth. However, compared with the overdispersion predicated by the binomial
distribution, the calculated dispersion decreased more slowly along with the increment of the
sequencing reads, and many false discoveries were observed from the testing based on the binomial
distribution. This indicated that overdispersion exists and is introduced by library preparation, and
that it decreases roughly linearly along with the increment in sequencing depth on a log scale. We
developed a method based on the beta-binomial distribution with a new parameter to model the
relationship between overdispersion and the sequencing depth. We borrowed the information from
all genes by introducing the overdispersion parameters in a function of the number of reads to
estimate the specific means and dispersion of each gene. We used the maximum likelihood method
to determine the parameters. And by comparing the false discovery rate (FDR) and receiver operator
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characteristics (ROCs), we showed that our modified beta-binomial model was superior to the
binomial model without an overdispersion parameter and to the beta-binomial model with an
overdispersion parameter that is constant for all genes.
The advantages of modeling the proportion of measurement counts to detect the differential
expression drove us to adapt the beta-binomial distribution rather than the Poisson model. Many
studies have reported highly non-uniformly distributed patterns of measurements from RNA-seq on
genes [4], and that this non-uniformity is correlated with the local sequence around a random
hexamer primer [3,4]. In this situation, the Poisson rate could fluctuate by even a hundred-fold at
different positions of the some gene. However, the non-uniform distribution was similar between
replicates of the same sample or even among measurements of samples from different tissues [4].
Therefore, we could avoid estimating the highly fluctuating Poisson rate on the same genes by
comparing the proportion of measurement of two samples. By modeling the proportion, the nonuniformity was estimated indirectly only through the dispersion. Avoiding estimating the highly
fluctuating Poisson rates is therefore advantageous for modeling the proportion of measurements
based on the beta-binomial distribution.
In our model, parameter in Eq.2 describes the decreasing rate of overdispersion along with the
increasing sequencing depth. Our model will reverse back to the pure beta-binomial distribution
when the parameter goes to 0. Interestingly, we observed that the estimated values were
dissimilar across the different datasets. This phenomenon is commonly found in measurements from
different experiments; for example, the GC count bias in sequencing data has been reported to vary
between experiments [9]. Therefore, the experimental protocol might influence parameter which
indicates the decreasing rate of overdispersion along with an increasing sequencing depth. Because
of the non-uniformity of measurements on genes, it is interesting to investigate the property of
overdispersion on each position and it will be more accurate to model measurements on the position
level. We carried on the study and proposed another parameterization of overdispersion based on the
position, which we describe in the next chapter.
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CHAPTER 3
Modeling the Non-uniformity of Measurement from RNA-seq for
Differential Expression Analysis

Many biases and spurious effects are inherent in RNA-seq technology. A number of methods
have been proposed to handle these biases and undesirable effects in order to accurately analyze
differential RNA expression at the gene level. However, modeling at the base pair level is required to
precisely estimate the mean and variance of the measurement, because the sequencing reads are nonuniformly distributed on one gene. As a consequence, each position on one gene has a specific mean
and variance. It has been reported that priming with a random hexamer contributes to the nonuniformity, which is related to the local sequence around the priming site. In Chapter 2, we showed
that the overdispersion rate decreased as the sequencing depth increased on the gene level. On the
basis of these findings, we developed three corresponding hypotheses. (1) In comparison of the gene
expression of two samples, the null hypothesis is that there is no difference between two samples,
even on each position of a gene. Therefore, the proportion of the measurement on each position will
be a constant. With this assumption, modeling on the proportion of the measurement based on a betabinomial distribution will be appropriate, with the advantage that the non-uniformity of the
measurement is transformed to a constant mean. (2) On the position level, random hexamer priming
influences the overdispersion rate through the local sequence around hexamer primers. (3) Similar
with what we observed on the gene level, the overdispersion rate decreases along with the increasing
sequencing depth on the position level as well. Based on these hypotheses, we developed two betabinomial models. One was a full model based on all three hypotheses, and the other was a reduced
model based on hypotheses 1 and 3.
First, we investigated the impact of the sequencing depth and local primer sequence on the
overdispersion rate. Second, we inspected the impact of different sequencing protocols on the
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overdispersion rate. Third, we proposed four models and compared them with each other and DESeq
regarding the likelihood value, AIC, goodness-of-fit

test, and the testing error indicators FDR and

AUC.
Similar to our observations on the gene level in Chapter 2, we demonstrated that the
overdispersion rate decreased along with the increasing sequencing depth on the position level. Also,
the influence of priming with a random hexamer on the overdispersion was validated and relates to
the local sequence around the hexamer primer. However, after stratification by sequencing depth, the
influence was no longer significant. In addition, our beta-binomial model with a dynamic
overdispersion rate on the position level was superior to the other models we proposed in this study.
Furthermore, as expected, our proposed model was more desirable than DESeq, which was based on
a negative binomial distribution, with many advantages in differential expression analysis for the
same biological samples.
The current study provides a thorough understanding of the property of the overdispersion rate
on the position level, especially the relationship between the overdispersion rate and sequencing
depth. We also clarified that random hexamer priming could influence the overdispersion rate by
affecting the sequencing depth of each position. These properties will aid in the quality control and
development of statistical methods for downstream analysis. Based on those properties, we
suggested a more desirable method to model the non-uniformity measurement. Our method was
based on a beta-binomial model with a dynamic overdispersion rate, and a better estimation was
obtained from it on each position when compared with the other models, assuming the
overdispersion rate is a constant for all points of one gene.

3.1 Methods
3.1.1 Datasets Used
Two datasets were used, the Lichun dataset with spike-in data [24] and the Bullard dataset with
the gold standard data [37] (Table 3.1).
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Lichun dataset with spike-in data. The Lichun dataset consists of several libraries with
different RNA sources (whole cell, cytosol, and nucleolus) and identifications (longPolyA and
longNonPolyA). Synthetic spike-in standards from the External RNA Control Consortium (ERCC)
were sequenced along with human samples. These libraries were prepared using the dUTP protocol:
(1) First-strand synthesis is performed using a random hexamer primer. (2) Second-strand synthesis
is performed by RNAse H and DNA polymerase 1. (3) cDNAs are fragmented by sonication, and
adapters are ligated to both end of cDNAs. (4) The second strand is eliminated through UNG
digestion. (5) Fragments are selected with sizes at 200 base pairs. (6) Paired-end sequencing is
performed. The human libraries are mapped to the human genome (hg19) using STAR software, and
the ERCC libraries are mapped to the ERCC reference using Bowtie, version 0.11.3 with parameters
–v2 –m1. In the present study, we analyzed only libraries from whole cells and longNonPolyA.
Because we assumed that the number of reads would influence the overdispersion rate, we selected
samples (shown in red in Table 3.1) with approximately the same total counts as the training set to
eliminate noise. To avoid the transcription initiation bias in the sequencing [79], we truncated 50
nucleotides on both ends.
Bullard dataset with gold standard data. Two distinct biological samples, brain and UHR,
were examined in the Bullard dataset. The UHR samples were from three library preparations, UHR
libraries A, B, and C, and the brain samples were from one library preparation. RNA was first
fragmented and then converted into cDNA using random hexamer priming. The cDNA was
sequenced using the standard Illumina protocol, including adapter ligation, polymerase chain
reaction (PCR), size selection, and injection into flow-cells. We used Bowtie, version 0.12.7, to align
reads to the genome (H. sapiens, NCBI 37.1 assembly). The Bowtie command for implementing this
mapping strategy was ./bowtie –a –v –t –m 1 –best –stratah_sapiens_37_asm. Additionally, about
1000 genes have previously been assayed by real-time PCR; thus, these genes can be applied as a
gold standard. All 3 sampled UHR libraries had almost the same yield and thus could be used as the
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training set to estimate parameters. Three of them were left for the test set (shown in blue in Table
3.1). Also, 50 nucleotides were truncated on both ends to avoid the transcription initiation bias.

Table 3.1 Two datasets used
Dataset
Lichun

ERCC

Bullard

Human
Brain

GSM758567 GSM758572 GSM758573 GSM758577 GSM765389
GSM765391 GSM765396 GSM765398 GSM767845 GSM767847
GSM767851 GSM767854 GSM767855 GSM767856
GSM767847 GSM758577

SRR037455
SRR037456
SRR037457
SRR037458

UHR library A

UHR library B

UHR library C

SRR037466
SRR037467
SRR037468
SRR037469

SRR037470
SRR037471
SRR037472

SRR037473
SRR037474
SRR037475
SRR037476

3.1.2 Normalization
RPKM normalization was applied. RPKM was computed as the number of reads that mapped
per kilobase per million mapped reads for each gene, for each sample.

3.1.3 Calculation of Overdispersion Rate
Let

and

per Base Pair

be the tags mapped to the -th nucleotide of the -th gene for the experimental

sample and control, respectively. The probability mass function according to the beta-binomial
distribution is
(
where

and

|

)

(

)

(

)
(

,

)

are two parameters of the beta-binomial model. It is equivalent to using the

following parameters:

for all and

. Analytically,

of the proportion, which can be estimated in the binomial model as ∑

is the expected value

∑
∑

.

The proportion ̂ of each gene should equal the proportion of all the reads of all genes, that is,
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where denotes the -th particular pair among R total pairs of replicates.
We developed a 2-step strategy to calculate

. In the first step, the variance of proportion per

base pair was estimated per pair of replicates separately. Then we calculated

according to

formula (2).

3.1.4 Base Pair-Based Model
After the reparameterization, the log likelihood of the beta-binomial distribution was derived as

∑∑[ ∑

(

)

∑

(

)

∑

(

)] ( )

Full model. On the basis of all of our assumptions, a full model was suggested, in which

is

related to the local sequence around the primer:
∑

∑

(
In this model,

(

)

)

( )

is the length of the probe around the -th nucleotide of the -th gene. We set

as suggested in a previous study [73]. Also, (
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) is 1 when the -th base pair is letter

h, which is A, T, or C exclusively, and 0 otherwise. The parameters we want to estimate are

and

, and ε is Gaussian noise.
There are 3 x 80 = 240 parameters on the local sequence in this model, which makes it quite
difficult to use the usual ways of estimation, such as maximum-likelihood estimation. We took the
log of Eq. 4 and obtained another formula that can facilitate model fitting:
(

( )

)

This linear model of

∑

∑

(

)

(

)

( )

made the estimation fast and robust. The number of parameters, 240, is a

really small number compared to the sum of all the positions in all the genes.
Reduced model. On the basis of our third hypothesis, that the overdispersion rate of RNA-seq
reads decreases as the sequencing depth increases, we proposed a reduced beta-binomial model for
the comparison of two replicates, in which
(
where

( )

)

is for all nucleotides of any genes and represents the decreasing slope of the

overdispersion rate plotted against the number of reads.
Counts-excluded model. In order to determine the dependency of the overdispersion rate on the
local primer sequence, we excluded the count term from the full model:
(

)

( )

∑

∑

(

)

( )

3.1.5 Fitting the Beta-binomial Models
The parameter

was determined by maximizing the log likelihood (Eq. 3) of the reduced

model and the full model, respectively. We used the following strategy to fit our models:
1. Initialize ̂ as Eq. 1 in the training set.
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2. Set ̂ as a known parameter and fit the beta-binomial model to obtain

and

. Apply the

least-squares estimation method based on the linear model (Eq. 5).
3. Set

according to Eq. 6 and Eq. 4 as a known parameter in the reduced model and the full

model, respectively, to update

.

4. Jump to step 2 unless the deviance decreases less than 1%.
The above procedure maximizes the likelihood by iteratively optimizing

in step 2 and

in

step 3.

3.1.6 Estimating Cross-validation
We used the leave-one-out cross-validation strategy to estimate

. The training set was

randomly split into five groups of equal size. In each round, we fit our model using four of these five
groups, and then calculated

on the remaining subset by the regression sum of squares divided by

the total sum of squares. The final cross-validation

was determined as the mean.

3.1.7 Likelihood Ratio Test
According to the likelihood ratio test,
where

is the proportion for gene and

(

)

(

) follows the

distribution,

is the normalized proportion corresponding to no change

in gene expression. In multiple-samples testing, we summed over their pairwise

scores and

obtained p-values with a summation of degree of freedom.

3.1.8 Methods for Model Comparison
Goodness of fit was examined for 4 models: the binomial model, the beta-binomial model with
a constant overdispersion rate of

, the reduced model with

as in Eq. 4.
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as in Eq. 6, and the full model with

Likelihood-value goodness of fit. Proportion

was estimated and fixed for all four models.

Sequentially, the other parameters were determined by the maximum-likelihood estimation method
or the least-squares method, and the likelihood value was calculated by pairwise comparison of the
replicate data. The

(

test was performed on

)

(

), where

and

denote the likelihood for the null model and alternative model, respectively.
Akaike information criterion (AIC) is a measure of the relative goodness of fit of a
statistical model. The
of parameters and

is calculated by definition as

is the maximum-likelihood value. The final

( ), where

is the number

is determined by the mean of all

from pairwise replicates.
FDR and AUC. The false discovery rate (FDR) and the area under the receiver operating
characteristic curve (AUC) were determined by the method described in our previous study [73]. For
the Lichun dataset, which lacked gold standard data, the AUC was not determined.

3.2 Results
3.2.1 Overdispersion Rate on Base Pairs Decreased with Sequencing Depth
In order to test our third hypothesis, we empirically investigated the impact of sequencing depth
on the measurement of the overdispersion rate per base pair. Analyzing the spike-in data, we
calculated the variance of the proportion of the reads mapped to the -th base pair of the -th gene
from two replicates of the same sample, then determined the overdispersion rate
C). In Figure 3.1, we plot the estimated

(Methods, part

against the number of counts on the corresponding

nucleotide position. The results show that the overdispersion rate was strongly inversely correlated
with sequencing depth—that is, the overdispersion rate kept decreasing as the sequencing depth
increased and without a sign of saturation. This density plot shows that most of the points are
concentrated on a line. Examination of the points corresponding to the local sequence, starting with
GGGG and AAAA (blue and red points, respectively), also shows that most of the points are on or
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close to the line of concentration. However, at positions with large read numbers, the estimated
seemed to depart from the decreasing trend, suggesting that statistical noise may exist and have a
greater effect on overdispersion than the library preparation effect at positions with large sequencing
depth.

Figure 3.1 The overdispersion of proportion
on base pairs versus the mean tag counts in base 10
log scale. The
values were computed from replicates from the Lichun spike-in training dataset.
The blue and red points are for the positions with a local sequence starting with GGGG and AAAA,
respectively.

3.2.2 Sequencing Procedure Introduced Extra Noise
Elements of the sequencing procedure (e.g., fragmentation methods, random hexamer priming,
etc.) usually introduce bias to RNA-seq measurements. We examined the overdispersion rate
estimated from two datasets (Figure 3.2). Interestingly, in the Lichun dataset, the overdispersion rate
was significantly larger at the tail of the gene (less than about 200 base pairs). However, no such
difference was observed in the Bullard dataset. The same results were obtained in the calculation of
the variance (Supplementary Figure S3.1).
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To explain these findings, we inspected the Lichun and Bullard protocols. We found three
major differences between them. First, Lichun et al. applied the dUTP protocol to obtain strandspecific sequencing, while Bullard et al. used a regular non-strand-specific sequencing protocol.
Second, Lichun et al. performed paired-end sequencing, while Bullard et al. tried to obtain singleend sequencing data. Third, fragmentation was carried out before PCR in creating the Lichun
dataset; while PCR was performed first in creating the Bullard dataset. The first two differences were
ruled out as potential causes for the extra noise on the gene tails in the Lichun dataset, because those
differences would not influence the measurement of only part of the gene. However, the third
difference can explain the extra noise. In the Lichun dataset, the fact that fragment selection was
performed after fragmentation might lead to the loss of many fragments located at the gene tails,
thereby introducing an extra error. By contrast, according to the protocol used by Bullard et al.,
fragmentation was carried out before cDNA PCR and size selection. Thus, it was more like a random
process across the whole gene, and thus no difference would be observed.
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Figure 3.2 The overdispersion rate estimated on any position in 10 equal categories according to the
distance of that position from the last nucleotide of the gene. (a) Lichun spike-in dataset. (b) Bullard
dataset. Lichun reads start to appear at 76 nt away from the end of the gene because only mate2 on
the antisense strand was investigated and the last sequencing reads were mapped to 76nt before the
ending. However, Bullard reads start from 50 nt away from the end of the gene because we
truncated the genes by 50 nt from the gene head and tail separately.

3.2.3 Models of the Overdispersion Rate
We proposed three models to examine the relationship between the local primer sequence and
the overdispersion rate, including the full model, the reduced model, and the counts-excluded model.
Using the linear formula transformation (Eq. 5), 240 coefficients of 80 positions around the primer
were estimated efficiently. By modeling on the Bullard data, we plotted those coefficients estimated
against their corresponding positions (Figure 3.3). We observed a pattern in our counts-excluded
model that was similar to the pattern reported in the papers by Hansen et al. and Li et al. [3,4]
(Figure 3.3 a,c). However, no such pattern was observed with our full model (Figure 3.3 b,d).
Observations were similar for the Lichun spike-in data (Figure 3.4). Both Hansen et al. and Li et al.
demonstrated a relationship between hexamer primers and measurement count number. Plus, from
Figure 3.1, we conclude that the overdispersion rate on base pairs decreases with increasing
sequencing depth. It is reasonable to infer that using a hexamer primer might influence the
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overdispersion rate by affecting the count number; thus, upon stratification by counts, the
relationship between the use of a hexamer primer and the overdispersion rate would no longer be
significant. In addition, we calculated

using the cross-validation method (Methods 3.1.5).

values of 0.481 and 0.488 were obtained for the reduced model and the full model, respectively, with
the Bullard data; while values of 0.270 and 0.273, respectively, were obtained with the Lichun spikein data. About half of the variance was explained for the Bullard dataset, while the relatively lower
was obtained for the Lichun dataset because of its small sample size (only 100 ERCC genes). As
expected, compared with the full model, the reduced model achieved a rather similar

.

We investigated the influence of primers corresponding to the reads mapped to the antisense
and sense strands, respectively. We observed from the Bullard dataset that reads mapped to the
antisense and sense strands showed quite similar patterns (Figure 3.3 a,c), which was consistent with
the finding of Hansen et al. [3]. However, according to sequencing protocols, the sense strand reads
should not have a bias caused by the use of a hexamer primer as the second strand is synthesized by
RNAse H niche technology. The explanation of Hansen et al. [3], that the hexamer primer is not
completely digested, is quite reasonable. In contrast, different patterns on the sense and antisense
strands were observed in the Lichun spike-in dataset (Figure 3.4 a,c). The reason for that is still
unknown; one or multiple processes in their strand-specific protocol might impact differently on the
paired-end reads. As suggested by the above observations, we estimated coefficients separately for
each strand in the present study.
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Figure 3.3 Coefficients estimated from linear models from the Bullard dataset. Plotted on the x-axis
are the positions around the 5’ end of mapped reads, labeled 0. Coefficients were calculated by 2
models. (a) Counts-excluded model on antisense strand. (b) Full model on antisense strand. (c)
Counts-excluded model on sense strand. (d) Full model on sense strand.
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Figure 3.4 Coefficients estimated from linear models from the Lichun dataset. Plotted on the x-axis
are the positions around the 5’ end of mapped reads, labeled 0. Coefficients were calculated by 2
models. (a) Counts-excluded model on antisense strand. (b) Full model on antisense strand. (c)
Counts-excluded model on sense strand. (d) Full model on sense strand.

3.2.4 Comparison of Four Models
Likelihood-value goodness of fit. Comparing maximum likelihood values is a straightforward
way to select models. We calculated the likelihood values from four models: the binomial model,
beta-binomial model with a constant overdispersion rate of
as in Eq. 6, and full beta-binomial model with
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, reduced beta-binomial model with

as in Eq. 4. Then, the percentage of change in

the likelihood value of each model was measured compared with the next neighbor model that
preceded it (Figure 3.5 a,b). As expected, models with more parameters had higher maximum
likelihood values. The beta-binomial model with a constant overdispersion rate of
jump from the binomial model (30% to 90%). And the parameter

in dynamic

made a huge
(Eq. 6) also

improved the fit by roughly 15%. However, the full model we proposed showed almost the same
maximum likelihood value as our reduced model. Further, the goodness-of-fit
beta-binomial model with a constant overdispersion rate of
with

test showed that the

and the reduced beta-binomial model

as in Eq. 6 (p-value = 0) improved the fit significantly more than the full beta-binomial

model with

as in Eq. 4 (p-value = 1). Additionally,

measured for the four models showed

that the reduced model had the least score and there was an increase for the full model (Figure 3.5 c).
The above results were observed in both the training and the test datasets and suggested that a
dynamic overdispersion rate significantly improves the model fit and that our reduced model is a
better choice than the other three models. Although we observed the same pattern with the Bullard
dataset (Figure 3.5 b,d), no such significant improvement was shown, even for the second model.
This is due to the small experimental library effect in the Bullard dataset, which was reported in our
previous study [73]. Consistent with our earlier conclusion, we found that overdispersion rates vary
dramatically in different studies.

43

Figure 3.5 Goodness-of-fit examination. (a,c) Lichun dataset. (b,d) Bullard dataset. (a,b) The
percentage of change in the likelihood value comparing neighboring models. (c,d)
measured for
4 models. bi denotes binomial model, bb+D denotes beta-binomial model with constant
overdispersion rate, bb+D+g denotes reduced beta-binomial model, and bb+D+g+coe denotes full
beta-binomial model.

FDR and AUC. Further, we compared the FDR and AUC for genes deemed to be differentially
expressed by these four models. Bullard UHR sample data showed that our reduced model as well as
the full model had the lowest FDRs and largest AUCs (Figure 3.6 c,d). Again, as a result of the small
library effect, no big difference was observed between the four models for the Bullard dataset, which
agrees with our previous results [73]. Also, our proposed reduced models showed a good
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performance for the Lichun spike-in data, though the binomial model with a constant overdispersion
rate seemed superior (Figure 3.6 a). Using the same overdispersion rate parameters, our analysis
showed a similar result when testing the human samples from the Lichun dataset (Figure 3.6 b). Our
FDR and AUC results indicate that among these four models, the binomial model had the worst
performance and the beta-binomial models with a dynamic overdispersion rate were preferable,
although the beta-binomial model with a constant overdispersion rate had the lowest FDR caused by
overfitting. Testing the same sample and different library preparations sequenced by the Illumina
sequencer, the beta-binomial model with a constant overdispersion rate shows insufficient small pvalues (Figure 3.7 a), and the binomial model has an overabundance of small p-values (Figure 3.7 b).
In contrast, the histogram of the p-values is flat for the beta-binomial models with a dynamic
overdispersion rate (Figure 3.7 c,d). This indicates that the errors between samples from different
library preparations are consistent with the beta-binomial distribution with a dynamic overdispersion
rate.
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Figure 3.6 FDR and ROC curves for 2 datasets. (a) FDR for Lichun spike-in dataset. (b) FDR for
Lichun human dataset. (c) FDR for Bullard dataset. (d) ROC curve for Bullard dataset. About 1000
genes previously assayed by real-time PCR are used as a gold standard to evaluate our test method.
In FDR plots, the FDR on the y-axis is plotted against the -values in log10 scale on the x-axis. bi
denotes binomial model, bb+D denotes beta-binomial model with constant overdispersion rate,
bb+D+g denotes reduced beta-binomial model, and bb+D+g+coe denotes full beta-binomial model.
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Figure 3.7 Histograms of p-values from replicates of the Bullard dataset. P-values were calculated by
(a) binomial model, (b) beta-binomial model with constant , (c) the reduced beta-binomial model
and (d) the full beta-binomial model. In histogram plots, the blue line indicates estimated uniform
distributions; green line indicates the mixture distribution of beta distribution and uniform
distribution [77].

3.2.5 Comparison of Our Model with DESeq
Compared with our method, DESeq performed slightly better on the AUC (Figure 3.6 d). This
is reasonable because DESeq estimated variance by local regression, which is more flexible than our
parametric method. Both DEseq and our reduced model were better than the binomial model and
significantly superior to the student t-test (Figure 3.6 d). The weak performance of the t-test might be
because of the small sample size.

3.3. Discussion
In this study, we found that the overdispersion rate decreases as the sequencing depth increases
on the base-pair level, in agreement with what we previously reported on the gene level [73]. Also,
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we found that the influence of random hexamer priming on the overdispersion rate is not significant
after stratification by sequencing depth. Finally, compared with our other proposed models, we
found our beta-binomial model with a dynamic overdispersion rate to be superior. Furthermore, as
expected, this model was more desirable than DESeq in a comparison of samples without biological
variance.
The property of overdispersion in our model. In this study, we demonstrated that, comparing the
reads mapped on specific base pairs, the overdispersion rate decreases as the RNA-seq depth
increases. This discovery is consistent with the findings of our previous study at the gene level
(described in Chapter 2). First, we observed a strong linear association between the calculated
overdispersion rate and the count number. Second, compared with models that ignore the
overdispersion rate or which have a constant overdispersion rate, our model that accounts for a
dynamic overdispersion rate fit the RNA-seq counts best, demonstrating superior performance based
on the likelihood value, AIC, goodness-of-fit

test, and the testing error indicators FDR and AUC.

Rather than considering that the total experimental dataset has a constant variance parameter, other
testing methods had been developed as well, including DESeq. DESeq assumes that genes with
similar expression levels have the same variance. DESeq performed better than both the models that
ignore the overdispersion rate and those with a constant overdispersion parameter [30].
Experimental protocols affect variance. We concluded that experimental protocols have
different impacts on the variance of the RNA-seq reads and that even the order of the steps in the
protocol matters. We observed extra noise on the tails of genes when fragmentation was performed
before PCR. Therefore, we suggest removing the reads on the last 200 base pairs when data from this
kind of protocol are analyzed. Because RNA-seq technology involves complex experimental
protocols, many biases have been found in library generation, read mapping, and coverage.
Systematic errors have been found in differential RNA-seq protocols and platforms [80,81]. Our new
finding that conducting fragmentation before PCR introduces extra noise will allow us to develop
specific strategies to avoid these biases in our analyses.
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Effect of spike-in data on overdispersion rate estimation. Cost issues may prompt consideration
of performing experiments without replicates. As measured along with samples that do not have
replicates, spike-in samples can be considered as replicates. Our model has only three parameters
(Eq. 3 and Eq. 6); therefore, it is quite sufficient to estimate them from roughly 100*1000 counts
based on base pairs. Consequently, when testing samples without replicates, one still can borrow the
overdispersion rate from the spike-in data. DESeq also tries to handle experiments without replicates
by assuming that most genes do not change in expression [30]. However, based on the analysis of
samples from a single cell line, our observations indicate that the variance of replicates between two
libraries is smaller than the variance between two conditions (Supplementary Figure S3.2). The extra
variance caused by gene expression changes would lead to the loss of test power.
Selection of variables. We observed that the overdispersion rate is related to both the local
sequence and the sequencing depth. Therefore, we proposed a full model with both variables and a
reduced model with only the count number as a variable. The results showed that with the covariate
count number, the local sequence has little influence on the overdispersion rate. That is reasonable as
the local sequence and count number are dependent, as reported by two groups [3,4]. Consequently,
it is preferable to use a model with only the count number as a variable for estimating the
overdispersion rate. And we concluded that the reduced model was a better choice for modeling the
overdispersion rate and was reasonably economical in terms of time and computing power.
Our model vs DESeq in application. DESeq is widely used in DE testing on RNA-seq. That
model performed well when estimating the variance of the counts, including the biological variance.
Our model has four main advantages: (1) Modeling based on the proportion in a base-pair unit and
modeling the non-uniformity of measurement across the gene. As for the uniformity of measurement,
the measurement on each base pair has a specific mean and variance. When considering the total
counts as the indicator of the expression level, the estimated expression of one particular gene might
be determined by several positions with high counts. Therefore, modeling on the proportion is more
desirable because it avoids modeling the highly fluctuating Poisson rate. (2) Tags from strongly
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fluctuating positions are down-weighted. Gene expression is no longer the sum over tags from all
positions, but is weighted by the overdispersion rate. (3) Our model is based on base pairs with much
higher resolution. (4) Spike-in data can be utilized as replicates when estimating the overdispersion
rate. (5) With the information from the spike-in data, more accurate estimations can be obtained on
samples without replicates, as discussed above. Our model and DESeq are compared in Table 3.2.
DESeq testing is performed on the gene expression level, with the hypothesis that the normalized
reads on one gene are equal for two samples. In contrast, our model tests on the base pair level with
the hypothesis that the normalized reads on each base pair are equal for two samples. Consequently,
it depends more on the hypothesis whether there is no difference in the pattern of expression across
one specific gene. To reject the null hypothesis that measurements on each base pair are equal, our
model is desirable for identifying differential expression on partial genes, but to reject the null
hypothesis that measurements on one gene are equal, our model is more suitable for samples with
library preparation variance than for samples with biological variance. Also, in this study, we
investigated the relationship between overdispersion and the sequencing depth using replicates from
the same biological samples. This relationship for different biological samples remains elusive. In
other words, our model is desirable for experiments involving samples from a single cell line or the
same animal, such as experiments involving one knockout gene from a single cell line. We suggest
applying our model to experiments involving samples without biological variance; otherwise, DESeq
is more appropriate. In a future study, we will investigate the properties of overdispersion
introduced by biological variance.

Table 3.2 Comparison of our model with DESeq
Our Model

DESeq

Main overdispersion source

Library effect

Library effect + biological variance

Hypothesis

measurement on each base pair are

measurement on each gene are equal
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equal
Experiments suitable for analysis

All, especially for single cell line

All

Nonuniformity modeling

Yes

No

Borrow information from spike-in data

Can

Can not

Parameter estimation

Maximum likelihood estimation

Local regression (depends on local
structure)

Unit for modeling

Base pair

Gene

Expression estimation

Tags were weighted by overdispersion

Sum over tags

rate
Replicates required

No, but require hypothesis that most of

No, but require hypothesis that most of

genes do not change between samples

genes do not change between samples

within two conditions, which is

within two conditions, which is

inaccurate. Also our method can use

inaccurate.

spike-in data

Many models have been reported to test DE from RNA-seq data. However, it would make
much better sense to model the non-uniform measurements of this technology. We modeled the
proportion of counts toward this aim, but encountered a limitation of our approach, which is that it
may not handle biological variance precisely. Therefore, our model is most appropriate for
experiments involving samples from a single cell line or the same animal. The current study provides
a detailed understanding of the relationship between the overdispersion rate and sequencing depth,
which will aid in the analysis of RNA-seq data for detecting and exploring biological problems.
Additionally, we suggest a more desirable beta-binomial model with a dynamic overdispersion rate
to cancel the non-uniformity bias and estimate the overdispersion rate more accurately.
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CHAPTER 4
A New Type of Bias in RNA-seq

RNA-seq has been widely used in genomic research. However, many studies have reported that
inherent biases and spurious effects exist in sequencing technology because of the complexity of the
protocol and mechanisms studied. We aim to investigate biases in RNA-seq by exploring the
measurement of an external control, spike-in RNA. Tag hybridization has been reported to be the
major process through which bias is introduced into microarray analysis. Signals from spike-in
transcripts could be influenced by cross-hybridization with tags designed for detecting target
transcripts. However, the relationship between spike-in transcripts and sample transcripts has not
been fully studied yet. Apart from a concern with cross-hybridization in sequencing technology, it is
easy to overlook other possible factors that influence the sequencing measurements. Therefore, this
study is important and could aid our understanding of sequencing technology and benefit
downstream analysis.
This study is based on two datasets with spike-in controls. The Encode dataset contains
measurements from 51 replicates of human samples, and the modENCODE dataset contains
sequences from 6 fly samples under difference scenarios. Detailed investigations and correlation
analyses were performed among the samples. Also, the alteration of measurements between two
samples was modeled with the local sequence as a factor. Furthermore, correction was performed
based on the modeling.
We found that an undiscovered bias exists within the measurement of spike-in transcripts, and
that it is influenced by the sample transcripts in RNA-seq. Also, we found that this influence is
related to the local sequence of the random hexamer used for priming. We suggested modeling the
inequality between samples and correcting for this type of bias. After this correction, the Pearson
correlation coefficient increased by 0.1. Thus, we revealed a new bias that may be introduced by
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resource competition. The current study provides a detailed understanding of the relationship
between this new bias and the local sequence, which will aid in our understanding of RNA-seq
technology and allow us to correct this bias in the analysis of RNA-seq data.

4.1 Methods
4.1.1 Datasets Used
Two datasets from Lichun et al. [24], ENCODE and modENCODE, containing synthetic spikein standards from the External RNA Control Consortium (ERCC) were used (Table 4.1).
ENCODE. ENCODE datasets consist of several libraries with different human RNA sources
(whole cell, cytosol, and nucleolus) and identifications (longPolyA and longNonPolyA). These data
were sequenced along with human samples. The libraries had been prepared using the dUTP protocol
for measuring strand-specific transcripts, as described by Lichun et al. [24]. From Illumina GAIIx,
2x76 bp sequencing reads were obtained. The reads were mapped to the human genome (hg19) using
STAR software, and the ERCC libraries were mapped using Bowtie, version 0.11.3, with parameters
–v2 –m1. To avoid the transcription initiation bias in the sequencing [79], we truncated 50
nucleotides on both ends.
modENCODE . The D. melanogaster S2 cell line was used to prepare poly-A+ mRNA. As
shown in Table 4.1, modENCODE datasets were obtained from two batches, and each sample was
made from a specific library preparation. In batch 1, samples were from four different sample RNA
pools, but the sample RNA was from the same pool. The ratio of ERCC and the total RNAs are
shown in Table 4.1. Four experiments in batch 1 have ERCC concentrations of 5%, 2.5%, 1% and
100%, which means that only pure ERCC was sequenced. Experiments in batch 2 have the same
ERCC concentration of 2.5%. The cDNA was fragmented and the first-strand cDNA was
synthesized with random hexamer primers, then the second-strand DNA was synthesized, followed
by end repair, poly A addition and adapter ligation. Two methods were used in the preparation. In
method A, size selection preceded PCR amplification. This was reversed in method B. The Illumina
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GA II platform yielded 36-bp reads. Bowtie version v0.10.0 with parameters -m 1 -v 2 was used to
align the reads to the Drosophila genome sequence (BDGP release 5, dm3) and ERCC reference
sequence. Also, 50 nucleotides were truncated on both ends.

Table 4.1 Two datasets used

Samples
GSM758559 GSM758560 GSM758561 GSM758562 GSM758563 GSM758564
GSM758566 GSM758567 GSM758568 GSM758572 GSM758573 GSM758575
GSM758576 GSM758577 GSM758578 GSM765386 GSM765387 GSM765388
GSM765389 GSM765391 GSM765394 GSM765395 GSM765396 GSM765398
GSM765401 GSM765402 GSM765403 GSM765404 GSM765405 GSM767840
GSM767844 GSM767845 GSM767847 GSM767848 GSM767849 GSM767850
GSM767851 GSM767852 GSM767853 GSM767854 GSM767855 GSM767856
GSM758565 GSM758569 GSM765390 GSM765392 GSM765393 GSM765399
GSM765400 GSM767846 GSM767857

ENCODE
(51 replicates)

Library

modENCODE

1
2
3
4
5
6

Samples

Sample RNA

ERCC

pool

%

1
2
3
4
5
5

5
2.5
1
100
2.5
2.5

Batch

GSM517059
GSM517060
GSM517061
GSM517062
GSM516588
GSM516589

1
1
1
1
2
2

Method

A
A
A
A
A
B

4.1.2 Correlation Analysis of Multiple Samples
To assess the correlation of multiple samples, we calculated the Pearson correlation coefficients
on both the gene level and the base level. We sum over the measurement reads on each gene to
evaluate the correlation on the gene level and use data on 96 spike-in genes. In comparison, we
assess the correlation from the measurement reads on each base pair and use a total of 86,329 reads
counts. Hierarchical clustering was performed on the calculated Pearson correlation coefficients to
investigate the correlations across multiple samples.
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4.1.3 Local Sequence Modeling on Measurement Difference across Samples
In order to model the influence of the local sequence on the measurement difference across
samples, we developed a linear model with different sequences on each position as variables. As the
outcome variable we used the fold change, which was widely used for measuring change in the
expression level of a gene. A log transformation of the fold change would be required in the
following linear models.
∑

∑

(

)

( )

In this model, we linked all genes head to tail into one gene. Here, denotes the -th position on
the imaginary gene;
, where

denotes the fold change of reads across two samples on the -th position by
and

are the measurements on the -th position of two samples,

the length of the probe around the -th nucleotide of the imaginary gene. We set
suggested in a previous study [4]. Also, (

and .

is

as

) is 1 when the -th base pair is letter , which is

A, T, or C exclusively, and 0 otherwise. The parameters we want to estimate are

and

, and is

Gaussian noise.
Li et al. used a similar model to predicate measurement reads from RNA-seq [4]. This linear
model made the estimation fast and robust. A total of 3 x 80 = 240 parameters on the local sequence
were estimated, which is rather a small number compared to the sum of all the positions in all the
genes. For the spike-in transcripts, we used reads on all ERCC genes. However, we only used reads
on the top 1000 highly expressed genes for the sample transcripts. In order to avoid noise introduced
by the low number of reads, we discarded all data points with reads less than 30 mapped to the
mRNA transcripts and 5 mapped to ERCC.

4.1.4 Estimating Cross-validation
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We used the leave-one-out cross validation strategy to estimate

. Data points used in

modeling were randomly split into five groups of equal size. In each round, we fit our model using
four of these five groups, and then calculated

on the remaining subset by the regression sum of

squares divided by the total sum of squares. The final cross-validation

was determined as the

mean.

4.1.5 Bias Correction
Once the parameters

and

in Eq 1 were estimated, we performed the bias correction based

on our model according to Eq 2. We randomly split the data points into five parts and used four of
them as the training data and left one out to serve as test data for evaluating the correction.
( )
In this equation,
gene of sample

denotes the corrected measurement on the -th position of the imaginary

according to the coefficients on the local sequence of the probe calculated from

the fold change of reads across two samples.

4.2 Results
4.2.1 Pattern of Reads on Spike-in Transcripts
In order to investigate the sequencing reads on each position of the spike-in transcripts, we
plotted the read counts mapped on the spike-in transcripts. Figure 4.1 shows an example of ERCC00002, one of the genes with the highest yield of reads. We observed that the pattern of reads of the
spike-in transcripts were divergent between samples, although they were consistent between
replicates from the ENCODE datasets. And from the modENCODE datasets, we observed that the
patterns of the reads differed between batches, but the influence of the different libraries was small.
And we noticed a dissimilar pattern in experiments with both ERCC and a sample pool when
compared with experiments that used only pure ERCC transcripts. However, no significant
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difference was found for the different order of size selection and PCR amplification in sample
preparation. We validated our finding statistically by comparing correlations of the sequencing reads
from pairwise samples (described in Methods, 4.1.2). From the heatmap of hierarchical clustering
based on correlations of counts on each position across samples (Figure 4.2) and pairwise correlation
plotting of modERCC datasets (Figure 4.3), we observe that replicates are clustered together for the
ENCODE samples and samples in the batch are clustered together, except the samples from
sequencing pure ERCC transcripts. Without sample mRNA, the dissimilar of correlation between
batches was reduced but increased when other samples were sequenced along with the sample
transcripts in the same batch. Also, we concluded that compared with the correlation of the total
counts on each gene, the correlation of the counts on each position was more precise (Figure 4.2).
The same patterns of correlation across samples were also observed on target transcripts (Figure 4.2
E, F). The top 1000 highly expressed genes were used to calculate the correlation. Distinct patterns
were observed on both the base level and the gene level, which might indicate that the discrepancy
originated in the sample transcripts.
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A

B

Figure 4.1 Distributions of sequencing reads on ERCC-00002 of different samples. The positions of
ERCC-00002 are plotted on the x-axis and the number of sequencing reads are plotted as bars. The
distribution of sequencing reads on ERCC-00002 samples from (A) ENCODE datasets and (B)
modENCODE. The same label denotes the replicates.
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A

B

C

D

E

F

Figure 4.2 Heatmaps of hierarchical clustering on samples. The clustering was based on correlations
of (A) counts on each position of spike-in transcripts across samples of ENCODE datasets, (B)
counts on each gene of spike-in transcripts across samples of ENCODE datasets, (C) counts on each
position of spike-in transcripts across samples of modENCODE datasets, (D) counts on each gene of
spike-in transcripts across samples of modENCODE datasets, (E) counts on each position of the top
1000 highly expressed sample transcripts across samples of modENCODE datasets, (F) counts on
each gene of the top 1000 highly expressed sample transcripts across samples of modENCODE
datasets.
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Figure 4.3 Pairwise comparison matrix of the measurement on each base pair of ERCC transcripts
from modENCODE dataset. Pairwise plots of sequencing reads mapped on each base pair on the
log10 scale are shown in the bottom panel, and calculations of pairwise Pearson coefficients are
shown in the top panel.

4.2.2 Modeling on the Local Sequence
We modeled the influence of the local sequence. Using the linear model, we estimated 240
coefficients of 80 positions around the primer from modENCODE mRNA and spike-in reads
separately. We plot those estimated coefficients against their corresponding positions in Figure 4.4.
We observe that significant coefficients were estimated from the difference between two samples
from two batches, as well as separately from the comparison of two samples with and without target
transcripts. The significant coefficients expanded to a range from -20 to 15 around the start site of
the primer. As expected, no significant coefficients were found by comparing samples with different
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ERCC concentrations in the same batch. And interestingly, the order of the size selection and PCR
amplification only affected the measurements through the first 2 nt of the hexamer primer.
Consistent with our above findings, the patterns of the coefficients were concordant between mRNA
and ERCC. Cross-validated

were calculated from the sample mRNA transcripts as shown in Table

4.2, indicating our model could explain around 40% of the differences in two samples.

ERCC

mod mRNA

GSM517059 vs
GSM517062

GSM517060 vs
GSM517061

GSM517088 vs
GSM517089

GSM517088 vs
GSM517059

Figure 4.4 Coefficients estimated by the linear model, Eq.1, from the modENCODE dataset. Plotted
on the x-axis are the positions around the 5’ end of the mapped reads, labeled 0. Coefficients were
calculated on ERCC spike-in transcripts (left panel) and mod mRNA transcripts (right panel).
Comparing GSM517059 vs GSM517062 captures the discrepancy from ERCC with and without
mRNA transcripts. Comparing GSM517060 vs GSM517061 captures the discrepancy from the
ERCC ratio (2.5% vs 1%). Comparing GSM517088 vs GSM517089 captures the discrepancy from
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the order of the sample preparation (size selection preceding PCR amplification vs the reverse order).
Comparing GSM517088 vs GSM517059 captures the discrepancy from different batches.

Table 4.2 Cross-validated

GSM516588
GSM516589
GSM516590
GSM517059
GSM517060
GSM517061

GSM516588
-

GSM516589
0.257
-

GSM516590
0.274
0.035
-

Calculated
GSM517059
0.299
0.382
0.408
-

GSM517060
0.313
0.371
0.390
0.138
-

GSM517061
0.260
0.329
0.348
0.172
0.163
-

4.2.3 Correction of bias
We estimated the coefficients of the local sequence by comparing the training set randomly
selected from two samples. According to our model and estimated coefficients, we performed a
correction on the test set. As a result, our correction increased the Pearson correlation from 0.48 to
0.58 (Figure 4.5).

Figure 4.5 Pairwise comparison matrix of the original and corrected measurements on each base pair
of mRNA transcripts. Pairwise plots of sequencing reads mapped on each base pair on the log10
scale are shown in the bottom panel; calculations of the pairwise Pearson coefficients are shown in
the top panel.
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4.3 Discussion
In this study, we found that an unreported bias in the measurement of spike-in transcripts exists,
and that it is influenced by sample transcripts in RNA-seq. Also, we found that this influence is
related to the local sequence of the random hexamer used for priming. We proposed to model the
inequality between samples and suggested a method to correct this bias based on this model.
A new Bias in RNA-seq. In our study, when comparing the reads mapped on specific base pairs,
we found similar patterns in replicates but not across different samples. Although many factors could
contribute to this discrepancy, we failed to observe a significant difference from the preparation
methods and library preparations. This indicates that inconsistency in the library preparation did not
contribute to this bias. Interestingly, a rather significant difference was observed on the measurement
of the spike-in transcripts sequenced along with different sample transcripts. And diverse sample
sources or batches could result in the difference in the sample transcripts. Cross-hybridization has
been reported as an inherently problematic issue in microarrays. Unspecific tags could hybridize
with other sequences besides the target and introduce a bias in measurements [10,11]. The
measurement of spike-in transcripts could be influenced by incorrect interactions with probes
designed for target transcripts [13]. Similar to cross-hybridization in microarrays, a mechanism may
exist that affects the measurement of spike-in transcripts by sample transcripts. This mechanism may
be from the competition of sequencing resources, such as dNTP and the hexamer primer. The source
of this bias needs to be studied further for clarification..
In this study, we proposed a statistical method to model the influence of the local sequence on
this new bias. And we observed significant coefficients ranging from -20 to +15 around the
beginning of the hexamer primer. This range of coefficients has been reported in the study of nonuniformity by Li et al. [4] and in our study of overdispersion in Chapter 3. This finding may indicate
that the bias from hexamer priming affects more than one property. Besides affinity abilities,
resource competition involving the hexamer primer may play a role in introducing bias. Our model
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can be used to correct this type of bias, and, indeed, the Pearson correlation coefficient increased by
0.1 after we made this correction.
Novelty and strength of our study. First, we discovered a new type of bias that may be generated
from resource competition and which is related to the local sequence, as described above. We
suggested a statistical model to model the bias and perform the correction. Our findings will
contribute to understanding RNA-seq technology, exploring inherent biases and estimating true
measurements for downstream analysis.
Second, for the first time, to our knowledge, we found that the order of size selection and PCR
amplification could influence the measurement through the first 2 nt of the hexamer primer in RNAseq. One possible explanation is that PRC amplification is influenced by the first 2nt of the reads and
causes the bias, together with the size selection by the imprecise isolation of agarose gel
electrophoresis.
Third, we demonstrated that a comparison of measurements on each position is more precise
than a comparison based on the gene. In this study, we observed much more precise correlations of
measurements between replicates with higher resolution compared with correlations on genes.
Therefore, we suggest utilizing all information from all base pairs in analyzing sequencing data.
However, more exhaustive research on sequencing bias and sophisticated methods were required in
this analysis. We have suggested a powerful method to estimate the overdispersion rate based on
base pairs (Chapter 2).
Fourth, rather than modeling based on measurements of one sample, we modeled the fold change
between two samples. Benefiting from this effort, we discovered the new bias and were able to offer
a method of correction.
Many biases have been reported in RNA-seq data and several methods have been proposed for
bias correction. However, the research on RNA-seq technology is still in its infancy. Here, we
revealed a new bias that may be introduced by resource competition. Our study provides a detailed
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understanding of the relationship between this new bias and the local sequence, which will aid in
understanding RNA-seq technology and in correcting for this bias in the analysis of RNA-seq data.
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CHAPTER 5
New CpG Island Methylator Phenotype (CIMP) and Biomarker
Identification by Integrating Methylation and mRNA Expression

The expression of a gene can be turned off when its promoter is highly methylated. Several
studies have reported that a clear threshold effect exists in the gene silencing that is mediated by
DNA methylation. It is reasonable to assume that a specific DNA methylation threshold exists for
each gene because of the complicated transcription regulatory system. Therefore, we must determine
that threshold in order to predicate whether the gene was inhibited by DNA methylation. According
to the estimated thresholds, DNA methylation status could be dichotomized and makes the task of
biclustering easier, which is a good way to identify CIMP. We aimed to develop a method to
determine the DNA methylation threshold and investigate whether CIMP exists in breast cancer.
Only limited research has claimed the identification of CIMP with hypermethylated genes in breast
cancer.
We developed a method to determine the DNA methylation threshold from 997 samples across 7
cancer types from TCGA datasets obtained from Illumina Infinium Hman DNA Methylation27
arrays and Illumina GA II and HiSeq platforms. Then, from 285 tumor samples and 21 normal
samples of breast tissue, we selected 128 “L-shaped” genes according to our criteria and identified
CIMP by biclustering and hierarchical clustering. Gene-set enrichment analysis and correlation
analysis on expression, mutation and clinical features were performed.
We suggested a method based on mutual information calculation to determine the threshold of
DNA methylation and distinguish the genes for which the expression levels were significantly
regulated by DNA methylation. Based on the dichotomized methylation status predicated on 128
“L-shaped” genes, we identified a new CIMP of BRCA with 11 markers. We observed significant
correlations of CIMP+ with wild-type TP53 mutation, ER+/PR+ positive status, higher age at initial
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pathologic diagnosis, better treatment response and perhaps a longer survival time. The 11 CIMP
markers were shown to be associated with TP53 directly or indirectly, and were enriched in cancer
and other disease networks. Also, we found that 7 epigenetic genes were correlated strongly with
both the new CIMP and TP53 mutation. Based on our findings, we proposed a model of a TP53mediated regulatory network with two components: “Guidance” and “Sustainer.”
We developed a powerful method to dichotomize the methylation status and identify a CIMP of
breast cancer with a distinct classification of molecular characteristics and clinical features. Our
results suggest that methylation may play an important role in resisting tumor development. The
regulatory component of “Guidance” which we defined, and genetic modifiers BMI1, IDH1 and
TET1 might be potential targets for new treatments.

5.1 Methods
5.1.1 Datasets Used
Methylation datasets. We obtained methylation datasets from TCGA generated by the
Illumina Infinium Human DNA Methylation27 array for 3382 samples across 12 cancer types (Table
5.1). For breast cancer, 318 tumor and 29 normal samples were measured. Level 3 preprocessed data
were available for beta values, which is the ratio of the methylated probes among all probes for each
detected site.
mRNA expression datasets. Also from TCGA, we downloaded mRNA expression datasets
generated by the Illumina GA II and HiSeq platforms. Data for 2271 samples across 9 cancer types
were available as of February 25, 2012 (Table 5.1). For breast cancer, 775 tumor and 102 normal
samples were measured. In each sample, RPKM for 20532 genes were calculated as level 3 data. In
order to avoid the 0 value, we replaced them with the minimum non-zero value of the same gene
among all samples. And we took log2 scale of the RPKM value.
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Overlapping datasets used in mutual information (MI) calculation. A total of 997 samples
across 7 cancer types had both methylation status and mRNA expression data (Table 5.1). Among
these 997 samples, 285 tumor and 21 normal samples were measured for breast cancer.

Table 5.1 Datasets used
BRCA

COAD

GBM

KIRC

KIRP

READ

LAML

LUSC

LUAD

OV

STAD

UCEC
117

LIHC

HNSC

DNA Methylation

Tumor

318

168

296

438

16

70

384

134

128

576

82

(3382)

Normal

29

45

6

410

6

11

0

32

27

25
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mRNA Expression

Tumor

775

192

468

16

71

221

306

17

18

(2271)

Normal

102

0

68

0

0

17

3

8

0

Overlapped

Tumor

285

161

207

16

67

126

113

(997)

Normal

21

0

0

0

0

0

0

3

5.1.2 Determining Methylation Threshold
Mutual information computation. Mutual information computation of the density of the
distribution can be improved by taking into account the natural measurement of uncertainty. At low
ranges of gene expression, especially for the log-transformed RNA-seq data, the large difference is
not real, but is due to the randomness of the measurement. This can introduce noise into the mutual
information calculation, especially when the number of samples is small. To solve this problem, a
pair of methylation-expression measurements is not assigned to its bin, instead, it is represented by a
smeared density function centered at the methylation-expression values. The uncertainties in both
directions are taken from the estimated measurement errors.
Measurement values were assumed to be distributed as normal distributions. Their uncertainties
were calculated from 6 replicates. Subsequently, we calculated the probability of expression and the
methylation value for each patient by summing up the probabilities from all patients. We can write
the joint and marginal probabilities as
(

∑

√
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is the marginal probability of the -th pseudo patient’s expression level of one

particular gene. Similarly,

is the marginal probability of the methylation

is the joint probability of the mRNA expression level and methylation

value. In Eq.(3),

value.

denotes the total

number of patients and pseudo and indicate the -th and -th patients, respectively. The expression
is denoted by

and the methylation values are denoted by

In addition,

and

are the

uncertainties in both directions for the -th patient.
In order to determine the methylation threshold, we slide the cutoff point from the minimum to
the maximum methylation values. Mutual information values are calculated for two parts besides the
cutoff, and the sum is taken as Eq.(4). In the same way, we can calculate expression mutual
information. Using Eq.(5), we calculated the “2-way” mutual information integrating mRNA
expression and DNA methylation.
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Criteria. Aiming to identify “L-shaped” genes, we applied the following three criteria: (1) the
range of mutual information is no less than 0.3, (2) samples are split into 4 quadrants by the
thresholds of mRNA expression and DNA methylation, with at least 200 samples located in each of
the first and fourth quadrants, (3) no fewer than 600 samples are in the first and the fourth quadrants.
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Binary coding. Once we obtained the threshold of the DNA methylation beta value, each gene
was assigned to 1 or 0, where 1 means the methylation status of a gene changed compared to that of
normal samples.

5.1.3 Gene Set Enrichment Analysis
MsigDB. MsigDB (http://www.broadinstitute.org/gsea/msigdb/index.jsp) has more than 6000
integrated datasets and a comprehensive analysis platform. It covers positional gene sets, curated
gene sets, motif gene sets, computational gene sets and GO gene sets.
BioProfiling.de . BioProfiling.de (http://www.bioprofiling.de/index.html) is another online tool
we used for comprehensive analysis of gene sets. It provides a handful of types of analysis, including
GO gene function, IntAct protein interaction and KEGG pathway relationships, cancer relationships
and miRNA regulatory predication.
Ingenuity Pathway Analysis (IPA). We used IPA software to obtain gene sets of enriched signal
pathways and found potential upstream regulators.

5.1.4 CIMP Identification
Biclustering. Finding contiguous blocks with changed methylation status is of interest and we
used the biclustering algorithm BicBin to handle our binary and sparse data matrices.
Hierarchical clustering. For the block found by Bicbin, we applied hierarchical clustering to
find biomarker genes of the CIMP. We used R package hclust and OOMPA, applying the “ward”
agglomeration method and the “binary” distance measure.

5.1.5 Clinical Correlation Analysis
We downloaded from TCGA a clinical dataset for breast cancer that contained 919 patient
samples, 316 of which overlapped with both the methylation and mRNA expression datasets. We
applied a generalized linear model to investigate the correlation of the methylation status with
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clinical features, including "pretreatment_history," "ajcc_cancer_metastasis_stage_code,"
"prior_diagnosis," "ajcc_neoplasm_disease_stage," "ajcc_tumor_stage_code," "gender,"
"age_at_initial_pathologic_diagnosis," "days_to_death,"
"breast_carcinoma_progesterone_receptor_status," "breast_carcinoma_estrogen_receptor_status,"
and "lab_proc_her2_neu_immunohistochemistry_receptor_status."

5.1.6 Survival Analysis
From the “days_to_death” values in the above clinical dataset, we applied the Cox model for
right-censored survival analysis using the R library “survival.” Also, we examined survival analysis
from BioProfiling.de based on texting mining information.

5.1.7 Mutation Analysis
We downloaded a genetic mutation pre-processed dataset from TCGA that contained 507
samples, 301 of which overlapped with both the methylation and mRNA expression datasets. Again,
we used a generalized linear model to inspect the correlation with methylation status and mRNA
expression.

5.1.8 Identifying TP53-Mediated “Rescue” Genes
“Guardian.” In this study, we identified the “guardian” genes of the TP53 system according to
the following criteria: (1) a significant different value exists for CIMP+ compared with normal
samples and CIMP-, with the same trend; and (2) no significant difference exists between CIMP- and
normal samples.
“Sustainer.” We identified the “sustainer” genes of the TP53 system according to the
following criteria: a significant different value exists for CIMP- compared with normal samples and
CIMP+, with the same trend.
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5.2 Results
5.2.1 Determining Methylation Threshold
For each gene, we calculated the mutual information score (MI score) on both the methylation
and mRNA expression dimensions according to Eq (5). As shown in Figure 5.1, along with the
increments in the measurement value on each dimension, the MI score decreased and then increased.
The point with the lowest MI score indicated the optimal threshold. A plot of mRNA expression
against DNA methylation would exhibit an “L” shape for a gene that could be turned off by DNA
methylation. As an example, the ESR1 gene is a typical “L-shaped” gene that encodes an estrogen
receptor that is an important breast cancer biomarker. From our analysis, 271 among 285 breast
cancer samples and all 21 paired normal samples showed ESR1 hypomethylation status and high
mRNA expression level (Figure 5.1 A). Compared with ESR1, HOXA9 showed a reverse “L” shape,
as the threshold of methylation was much higher and it was hypomethylated in breast cancer samples
but was hypermethylated in normal samples (Figure 5.1 B). The 3-D MI score of HOXA9 is shown
in Figure 5.2. Also, the results show that mRNA expression levels are dissimilar across cancer types
(Figure 5.1).
In Figure 5.3, for all genes, histograms of the thresholds identified show that they were enriched
in small methylation values and large mRNA expression levels. However, for genes with MI
differences larger than 0.3, the thresholds estimated were highly gene-specific, and they were
enriched in small mRNA expression levels, which is expected as the character of “L-shaped” genes.
Also, a small peak that is seen on the right tail of the histogram for mRNA expression might have
been formed by a reverse “L-shaped” gene, such as HOXA9 (Figure 5.3 D).
As expected, the MI scores of the “L-shaped” genes show a deep “U” shape (Figure 5.1). And
the depth of this kind of “U” shape shows the difference in the maturity of the information before
and after being split apart by the threshold cutoff. Therefore, the depth of this “U” shape is a good
indicator of “L-shaped” genes. The histogram of the depth, displayed in Figure 5.4, shows that 449
genes reached our criteria depth of 0.3. We performed a differential analysis between breast cancer
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and normal samples for both DNA methylation and mRNA expression. After adjusting for the FDR,
we plotted the p-values of differential methylation against that of mRNA expression. Using the
normal samples as the baseline, a minus score means the measurement of tumor samples is lower
than that of the normal samples. We observe in Figure 5.4 that genes with a deep “U” shape are
enriched in the lower-right and upper-left quadrants, which indicates that they tend to have correlated
methylation status and mRNA expression, in the way that high expression correlates with low
methylation status or low expression correlates with high methylation status. However, we also
observed reverse correlations of methylation status and mRNA expression for many genes. And,
based on depths larger than 0.3 as one of our criteria (see Methods), most genes were filtered out
because of moderate changes in MI scores.
In order to validate the hypothesis that beta value thresholds are tailored to each microarray
probe, we examined the MI scores of 29 genes as epigenetic prognostic signatures from the colon
cancer study by Yi et al [82]. As the dichotomized methylation status will more accurately reflect the
on-off state of a gene due to DNA methylation, we found that 16 of 25 overlapping genes have a
depth of MI score larger than 0.1 (compared with 2,363 genes among 12,783; chi squared test, pvalue 9.397e-05) (Table S5.1) and exhibit “L” shapes when the methylation value is plotted against
the mRNA expression value (data not shown).
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A

B

Figure 5.1 Threshold determination from integrating mRNA expression and DNA methylation
datasets. A) ESR1 gene; B) HOXA9 gene. Threshold determination of ESR1 genes and pattern of
mRNA expression against DNA methylation status is investigated for 997 patient samples across 7
cancer types (top left); red points are from BRCA samples; green points are from normal samples;
and blue points are from other cancer types. Mutual information score is calculated for DNA
methylation (top right) and mRNA expression (bottom left) by sliding the cutoff point. Thresholds
are determined with the minimal mutual information score (bottom right). B exhibits results in the
same way for the HOXA9 gene.
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Figure 5.2 3-D plotting of mutual information score calculated for HOXA9 genes.

A

C

B

D

Figure 5.3 Histogram of thresholds estimated. A, B are for all genes; C, D are for differences in MI
larger than 0.3; A, C are for DNA methylation status; and C, D are for mRNA expression level.

76

Figure 5.4 Comparison of transcriptome versus epigenetic differences between BRCA and normal
samples. Starburst plot is shown for comparison of DNA methylation and mRNA expression data for
12,783 unique genes. Log10 (FDR-adjusted p-value) is plotted for DNA methylation (x-axis) and
gene expression (y-axis) for each gene. If a mean DNA methylation β-value or mean gene expression
value is higher (greater than zero) in the BRCA samples, −1 is multiplied to log10 (FDR-adjusted pvalue), providing positive values. The dashed black lines indicate FDR-adjusted p-value at 0.05.
Data points in grey indicate no significance in the comparison. Data points in purple indicate mutual
information scores larger than 0.05; points larger than 0.1 are denoted by blue, and points larger than
0.3 are denoted by yellow. Points in red indicate genes identified to be differentially methylated
when comparing BRCA with normal samples by biclustering. A histogram of the marginal mutual
information score before and after data splitting is shown (bottom right).
5.2.2 Identification of “L-shaped” Genes
Aiming to investigate genes for which DNA methylation plays a large regulatory role, we
identified “L-shaped” genes according to the following three criteria on MI scores and a plotting
77

pattern: (1) the range of mutual information scores is not less than 0.3; (2) samples are split into 4
quadrants by the thresholds of mRNA expression and DNA methylation, and at least 200 samples
are located in each of the first and fourth quadrants; and (3) no fewer than 600 samples are in the
first and the fourth quadrants. As shown in Figure 5.1, both oESR1 and HOXA9 are selected as “Lshaped” genes, which satisfy our criteria. With our criteria, a total of 128 “L-shaped” genes out of
12,783 genes were selected and expected to be selected with high specificity. Table S5.2 shows the
details of the genes sets, including the gene names, thresholds, MI scores and depths. Among these
128 “L-shaped” genes, 17 are transcription factors (chi squared test, p-value=0. 27), including 7
homeobox genes (chi squared test, p-value=2.02e-06) CDX1, HNF1A, HNF1B, HOXA9, PAX8,
POU3F3 and POU4F1. Table S5.3 shows the top curated gene sets, GO gene sets and oncogene
signature enriched sets, which is from MsigDB gene enrichment analysis. From the results, we found
that these 128 enriched genes were associated with multiple cancer types. And 10 genes were
reported to be hypermethylated in lung cancer samples (p-value=6.53e-05). The top results of IPA
associated network functions and biofunctions are shown in Table S5.4, which indicates that these
128 “L-shaped” genes are tightly associated with cancer, cellular disorder and disease development.

5.2.3 A New CIMP
5.2.3.1 CIMP Identification
In this study, we focus on CIMP identification for BRCA. The values of DNA methylation
status were binary coded based on the estimated methylation threshold. Aiming to identify the most
differentially methylated genes in the tumor samples compared with normal samples, we performed
biclustering and identified 25 out of 128 genes by discriminating a block of 1 in breast cancer
samples and 0 in normal samples (Figure 5.5; Table 5.2). Most of the selected genes had significant
differences in DNA methylation status and mRNA expression levels between cancer and normal
samples (Figure 5.4). These included CFI, HOXA9, HSPB2, COL17A1, AQP1, POU3F3, PLD5,
IL1A, POU4F1, CRYAB, LAMB3, TRIM29, SLC10A4, SCTR, MEP1A, IL20RA, SLC44A4, TFF1,
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C1orf64, C10orf81, ZG16B, SPDEF, RERG, PTK6, and BNIPL. Among these 25 “L-shaped” genes,
4 were transcription factors (chi squared test, p-value=0. 53), including 3 homeodomain proteins (chi
squared test, p-value=6.916e-06), HOXA9, POU3F3 and POU4F1. Table S5.5 shows the top curated
gene sets, GO gene sets and oncogene signature enriched sets, which indicate that these 25 genes are
associated intensively with breast cancer. The top results of IPA of associated network functions and
biofunctions are shown in Table S5.6, which indicates that these 25 genes are tightly associated with
cancer, cellular disorder and disease development, as expected, and are also associated with the cell
cycle, cellular movement and cell death.

Figure 5.5 Coordinated analysis of breast cancer CIMP defined from dichotomized methylation
status. CIMPs are identified by biclustering and a sequential supervised hierarchical clustering on the
128 “L-shaped” genes. The green and red heat map displays the sample and gene consensus. For
each breast cancer sample, genes with unchanged methylation status compared with that of the
normal samples are denoted in green; and genes with changed relative methylation status are denoted
in red. The vertical and bottom horizontal black lines indicate the boundary of the bi-clusters. The
other two black lines indicate empirically identified CIMP markers. The methylation status of CIMP
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biomarkers is shown in the left panel; associations with molecular and clinical features are shown in
the top panel.
Table 5.2 Demographics of CIMP subtypes in this study.

TP53
ER
PR
HER2

PAM50 subtypes

Mutated
Wild
+
+
+
Luminal A
Luminal B
HER2-enriched
Basal
Normal-like

CIMP1 +
31
130
164
6
137
33
37
95
68
57
13
1
2

CIMP1 81
61
76
65
66
75
34
74
43
11
28
49
1

Normal
10
17
21
6
19
8
7
16
0
0
0
0
0

P-value
2.38e-11
2.20e-16
1.00e-09
0.660
0.209
9.068e-06
0.012
2.586e-11
1

A supervised hierarchical clustering analysis of the binary DNA methylation data was
performed on the 25 genes selected from biclustering, and 3 clusters were identified (Figure 5.5).
Cluster 1 contains 11 genes (SLC44A4, IL20RA, LAMB3, IL1A, TFF1, CRYAB, C1orf64, MEP1A,
SLC10A4, POU3F3, and POU4F1) while cluster 2 contains 3 genes (TRIM29, PLD5, and SCTR) and
cluster 3 contains the remaining 11 genes. Based on clusters 1 and 2, we defined two CIMPs. We
allowed for 10% measurement error tolerance, which means that for each patient in the CIMP+
group, at least 10 out of 11 genes as biomarkers had methylation status that changed compared with
that of the normal group. Among all 286 BRCA tumor samples, we defined 149 CIMP 1+ and 136
CIMP 2+ samples. As there were more CIMP1 markers than CIMP2, we focused on CIMP 1 in this
study. Most of the identified CIMP 1 markers have the most significant difference in DNA
methylation and mRNA expression levels between CIMP + and CIMP – samples and are
significantly down- or up-regulated and hyper- or hypomethylated (Figure 5.6, lower-right and
upper-left quadrants). A histogram of the methylation frequency distribution for the set of CIMP1
biomarkers shown in Figure 5.6 indicates that the distribution of the CIMP1 markers creates a good
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bimodal distribution, with two methylation frequency peaks at 0.2 and 0.9. Compared with the
normal samples, 5 (MEP1A, IL20RA, SLC44A4, TFF1, and C1orf64) out of 11 were
hypomethylated and 6 (POU3F3, IL1A, POU4F1, CRYAB, LAMB3, and SLC10A4) were
hypermethylated (Figure 5.5).

Figure 5.6 Comparison of transcriptome versus epigenetic differences between BRCA CIMP+ and
CIMP- samples. Starburst plot is shown for comparison of DNA methylation and mRNA expression
data for 12,783 unique genes. The x-axis and y-axis are defined in the same way as in Figure 5.4, as
well as the black lines and grey data points. Points in red indicate CIMP markers identified; points in
blue indicate significant up- and down-regulation in the gene expression levels and significant hyperor hypomethylation in BRCA CIMP+ tumors compared to CIMP- tumors. A histogram of the
methylation frequency of CIMP markers is shown (top right).
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5.2.3.2 CIMP Markers Enrichment Analysis
Among 11 CIMP markers, POU3F3 and POU4F1 are transcription factors (chi squared test,
p-value=0. 93) and both are homeodomain proteins (chi squared test, p-value=0. 01). From GSEA of
MsigDB, all significant enriched GO terms and oncogenic signatures are displayed in Table S5.7.
Our 11 CIMP markers are enriched in the gene sets with the following characteristics: (1)
differentially expressed between carcinoma and normal cells and between luminal-like breast cancer
cell lines and the basal-like cell lines (LAMB3, TRIM29, IL20RA, CRYAB and IL1A); (2) part of the
validated nuclear estrogen receptor alpha network (TFF1 and POU4F1); (3) discriminate between
ESR1+ and ESR1 tumors (TRIM29, TFF1 and SLC44A4); (4) respond to bystander irradiation
(LAMB3 and IL1A); (5) targets of polycomb gene EED, SUZ12 and BMI1 (IL20RA, SLC44A4,
SCTR, SLC10A4, IL1A and LAMB3); (6) down-regulated in metastases from malignant melanoma
compared to the primary tumors (LAMB3 and TRIM29); and (7) related to anti-apoptosis and
negative regulation of development (CRYAB and IL1A). Only two significantly associated network
functions were found by IPA. Interestingly, all 11 markers were shown to be associated with TP53
directly or indirectly. Seven of them are involved in the network “cancer, hematological disease,
immunological disease” and the other three are involved in “amino acid metabolism, cellular
compromise, cellular movement” (Figure 5.7).
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A

B

Figure 5.7 CIMP markers involved in networks. A. Network “cancer, hematological disease,
immunological disease.” B. Network “amino acid metabolism, cellular compromise, cellular
movement.” Genes in color (except TP53) indicate CIMP markers; red indicates hypermethylation in
CIMP+ samples and green indicates hypomethylation. TP53 in red indicates the wild-type TP53
gene and overexpression of TP53 as well.

5.2.3.3 Correlation with TP53 Mutation and Subtypes
We performed logistic regression analysis to investigate the correlation of our defined CIMP
subtype with the classic breast cancer markers estrogen receptor, progesterone receptor, HER2
receptor, status of TP53 mutation and TCGA defined CIMP PAM50 subtypes (Figure 5.5) [65].
Consistent with the strong correlation of CIMP and BRCA basal subtypes, our defined CIMP was
found to strongly correlate with TP53 mutation, estrogen receptor status, and progesterone receptor
status, but not with HER2 receptor status. No association was observed between CIMP and BRCA1
or BRCA2 mutations (data not shown). We further investigated the correlation to BRCA subtypes and
found a very strong correlation between CIMP1 and basal and luminal B subtypes. We observed a
mild correlation with the HER2-enriched subtype. Next, we performed genome-wide correlation
analysis, and found that TP53 was the only one gene that has significant correlation with the CIMP
in terms of its mutation status (Figure 5.8). We also checked the correlation of CIMP+ with mRNA
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expression of TP53 and other TP53-related genes, including two TP53 binding proteins (TP53BP1
and TP53BP2), four TP53-induced proteins (TP53I11, TP53I3, TP53INP1, TP53INP2), two TP53
target genes (TP53TG1 and TP53TG5) and one TP53 regulating kinase (TP53RK). Interestingly,
moderately significant correlations were found between CIMP and mRNA expression of TP53,
TP53BP1, TP53I3 and TP53TG5, and strong correlations existed with TP53BP2, TP3I11, TP53INP1
and TP53TG1 (Table 5.3). Also, we found significantly negative associations between TP53
mutation and expressions of TP53BP1 (p-value= 1.29e-07), TP53I11 (p-value= 1.28e-05),
TP53INP1 (p-value= 2.07e-12), TP53TG1 (p-value= 2. 93e-09) and TP53TG5 (p-value= 6.10e-04)
.We found the expression of TP53BP2 to be significantly and positively correlated with TP53
mutation (p-value= 1.64e-06).

Figure 5.8 Comparison of transcriptome versus mutation differences between BRCA CIMP+ and
CIMP- samples. Starburst plot is shown for comparison of mutation status and mRNA expression
data for 12,783 unique genes. The x-axis and y-axis are defined in the same way as in Figure 5.4, as
well as the black lines and grey data points. Data points in red indicate TP53 genes and several
TP53-related genes.
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Table 5.3 Association study of CIMP subtype with molecular and clinical features.
Object

Term

Lower

Higher

boundary

Boundary

Odd ratio

P-value

positive

23.39

9.67

56.60

2.73e-12

positive

4.78

2.87

7.97

1.78e-09

HER2 receptor

positive

0.80

0.45

1.41

0.44

TP53

mutation

0.18

0.11

0.30

5.87e-11

TP53

mRNA expression

1.32

1.13

1.54

4.48e-04

TP53BP1

mRNA expression

1.25

1.12

1.39

2.91e-05

TP53BP2

mRNA expression

0.62

0.54

0.71

2.46e-11

TP53I11

mRNA expression

1.40

1.24

1.59

1.05e-07

TP53I3

mRNA expression

0.75

0.66

0.86

2.78e-05

TP53INP1

mRNA expression

1.87

1.59

2.19

2.38-13

TP53INP2

mRNA expression

0.96

0.82

1.11

0.55

TP53RK

mRNA expression

1.08

1.00

1.18

0.04

TP53TG1

mRNA expression

1.38

1.19

1.61

2.68e-05

TP53TG5

mRNA expression

1.51

1.30

1.77

6.81e-07

pretreatment history

Yes

Inf

1.23

Inf

0.017

prior diagnosis

Yes

13.59

1.77

104.66

0.012

Higher stage

3.02

0.61

14.98

0.18

Higher stage

1.29

0.82

2.037

0.27

ajcc tumor stage

Higher stage

1.19

0.77

1.86

0.43

gender

Male

Inf

0.35

Inf

0.25

Older

55.62

2.96

1044.40

0.0076

estrogen receptor
progesterone
receptor

ajcc cancer
metastasis stage
ajcc neoplasm
disease stage

age at initial
diagnosis
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5.2.3.4 Clinical Correlation Analysis
Clinical correlation analysis was performed on 7 clinical features, including pretreatment
history, prior diagnosis, American Joint Committee on Cancer (AJCC) cancer metastasis stage,
AJCC neoplasm disease stage, AJCC tumor stage, gender and age at initial pathologic diagnosis
(Table 5.3). The contingency table is shown in Table 5.4. Significant correlation was found between
CIMP and age at initial pathologic diagnosis (p-value 0.0076), the mean age for patients with
CIMP+ tumors was 62 years, while it was 55 for patients with CIMP- tumors (Figure 5.9). Stratified
by age at initial pathologic diagnosis, prior diagnosis showed significant correlation with CIMP (pvalue 0.012). Because of the small sample sizes of patients in particular categories, we applied
Fisher’s exact test on the pretreatment history and gender, and found significant correlations between
CIMP and pretreatment (p-value 0.017).

Figure 5.9 Association study between age and CIMP subtypes. Category 0 indicates CIMP- subtype
and 1 indicates CIMP+ subtype.
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Table 5.4 Demographics of CIMP subtype according to clinical features
Methylation status
0

1

NO

143

164

Yes

0

7

No

142

154

Yes

1

17

ajcc cancer metastasis

M0

140

151

stage

M1

2

7

0

0

1

I

27

30

II

90

94

III

19

32

IV

2

7

T1

37

46

T2

93

93

T3

11

17

T4

2

14

Male

0

3

Female

143

168

Pretreatment history

prior diagnosis

ajcc neoplasm disease
stage

ajcc tumor stage

gender

5.2.3.5 Survival Analysis
Stratified by age at initial pathologic diagnosis, relative risk of methylation status was
estimated using a Cox model on survival data. Compared to patients with CIMP- tumors, those with
CIMP+ tumors tend to have longer survival times (odds ratio=1.29); although this difference is not
significant (p-value 0.457). We also investigated the survival analyses of each CIMP marker based
on curated datasets using GENESURV tools in bioprofiling.de. We found that 5 (SLC44A4,
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IL20RA, TFF1, C1orf64, and POU4F1) of 6 markers that show significant survival difference for
patients with breast cancer agreed with our finding that patients with tumors in which the
methylation status change have longer survival time. The last gene, which was the only gene that did
not agree with our finding, showed the least significant correlation, with a p-value of 0.0257 (Table
S5.8).
Clustering of correlations. We performed hierarchical clustering analysis on p-values from the
correlation analysis of each biomarker (Fig 5.10). All CIMP markers are clustered in one block with
9 features, including TP53 mutation status, TP53BP2 mRNA expression, age at initial diagnosis,
TP53BP1 mRNA expression, TP53I11 mRNA expression, TP53TG5 mRNA expression, TP53TG5
mRNA expression, TP53INP1 mRNA expression, estrogen receptor status, and progesterone
receptor status. This result coincided with the above correlation analysis, indicating a strong
relationship between our identified CIMP and several factors, including TP53 mutation, estrogen
receptor status, progesterone receptor status, age at initial pathologic diagnosis, and the expression of
TP53-related genes such as TP53BP1, TP53BP2, TP53I11, TP53TG1, TP53TG5, TP53INP1 and
TP53RK.

88

Figure 5.10 Consensus clustering analysis of association study for each marker. Unsupervised
hierarchical clustering was performed on 25 genes identified by biclustering. The green and red heat
map displays association significance and gene consensus. Red indicates a positive correlation
between methylation status and molecular or clinical features and blue indicates a negative
correlation. The methylation status of CIMP biomarkers is shown in the left panel, and CIMP
identified in Figure 5.5 is shown in the top panel.

5.2.3.6 Epigenetic Modifiers
GSEA has shown that 11 CIMP+ markers were enriched in polycomb target gene sets. We
investigated the mRNA expression level of 12 epigenetic modifiers from ploycomb repressive
complex 2 (PRC2) (BMI1), PRC1 (EED, SUZ12 and EZH2), DNA methyltransferases (DNMT1,
DNMT3A and DNMT3B), H3K4 histone methyltransferase (MLL), isocitrate dehydrogenases
(IDH1 and IDH2) and tet methylcytosine dioxygenases (TET1 and TET2). The mRNA expression
levels were compared among CIMP+ samples, CIMP- samples and normal samples pairwise, and
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their correlations with TP53 mutations were calculated as well (Table 5.5). Our results show that (1)
BMI1, IDH1 and TET1 have significant differential expression between CIMP+ samples and both of
the other two groups; (2) DNMTA, DNMT3B, EZH1 and IDH2 have significant differential
expression between CIMP- samples and both of the other two groups; and (3) all 7 genes are
significantly correlated with TP53 mutation (Table 5.5; Figure 5.11). Unfortunately, the mRNA
expression value of SUZ12 was missing. Unexpectedly, EED does not shown significant differential
expression between the CIMP+ subtype and the other two groups because of large variance (Figure
5.10 D). These findings indicate that (1) many epigenetic modifiers are tightly associated with TP53;
(2) eleven CIMP+ markers may be regulated by BMI1, IDH1 and TET1; (3) the expression of a large
proportion of these 12 epigenetic modifiers belongs to two distinct patterns; and (4) at least 2 types
of epigenetic modifiers that are functional in the TP53 system exist.
Table 5.5 Association study of epigenetic modifiers with CIMP subtype and TP53 mutation
CIMP+ vs CIMP-

CIMP+ vs Normal

CIMP- vs Normal

OR

P-value

OR

P-value

OR

P-value

OR

P-value

BMI1

1.28

2.19E-04

1.36

1.40E-02

1.06

6.30E-01

0.75

7.00E-05

EED

0.85

1.41E-03

0.91

3.28E-01

1.07

4.53E-01

1.21

3.84E-04

SUZ12

NA

NA

NA

NA

NA

NA

NA

NA

EZH2

0.76

4.49E-04

3.11

1.61E-16

4.09

1.85E-06

1.82

2.88E-14

DNMT1

0.91
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Figure 5.11 Boxplot of expression of epigenetic modifiers in BRCA CIMP subtype and normal
samples. (A-D) BMI1, IDH1, TET1 and EED. (E-H) EZH2, IDH2, DNMT3A and DNMT3B.
Category N indicates normal samples; - indicates CIMP- subtype; + indicates CIMP+ subtype. Data
points in red indicate samples with TP53 mutation.
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5.3 Discussion
In this study, we proposed a method to discriminate genes for which the mRNA expression
levels are affected by the DNA methylation level, and to determine the threshold of DNA
methylation as an indicator of whether one gene is expressed or depressed. Based on the estimated
dichotomized methylation status, we identified a new CIMP of BRCA with 11 markers. Interestingly,
the new CIMP+ samples we identified were correlated significantly with negative TP53 mutation
status, estrogen receptor-positive status, progesterone receptor-positive status, higher age at initial
pathologic diagnosis, pretreatment history and a possibly longer survival time. The 11 CIMP markers
were shown to be associated with TP53 directly or indirectly, and enriched in cancer and diseases
networks. Also, we found that 7 among 12 epigenetic genes were correlated strongly with both the
new CIMP and TP53 mutation. Based on our findings, we proposed a model in which there are at
least two groups of members in the TP53 regulatory network, which are named “guidance” and
“sustainer.”
Method for determining methylation threshold. In this paper, we estimated the methylation
threshold based on the calculation of the conditional mutual information score. DNA methylation is
considered to suppress gene expression and is often described as a binary measurement
(hypermethylation or hypomethylation) [83]. Intuitively, the genes with expression regulated
significantly by methylation will exhibit an “L” or reverse “L” shape when DNA methylation values
are plotted against mRNA expression values (and the data split by the threshold cutoffs should be
independent). ESR1 and HOXA9 are two examples of “L-shaped” genes, which also exhibit
dramatic changes in methylation patterns in different cancers. This finding is consistent with that of
Qiu et al. [83]. ESR1 encodes an estrogen receptor that has well-known involvement in pathological
processes of breast cancer and has been shown to have hypermethylation status [84]. Also, HOXA9
genes have been characterized under epigenetic silencing in tumors [85]. Our method was validated
by the observation that most of the 29-gene set from the colon cancer study has a large difference in
the values of the mutual information score measured before and after determining the methylation
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threshold [82]. Compared with the method that naively determines the methylation threshold by
searching for the turning point in the mRNA expression [86], our method is more precise and
flexible and has two advantages. First, we determined the threshold through measuring the
dependence between DNA methylation and mRNA expression data; therefore, our method used
more information than the naïve method that was based on only the change in mRNA expression.
Second, we estimated the smeared densities of both DNA methylation and mRNA expression for
each patient, which allows for a much smoother and more precise calculation.
For all genes, the estimated thresholds tend to be small for methylation but large for mRNA
expression. This observation is consistent with previous findings that most genes in the genome are
hypomethylated [87,88]. However, we found that for genes with MI score differences larger than
0.3, the thresholds of methylation corresponding to gene expression regulation are gene-specific,
which is concordant with our assumption. Also, it is reasonable as we found small thresholds for
mRNA expression levels for the gene sets enriched with “L-shaped”genes.
Identification of “L-shaped” genes. “L-shaped” genes were selected according to three criteria
(see Methods) from two aspects. First, “L-shaped” genes should have large differences in the mutual
information score as methylation value and expression value would be much more independent after
being split by threshold cutoffs. Second, for each “L-shaped” gene, both samples with
hypomethylation and high expression levels and samples with hypermethylation and low expression
levels should occupy considerable portions.
A total of 128 “L-shaped” genes were identified. These genes are tightly associated with cancer
and disease and are enriched in curated gene sets associated with multiple cancer types. These results
are reasonable because these “L-shaped” genes were selected from TCGA data of multiple cancer
types. As expected, 10 hyper-methylated genes are significantly related to lung cancer, which
supports our intention to investigate the relationship between DNA methylation, mRNA expression
and cancer. Interestingly, 7 of the 128 “L-shaped” genes were homeobox genes (p-value=2.02e-06),
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which is consistent with reports that homeobox genes are associated with tumorigenesis and are
epigenetically regulated by the polycomb complex [89,90].
Identification of a new CIMP. We identified 25 markers differentially methylated in tumor
samples compared with normal samples. In this study, we focused on one CIMP with 11 markers,
including SLC44A4, IL20RA, LAMB3, IL1A, TFF1, CRYAB, C1orf64, MEP1A, SLC10A4,
POU3F3, and POU4F1. By integrating gene expression and DNA methylation data, we found that
selected markers had rather significant DNA hypermethylation and down-regulated gene expression
or hypomethylation and up-regulated gene expression when comparing either tumor to normal
samples or CIMP+ to CIMP- samples. Also, using the strategy of integrating gene expression and
DNA methylation data, Noushmehr et al. identified 300 genes with significant hypermethylation and
gene expression changes for a CIMP of glioma [47]. However, those genes may not be “L-shaped.”
Most of our new CIMP markers have been reported to have significant associations between
their methylation status and various cancers. IL20RA has been reported to be hypermethylated in
lung cancer cell lines [91]. TFF1 has been validated as hypomethylated and overexpressed in breast
carcinoma [48,92]. Mahapatra et al. identified hypermethylated POU3F3 as a biomarker for systemic
progression of prostate cancer [93]. POU4F1 has been demonstrated to have lower methylation
frequency in leukemia cell lines compared to primary acute lymphoblastic leukemia samples, but
higher methylation levels in low-grade breast cancer compared to normal samples [49,94].
Methylation of the CRYAB gene promoter was reported to occur in distinct anaplastic thyroid
carcinomas [95]. The frequent up-regulation of LAMB3 by promoter demethylation has been
reported in breast cancer, gastric cancer and bladder cancer, but the opposite has been reported in
prostate cancer [53,96,97,98].
Among the 11 CIMP biomarkers we identified, we found 5 (MEP1A, IL20RA, SLC44A4, TFF1,
and C1orf64) to be hypermethylated and 6 (POU3F3, IL1A, POU4F1, CRYAB, LAMB3, and
SLC10A4) to be hypomethylated. Although most CIMP samples that have been identified have been
accompanied by hypermethylation markers, which were named CIMP-high samples (widespread
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promoter methylation) in some studies, the identification of CIMP-low samples (with less
widespread promoter methylation) is ongoing [99,100,101,102]. Also, a previous breast cancer study
revealed that hypomethylation at many CpG islands was significantly associated with epithelia to
mesenchymal transition [103]. In this study, we proposed a new CIMP — “CIMP-M” (“CIMPmixture”) because of the mixture of epigenetic markers with hypo- and hyper methylation status.
Although only a few studies have claimed CIMP with hypermethylated genes for breast cancer
[63,64,65], consistent with a study by Fang et al. and TCGA group, this study suggests clearly that
CIMP exists with a bimodal distribution and is significantly associated with certain molecular
markers and clinical features.
Consistent with the conclusion of Tommasi et al. that the methylation of homeobox genes
frequently occurs in breast cancer [104], the new CIMP biomarkers are enriched in homeodomain
proteins. Also, they were found to be enriched in gene sets corresponding to metastasis, antiapoptosis and negative regulation of development. And they were enriched in the TP53 and estrogen
receptor alpha signal pathway networks. In addition, they were significantly involved in networks
associated with cancer and disease, amino acid metabolism, cellular compromise and cellular
movement. These finding indicate that the new CIMP biomarkers play important roles in cancer.
In this study, we demonstrated that the new CIMP identified was significantly correlated with
TP53 mutation, estrogen receptor status and progesterone receptor status. Excitingly, we found that
CIMP+ was significantly associated with the luminal B breast cancer subtype, and CIMP- was
significantly associated with the basal breast cancer subtype. These findings were also exhibited by
GSEA of 11 CIMP biomarkers that were enriched in the TP53 network, ER1 network, gene sets for
anti-apoptosis and genes discriminating between the luminal-like and basal-like breast cancer cell
lines. Ronneberg et al. reported 3 clusters associated with luminal tumors and basal-like tumors and
found them to be significantly different in association with estrogen receptor status, and TP53
mutation [62]. However, only 1 gene, TFF1, among our 11 CIMP biomarkers overlapped with the
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findings from the study by Ronneberg et al. A possible reason for this discrepancy is poor
correlations between methylation status and mRNA expression levels for many genes because of the
complexity of the regulatory system. For this newly identified CIMP, we observed only a mild
association with the HER2-enriched subtype and no significant associations with BRCA1 or BRCA2
mutations. Associations with the HER2-enriched subtype and BRCA1 and BRCA2 mutations and
methylation clusters were found by Holm et al. [61].
TP53 was the only gene for which mutation was found to be associated with CIMP. And
consistent with previous studies [62,105], we found a strong correlation between TP53 mutation and
ER negativity. Several studies have been developed to investigate the relationship of TP53 and ER
expression. Estrogen receptor α has been reported to bind to TP53 and inhibit its transcription,
resulting in the inhibition of p53-mediated cell death. Therefore, benefits from a reactivated TP53
pathway, good prognosis and treatment response from anti-estrogens such as tamoxifen have been
reported [106,107,108]. In our study, we observed an older age at initial pathologic diagnosis, prior
diagnosis, pretreatment history and longer survival time in patients with the CIMP+ subtype with
wild-type TP53, which indicates that patients with the CIMP+ subtype are at risk later in life and are
more susceptible to treatment. Shirley et al. stated that p53 regulates ER expression through
transcriptional control of the ER promoter [105], which may be the reason most TP53 mutations
were found in patients with ER- tumors. Taken together, we observe that a feedback loop exists
between TP53 and ER expression; however, this complicated regulatory system remains elusive. We
also investigated 9 TP53-related genes and found 8 of them (TP53, TP53BP1, TP53BP2, TP53I3,
TP3I11, TP53INP1, TP53TG1 and TP53TG5) to be significantly associated with CIMP subtypes and
5 of them (TP53BP1, TP53I11, TP53INP1, TP53TG1 and TP53TG5) to be significantly negatively
associated with TP53 mutation. We found a positive association with TP53 mutation for one gene,
TP53BP2. It is known that TP53BP1 and TP53BP2 bind to TP53 and enhance TP53-mediated
transcriptional activation. The association we found between their expression and TP53 indicated
that feedback relationships might exist between TP53 and its binding proteins. And the opposite
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associations of TP53BP1 and TP53BP2 with TP53 mutation indicate that different feedback
mechanisms are involved. In summary, significant associations were found between both TP53
mutation and CIMP subtypes and TP53 binding proteins, induced proteins and target proteins.
Whether these TP53-related genes are involved in maintaining the specific methylation pattern of
CIMP will be of interest in future research.
Regulation through epigenetic modifiers. In this study, we investigated the expression of 12
epigenetic modifiers in samples of CIMP+ and CIMP- subtypes and normal samples. We found that
aberrant expressions of BMI1, IDH1 and TET1 exist when comparing the CIMP+ subtype to the
other two groups, and DNMT3A, DNMT3B, EZH2 and IDH2 were expressed differently in the
CIMP- subtype compared to the other two groups. All 7 genes were significantly correlated with
TP53 mutation. These findings are in accordance with the findings of Pietersen et al., that EZH2 and
BMI1 are inversely correlated with TP53 mutation and prognosis in breast cancer. They claimed that
tumors with high expression levels of BMI1 are associated with a good prognosis [109]. In contrast,
Guo et al. claimed that BMI1 promotes invasion and metastasis [110]. In our study, we observed that
higher expression of BMI1 correlated well with ER+/PR+ cancer subtypes, CIMP+ subtype and
wild-type TP53 and with older age at diagnosis, good response to treatment and longer survival time.
TET1 has been reported to suppress the invasion ability of breast tumors through demethylation
[111]. EZH2 has been found commonly overexpressed in breast cancer and has been reported to
repress DNA repair, leading to tumor progression [76,112]. A significant association has been found
for DNMT3B with breast cancer subtypes discriminated by methylation profiling [63]. All these
findings suggest that the 11 CIMP biomarkers we identified might be regulated by BMI1, IDH1 and
TET1, and that there is another group of epigenetic modifiers functional in the CIMP- subtype
specifically that includes DNMT3A, DNMT3B, EZH2 and IDH2. Other studies have reported that
EZH2 is functional in stem cell maintenance [113] and basal-like tumors are more like stem cells
compared with other subtypes [114,115]. As expected, 6 of 11 CIMP biomarkers are curated targets
of polycomb genes EED, SUZ12 and BMI1. Squazzo et al. found that a common set of promoters
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occupied by SUZ12 exist in MCF3 tumor cells and embryonic tumors [116]. However, we cannot
determine whether that gene is differently expressed between the CIMP+ and CIMP- groups because
of missing data.

Model of TP53-mediated regulatory system. In this study, biomarkers exhibited a different
methylation status in the CIMP+ group compared with the CIMP- and normal groups. We observed
that patients with the CIMP+ subtype were older at the time of the initial pathologic diagnosis, and
had a longer survival time compared with patients in the CIMP- subtype. It seems a paradox that the
methylation status of the CIMP- subtype was similar to that of the normal samples (Figure 5.5).
Patients with the CIMP+ subtype were older at the clinical onset of the disease, had a better
treatment response, and had the potential to survive longer. Also, the CIMP- subtype was found to be
tightly related to TP53 mutation. As TP53 is well known to be associated with response to genotoxic
and non-genotoxic stresses [117,118], we infer that aberrant CIMP+ methylation status results from
the response of TP53 to cellular stresses from a tumor.
Here, we infer that there is an in emergency rescue system in which a group of genes play an
important role along with TP53. We call this group of genes “guidance” genes because they react
when the cell is at risk and contain the 11 CIMP+ markers we found. We call another group of genes
that functional in the TP53 system the “skeleton” genes. “Sustainer” genes will not function when
TP53 mutation occurs. We suggest a model of the TP53 regulatory network that contains two
components, the “guidance” and “sustainer” genes, as shown in Figure 5.12. “Guidance” genes play
an emergency rescue role in the response to stresses, while “sustainer” genes act as the maintenance
department, taking responsibility for the operation of the TP53-mediated regulatory system.
Interestingly, as the “guidance” genes, the 11 CIMP biomarkers were found to be enriched in
response to bystander irradiation. For the CIMP+ group, enrichment of the estrogen and progesterone
receptors might be the stress signal from breast cancer that induces the response of the wild-type
TP53 gene acting in a “guidance” capacity. For the CIMP- group, the TP53-mediated regulatory
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system was silenced by the mutation of TP53, and the “sustainer” genes lost their function. We
predicated 1594 “guidance” genes and 2016 “sustainer” genes in terms of the mRNA expression
levels and 1591 “guidance” genes and 557 “sustainer” genes in term of the DNA methylation status.
Both “guidance” and “sustainer” genes were enriched in important processes of disease resistance
and metabolism. However, the “guidance” genes were enriched in the immune system process for
rescue action, while the “sustainer” genes were found to be enriched in gene sets responding to
changes in the cytoskeleton. We predicated “guidance” and “sustainer” genes according to our
criteria (see Method I). We identified 1594 “guidance” and 2106 “sustainer” genes in terms of the
mRNA expression level and 1591 “guidance” and 557 “sustainers” in terms of the DNA methylation
status. The 11 CIMP markers were significantly selected as “guidance” genes (Figure 5.13). IPA
showed that “guidance” genes were enriched in cell signaling, molecular transport, nucleic acid
metabolism, and development disorders, while “sustainer” genes were enriched in the cell cycle, cell
assembly and organization, cellular growth and proliferation and tumor morphology. MsigDB GSEA
showed that “guidance” and “sustainer” genes were very significantly enriched in chemical
reactions, response to stress, signal transduction, transport, transcription and cellular metabolic
processes. As expected, GSEA showed that “guidance” genes were enriched in the immune system
process for rescue action. And “sustainer” genes were found to be enriched in gene sets responding
to changes in the cytoskeleton, which is consistent with the findings from IPA that “sustainer” genes
play a role in cell assembly and organization and are responsible for tumor morphology. In addition,
“guidance” genes are found to be enriched as the targets of EED and SUZ12. Interestingly, the LET-7
family was found to regulate “guidance” genes and the MIR-506, MIR-30, and MIR-17 families and
MIR-124A were found to regulate both “guidance” and “sustainer” genes.
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Figure 5.12 Predicated model of TP53-mediated regulatory system. We proposed a model of the
TP53-mediated regulatory system with two components: “guidance” and “sustainer” genes.
“Sustainer” genes serve as the “skeleton” of the system and “guidance” genes serve as an emergency
rescue team. When cells are under stress, “guidance” genes will respond to resist the stress.
However, when TP53 is mutated, “sustainer” genes will lose their function and “guidance” genes
will not work under stress.
A

B

Figure 5.13 Comparison of transcriptome, epigenetic and mutation differences between BRCA CIMP
subtypes. A. Comparison of transcriptome and mutation differences. B. Comparison of epigenetic
and mutation differences. For both A and B, the x-axis and y-axis are defined in the same way as in
Figure 5.4, as are the black lines and grey data points. Data points in red indicate the identified CIMP
markers. Data points in blue denote predicated “guidance” genes and green denote “sustainer” genes.
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We also observed two distinct patterns of the expression of epigenetic modifiers, which were in
concordance. Therefore, we inferred that TP53 acts through at least two epigenetic mediation
systems, one for “guidance” genes, containing EED, SUZ12 and BMI1, and another for “sustainer”
genes, containing DNMT3A, DNMT3B, EZH2 and IDH2. Therefore, for patients with the CIMPsubtype, DNMT3A, DNMT3B, EZH2 and IDH2 might be potential targets of treatment for restoring
the TP53 regulatory system, and EED, SUZ12 and BMI1 might be targets for resisting tumor
development. The EZH2 inhibitor DZNep has been reported to induce robust apoptosis in breast
cancer cells [119]. Nevertheless, more research is needed to validate this TP53-mediated regulatory
model and predicate the “guidance” and “sustainer” genes.
In summary, we have presented a method based on the calculation of mutual information scores
to determine the threshold of DNA methylation and distinguish the genes for which the levels of
expression are significantly regulated by DNA methylation. We have identified a CpG island
phenotype (CIMP) of breast cancer with strong correlation with the wild-type TP53 mutation,
ER+/PR+ subtypes, higher age at the time of disease diagnosis, better treatment response and
possibly a longer survival time. Both hypermethylation and hypomethylation status were shown on
biomarkers of the CIMP+ group. In addition, we have suggested a model of the TP53-mediated
regulatory system in which TP53 might regulate “guidance” and “sustainer” genes through two
epigenetic mediation systems.
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CONCLUSIONS

To investigate the properties of overdispersion in RNA-seq data, we empirically calculated the
variance from replicated experiments. We observed a dependency relationship between
overdispersion and sequencing depth on both the gene and position levels, which is consistent with
the intuition that increments in sequencing depth will improve the sequencing accuracy. Based on
this property, we developed a function for estimating the overdispersion rate by borrowing
information from all genes. The Poisson distribution is usually applied to model discrete counts, but
it is not appropriate for modeling the RNA-seq data as the Poisson rate on each position fluctuates in
a large range because of the uniformity of mapped reads. Therefore, compared with the Poisson
model, a model based on the proportion of the sequencing counts between two samples has the
advantage of avoiding the estimation of the fluctuating measurement by converting non-uniform
measurements into a constant ratio for one gene. We adopted the beta-binomial distribution to model
the ratio of two measurements and the overdispersion. In the first study, we developed a statistical
model on the gene level for differential expression analysis by utilizing the property of
overdispersion. Our model obtained a better performance than models that did not incorporate the
overdispersion rate or which used a constant overdispersion rate. Next, aiming to more accurately
model the measurement, we modeled on the position level with a specific dispersion rate for each
position. We also investigated the influence of random hexamer priming on overdispersion and
found that the use of a random hexamer primer influenced the overdispersion mainly by affecting the
sequencing depth. Therefore, it is desirable to estimate overdispersion utilizing its dependency upon
sequencing depth. And, consistent with our model on the gene level, our model on the position level
was superior to the models that did not incorporate the overdispersion rate or which used a constant
overdispersion rate. Compared with DESeq which is a widely used method based on a negative
binomial model on the gene level, our model is technically more desirable because it avoids
modeling the highly fluctuating Poisson rate.
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Inspired by the cross-hybridization issue inherent in microarrays, we investigated the
measurement of spike-in transcripts sequenced along with different sample transcripts. Interestingly,
we observed that the measurement of spike-in transcripts was influenced by the sample transcripts.
Although the precise mechanism is still unknown, we developed an efficient statistical method to
correct for this bias introduced by sample transcripts, and obtained an increase of 0.1 in the Pearson
correlation coefficient after correction. The new type of bias observed in this study will aid the
understanding of sequencing technology and contribute to better accuracy in downstream analysis.
Aiming to identify “L-shaped” genes that were largely regulated by DNA methylation on
transcription, we developed a statistical approach for determining the DNA methylation threshold on
the inhibition of mRNA expression. We used a mutual information technique to determine the
threshold from 997 samples across 7 cancer types in TCGA datasets, and identified a total of 128 “Lshaped” genes. We performed biclustering and hierarchical clustering on BRCA samples and
identified a new CIMP with 11 biomarkers. We found a strong correlation between this new CIMP+
subtype in breast cancer and TP53 mutation, ER+ status, PR+ status, basal subtype, higher age at
initial diagnosis, prior treatment history and the possibility of a longer survival time. We also found a
strong correlation between 7 epigenetic genes and both of the new CIMP subtypes and TP53
mutation. Based on our findings in this study, we predicated a model of the TP53-mediated
regulatory network with two components: “guidance” genes that serve in an emergency capacity and
“sustainer” genes that serve in a supporting capacity.
We developed new methods for RNA-seq data analysis for differential expression analysis, bias
correction and integration of mRNA expression levels and DNA methylation status. We believe that
the new methods will be useful in furthering the accuracy of differential expression analyses, in
understanding the biases and spurious effects inherent in sequencing technology, and in CIMP
identification and biomarker discovery related to DNA methylation.
Next, we will extend our method to handle biological samples in differential expression
analysis. For the new bias identified in RNA-seq technology, which is introduced by using different
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sample transcripts, we will explore the underlying mechanism and develop a more powerful method
for correcting this bias. For the method to identify “L-shaped” genes, we plan to apply our method to
other cancer types. Also, we will work on integrating more datasets, with the aim of obtaining a
comprehensive analysis.
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APPENDIX
Appendix 1: Supplementary Figures

Figure S3.1 The variance estimated on any position in 10 equal categories according to the distance
of that position from the last nucleotide of the gene. (a) Lichun spike-in dataset. (b) Bullard dataset.
Lichun reads start to appear at 76 nt away from the end of the gene because only mate2 on the
antisense strand were investigated and the last sequencing reads were mapped to 76 nt before the
ending. However, the Bullard reads start from 50 nt away from the end of the gene because we
truncated the genes by 50 nt from the gene head and tail separately.

a

b
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Figure S3.2 Histogram comparing the sequencing reads from two samples. The fold change for
each gene was calculated as the log scale of the ratio of the reads counts of two samples. (a)
SRR037456 is a brain sample and SRR037472 is a UHR sample. (b) SRR03469 and SRR037476
were two UHR samples with different library preparations. Apparently, the variance between two
different samples is much larger than that between library preparations.

a

b
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Appendix 2: Supplementary Tables

Table S5.1 The mutual information scores calculated on 25 genes selected from the study by Yi et al
[82]. The column headings are defined as follows: “Gene” is the gene symbol, “Probe” is the probe
id from Illumina Infinium Human DNA Methylation27 array, MI_max is the maximum mutual
information score, MI_min_methy is the minimum mutual information score on data split by the
threshold on methylation, MI_diff_methy is the difference between the maximum and minimum
mutual information scores on methylation.Threshold_methy_1way is the threshold predicated
methylation by the 1-way mutual information method. MI_min_exp is the minimum mutual
information score on data split by the threshold on expression, MI_diff_exp is the difference between
the maximum and minimum mutual information scores on expression.Threshold_exp_1way is the
threshold predicated on expression by the 1-way mutual information method, MI_min_12 is the
minimum mutual information score calculated by the 2-way mutual information method, and
MI_diff_12 is the difference between the maximum and minimum mutual information calculated by
the 2-way mutual information method.

Gene

Probe

MI_max

MI_min_
methy

MI_diff_
methy

Threshold_
methy_1way

MI_min_
exp

MI_diff_
exp

Threshold
_exp_1wa
y

MI_min_1
2

MI_diff_
12

APC2

cg18133957

0.918801

0.714133

0.204668

0.64

0.841674

0.077128

-3.11018

0.718529

0.200272

CD109

cg23442323

0.317559

0.170615

0.146944

0.15

0.185321

0.132239

0.903185

0.29325

0.024309

CHD5

cg00282347

0.672821

0.43322

0.239601

0.15

0.604483

0.068338

-2.39189

0.532149

0.140672

EVL

cg17813891

0.242147

0.200957

0.04119

0.77

0.212001

0.030146

3.887943

0.207849

0.034298

EYA4

cg01805282

0.698954

0.364727

0.334227

0.56

0.648932

0.050022

-1.73657

0.356336

0.342618

EYA4

cg07327468

0.499959

0.258202

0.241757

0.3

0.407461

0.092498

-1.64256

0.327041

0.172918

FBN2

cg25084878

0.203767

0.109825

0.093943

0.44

0.161119

0.042649

0.983988

0.112375

0.091393

FLNC

cg25664034

0.180049

0.121759

0.058291

0.22

0.155523

0.024526

-1.1728

0.11843

0.061619

GPNMB

cg17274742

0.239358

0.209117

0.030241

0.27

0.222848

0.01651

4.917683

0.215993

0.023365

GUCY1A2

cg23984434

0.433081

0.304618

0.128464

0.52

0.364053

0.069029

-1.45504

0.285112

0.14797

HAPLN1

cg09893305

0.485798

0.361431

0.124367

0.67

0.451865

0.033933

-2.10028

0.363029

0.122769

ICAM5

cg11373429

0.330354

0.229248

0.101107

0.29

0.277045

0.05331

-2.49657

0.22655

0.103805

IGFBP3

cg22083798

0.270092

0.114852

0.15524

0.19

0.129001

0.141091

4.244468

0.162303

0.107789

LAMA1

cg07846220

0.344199

0.14664

0.197558

0.48

0.169132

0.175067

0.448955

0.116187

0.228012

MMP2

cg12317456

0.23921

0.195411

0.0438

0.18

0.202031

0.037179

3.006276

0.201968

0.037242

NRCAM

cg17885062

0.467722

0.31834

0.149382

0.25

0.366087

0.101635

-0.87651

0.309591

0.158131

NTNG1

cg02361557

0.370772

0.289216

0.081555

0.1

0.319383

0.051389

-2.71286

0.279319

0.091453

PPM1E

cg19141563

0.771768

0.454593

0.317175

0.11

0.571661

0.200108

-3.55218

0.445726

0.326043

PRKD1

cg21794225

0.354138

0.239484

0.114654

0.34

0.269377

0.084761

0.505021

0.269189

0.084949

RET

cg05621401

0.355159

0.222573

0.132586

0.39

0.307011

0.048148

-1.59387

0.203522

0.151637

SH3TC1

cg07816074

0.314486

0.136964

0.177522

0.54

0.167381

0.147105

1.117468

0.114844

0.199642

STARD8

cg20832009

0.214374

0.149339

0.065034

0.09

0.166904

0.04747

1.090363

0.192478

0.021896

SYNE1

cg26620959

0.384867

0.245108

0.139759

0.37

0.263686

0.121181

1.276008

0.212871

0.171995

TCERG1L

cg10175795

0.78407

0.516304

0.267766

0.29

0.64614

0.13793

-3.2857

0.491611

0.292459

ZNF569

cg03884783

0.378155

0.200037

0.178118

0.14

0.228017

0.150139

-1.15158

0.198254

0.179902
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Table S5.2 The mutual information scores calculated on128 selected “L-shaped” genes. The column
headings are defined as follows: “Gene” is the gene symbol, “Probe” is the probe id from Illumina
Infinium Human DNA Methylation27 array, MI_max is the maximum mutual information score,
MI_min_methy is the minimum mutual information score on data split by the threshold on
methylation, MI_diff_methy is the difference between the maximum and minimum mutual
information scores on methylation.Threshold_methy_1way is the threshold predicated methylation
by the 1-way mutual information method. MI_min_exp is the minimum mutual information score on
data split by the threshold on expression, MI_diff_exp is the difference between the maximum and
minimum mutual information scores on expression.Threshold_exp_1way is the threshold predicated
on expression by the 1-way mutual information method, MI_min_12 is the minimum mutual
information score calculated by the 2-way mutual information method, and MI_diff_12 is the
difference between the maximum and minimum mutual information calculated by the 2-way mutual
information method.

gene

probe

MI_max

MI_min_
methy

MI_diff_
methy

threshold_
methy_1way

MI_min_
exp

MI_diff_
exp

threshold_
exp_1way

MI_min_1
2

MI_diff_
12

ELF5

cg01473816

0.735515

0.365517

0.369998

0.65

0.403495

0.332021

-0.56323

0.433501

0.302014

ZNF660

cg22598028

0.810154

0.529791

0.280363

0.56

0.645475

0.164679

-3.13433

0.507875

0.302279

BNC1

cg10398682

0.7974

0.530258

0.267142

0.34

0.694086

0.103314

-3.43322

0.494801

0.3026

AQP1

cg04551925

0.488725

0.216458

0.272267

0.65

0.226185

0.26254

4.347634

0.186021

0.302704

HNF1B

cg12788467

0.706421

0.242299

0.464122

0.21

0.283626

0.422795

1.065114

0.401953

0.304468

SCTR

cg15250797

0.899921

0.592828

0.307093

0.34

0.766125

0.133797

-1.54074

0.594811

0.305111

RIMS4

cg19332710

0.967803

0.675715

0.292088

0.09

0.831937

0.135866

-4.23222

0.662516

0.305287

ZNF750

cg27285599

1.081205

0.554931

0.526274

0.71

0.584408

0.496797

-1.27621

0.769256

0.311949

MKRN3

cg23234999

0.569254

0.233338

0.335915

0.69

0.225356

0.343898

-0.60685

0.256656

0.312598

ZDHHC15

cg11272332

0.458103

0.162324

0.295779

0.61

0.175179

0.282924

-1.63846

0.144598

0.313506

AR

cg07780118

1.410697

1.139401

0.271296

0.55

1.185463

0.225234

-2.3349

1.096967

0.31373

AJAP1

cg17525406

0.749099

0.441601

0.307498

0.24

0.573167

0.175931

-1.48321

0.434429

0.31467

COL17A1

cg13448625

0.688208

0.377329

0.310878

0.73

0.408947

0.279261

2.316326

0.373186

0.315021

CDH8

cg27444994

0.785918

0.512933

0.272985

0.21

0.616816

0.169102

-2.44332

0.468805

0.317113

EYA4

cg01401376

0.628242

0.320893

0.307349

0.19

0.532458

0.095784

-4.83861

0.310776

0.317466

SLC2A2

cg17142134

1.391408

0.929798

0.46161

0.77

0.961738

0.42967

-2.60575

1.073395

0.318013

BNIPL

cg11584936

0.377669

0.112681

0.264988

0.48

0.090151

0.287518

1.390571

0.059333

0.318337

ABCC2

cg17044311

0.615384

0.29788

0.317505

0.61

0.353671

0.261714

-0.77229

0.29691

0.318475

IL17RE

cg15095327

0.47712

0.19049

0.28663

0.41

0.212958

0.264162

0.697661

0.158556

0.318564

CSF3

cg21432842

0.921367

0.583928

0.337439

0.44

0.675398

0.245969

-1.53257

0.602621

0.318746

PLA2G12
B

cg02044879

0.700094

0.391152

0.308942

0.67

0.461068

0.239025

-0.61664

0.381121

0.318972

GFRA1

cg23898073

0.812224

0.507971

0.304252

0.38

0.604805

0.207418

-1.24464

0.491249

0.320975

PTK6

cg21484834

0.495062

0.200641

0.294421

0.59

0.204655

0.290407

1.509966

0.172645

0.322417

GRIK3

cg06722633

0.800611

0.447245

0.353366

0.38

0.600492

0.200119

-0.159

0.477079

0.323532

SLC10A4

cg08209133

0.975948

0.7216

0.254348

0.24

0.829085

0.146864

-3.69717

0.651721

0.324227

MIOX

cg24867501

0.596044

0.269926

0.326118

0.53

0.305587

0.290457

-1.49346

0.27115

0.324894

FUT2

cg19025034

0.689034

0.421987

0.267047

0.64

0.412492

0.276541

1.776775

0.36339

0.325644
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C1orf64

cg08887581

0.753526

0.45742

0.296106

0.55

0.510592

0.242934

-1.15974

0.427017

0.326509

CTNND2

cg25302419

0.946794

0.591773

0.355021

0.15

0.74347

0.203324

-2.34925

0.619508

0.327286

ZFP82

cg25886284

0.556009

0.189931

0.366078

0.44

0.230526

0.325483

-0.45555

0.226114

0.329895

TFF1

cg02643667

0.765564

0.390236

0.375328

0.7

0.412194

0.35337

1.537345

0.435639

0.329925

SCNN1A

cg18738906

0.812605

0.399356

0.413249

0.84

0.422281

0.390324

2.530125

0.480903

0.331702

RERG

cg19205533

0.535646

0.258539

0.277107

0.52

0.266642

0.269004

1.029177

0.203494

0.332152

GJB5

cg01333788

0.684365

0.366705

0.317661

0.59

0.438701

0.245664

-0.46991

0.351345

0.33302

SLC27A6

cg07103493

0.921344

0.626766

0.294578

0.19

0.720875

0.200468

-2.0485

0.587686

0.333657

KLF8

cg06655100

0.414627

0.128344

0.286283

0.47

0.13434

0.280287

-0.44184

0.079397

0.33523

HSPB2

cg12598198

0.528822

0.181982

0.34684

0.73

0.187582

0.34124

1.587704

0.192111

0.336712

SPDEF

cg07705908

0.4796

0.188741

0.29086

0.48

0.215167

0.264433

0.329094

0.142267

0.337334

MYO3A

cg23771603

0.744835

0.396946

0.347889

0.3

0.523339

0.221497

-2.12864

0.406577

0.338258

ZNF280B

cg16184943

0.740464

0.410234

0.33023

0.32

0.541364

0.1991

-2.0221

0.402119

0.338345

SYT9

cg08185661

0.771767

0.496032

0.275735

0.36

0.57061

0.201157

-2.83131

0.433329

0.338438

ACSS3

cg01283289

0.512383

0.196294

0.316089

0.32

0.242489

0.269895

-0.74502

0.171965

0.340418

ZNF300

cg19014419

0.674167

0.3365

0.337667

0.45

0.343022

0.331146

-1.06142

0.333666

0.340502

SDCBP2

cg16173067

0.793389

0.496307

0.297082

0.54

0.507857

0.285532

1.690591

0.451909

0.34148

ESR1

cg11251858

0.556531

0.237457

0.319074

0.23

0.276133

0.280398

-1.95442

0.214283

0.342248

PCDHAC1

cg12629325

1.245624

0.917178

0.328446

0.7

1.004481

0.241143

-2.72548

0.900754

0.34487

QRFPR

cg00015770

0.775014

0.455846

0.319168

0.26

0.546744

0.22827

-2.1042

0.429645

0.345368

RNF186

cg09195271

0.488165

0.175055

0.31311

0.49

0.226956

0.261209

0.434018

0.139986

0.34818

NLRP6

cg09205751

1.032516

0.739321

0.293196

0.58

0.837747

0.194769

-1.31783

0.683545

0.348971

TRIM29

cg13625403

0.698953

0.38551

0.313444

0.72

0.410654

0.288299

3.132584

0.349665

0.349289

C19orf46

cg18542098

0.561077

0.229331

0.331746

0.58

0.21359

0.347488

1.251329

0.209131

0.351946

FUT6

cg00579402

0.48988

0.19361

0.29627

0.55

0.200781

0.289098

1.244701

0.135357

0.354523

FRMD1

cg00350478

0.915153

0.57194

0.343213

0.46

0.764102

0.15105

-1.17138

0.559785

0.355368

TRIM31

cg00679556

1.196369

0.776016

0.420353

0.32

0.78661

0.409759

1.542483

0.838973

0.357396

PKLR

cg02280309

0.566715

0.229336

0.337379

0.54

0.272666

0.294049

-0.56814

0.203941

0.362775

LAMB3

cg01580568

0.673686

0.347255

0.326431

0.64

0.379195

0.294491

2.501904

0.309883

0.363803

PTPRH

cg11261264

0.71989

0.383755

0.336135

0.49

0.438244

0.281647

0.992225

0.355374

0.364516

SLC5A8

cg10141715

0.832332

0.497111

0.335221

0.45

0.602577

0.229755

-3.29278

0.466493

0.365839

OPRK1

cg25990647

0.957108

0.526838

0.43027

0.5

0.618263

0.338845

-2.99389

0.590702

0.366406

CRYAB

cg15227610

0.502165

0.162421

0.339744

0.49

0.152555

0.34961

4.876306

0.135562

0.366604

GGT6

cg04511534

0.628586

0.312934

0.315651

0.62

0.30334

0.325246

1.38697

0.261784

0.366801

TSPYL5

cg15747595

0.607299

0.260296

0.347003

0.62

0.287044

0.320255

0.134197

0.240189

0.36711

C1orf51

cg09563216

0.479246

0.12577

0.353476

0.42

0.150387

0.328859

-0.03753

0.107255

0.371991

PDZD3

cg09799714

0.99307

0.633584

0.359486

0.61

0.737601

0.255468

-1.66304

0.620425

0.372645

POU4F1

cg08097882

0.570379

0.201465

0.368913

0.28

0.435486

0.134893

-4.37757

0.195556

0.374823

SLC44A4

cg07363637

0.531739

0.200281

0.331459

0.52

0.212227

0.319512

3.354669

0.156722

0.375017

IL1A

cg00839584

1.219214

0.862595

0.356618

0.45

1.002302

0.216912

-2.47846

0.842711

0.376503

ARSE

cg11964613

0.867826

0.469613

0.398213

0.43

0.493215

0.374611

1.468561

0.48941

0.378415

PROM2

cg20775254

0.646546

0.227767

0.418779

0.6

0.251476

0.39507

1.43697

0.267849

0.378697

MST1R

cg08687163

0.799316

0.34714

0.452176

0.74

0.358414

0.440902

1.225448

0.419

0.380316
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HOXA9

cg27009703

0.776843

0.435609

0.341234

0.59

0.448497

0.328346

0.966311

0.395496

0.381347

EFHA2

cg26831415

0.895025

0.546818

0.348207

0.41

0.618256

0.276769

-1.42114

0.51238

0.382645

C9orf167

cg07717632

0.464618

0.09617

0.368449

0.24

0.102045

0.362573

1.68074

0.081905

0.382714

ZNF625

cg17892556

0.51436

0.173167

0.341193

0.5

0.192065

0.322295

-1.0213

0.128129

0.38623

ZNF154

cg21790626

0.844424

0.502406

0.342019

0.55

0.537558

0.306867

-0.68034

0.45538

0.389044

IL20RA

cg22487322

0.527202

0.173394

0.353807

0.67

0.204838

0.322364

0.408141

0.136437

0.390765

ZG16B

cg26259865

0.699068

0.335499

0.363568

0.58

0.342143

0.356925

0.91889

0.305258

0.39381

MAP9

cg03616357

0.569406

0.215317

0.354089

0.5

0.228202

0.341203

0.202835

0.174758

0.394648

SPESP1

cg09886641

0.700947

0.30479

0.396157

0.7

0.373778

0.327169

0.327288

0.301781

0.399167

MUC13

cg09081544

0.60281

0.203562

0.399248

0.53

0.23206

0.37075

3.883348

0.199972

0.402839

C10orf81

cg10368842

0.56222

0.217218

0.345001

0.46

0.221419

0.340801

0.027331

0.159156

0.403064

AMT

cg20191453

0.529286

0.183579

0.345707

0.66

0.177

0.352287

1.208175

0.125002

0.404284

TRIM55

cg23322523

0.786631

0.400507

0.386124

0.53

0.472923

0.313708

-1.9437

0.380077

0.406554

C17orf73

cg03016571

0.538502

0.15689

0.381612

0.5

0.148801

0.389701

0.568318

0.128526

0.409976

ADHFE1

cg08090772

0.567394

0.196004

0.371391

0.46

0.22613

0.341264

-0.59164

0.155751

0.411644

FXYD3

cg02633817

0.525605

0.140403

0.385202

0.62

0.15792

0.367685

2.933435

0.109581

0.416024

S100P

cg22266967

0.555592

0.176513

0.379079

0.51

0.199093

0.356499

3.061998

0.139353

0.41624

PPP1R14
D

cg04968426

0.562222

0.178981

0.383241

0.58

0.186838

0.375385

2.089626

0.144708

0.417514

CFTR

cg25509184

1.091757

0.682676

0.409081

0.3

0.753909

0.337847

0.894448

0.671309

0.420448

WDR17

cg18443378

0.917938

0.545883

0.372055

0.21

0.613637

0.304301

-2.11554

0.496885

0.421053

ZNF542

cg26309134

0.564676

0.200377

0.364298

0.44

0.22219

0.342485

0.185751

0.143361

0.421315

PLD5

cg12613383

1.105161

0.714951

0.39021

0.33

0.95884

0.146322

-3.91296

0.683786

0.421375

GRIN2A

cg01722994

0.865231

0.521814

0.343417

0.28

0.69796

0.167271

-3.80076

0.442957

0.422274

ADH6

cg06518271

0.763355

0.295122

0.468233

0.64

0.34885

0.414505

-1.51351

0.338687

0.424668

FERMT1

cg09539538

0.80119

0.39755

0.40364

0.42

0.393227

0.407963

1.802201

0.374811

0.42638

CFI

cg12243271

0.556621

0.192373

0.364248

0.59

0.190559

0.366061

2.738497

0.125797

0.430824

SGK2

cg17463527

0.683206

0.285248

0.397958

0.57

0.309921

0.373285

0.40685

0.24935

0.433856

POU3F3

cg20291049

0.83464

0.422907

0.411733

0.23

0.446055

0.388585

0.173539

0.39827

0.43637

HKDC1

cg11762346

0.792341

0.397796

0.394545

0.5

0.476037

0.316304

-0.82915

0.354975

0.437366

ZNF135

cg16638540

0.656561

0.266618

0.389943

0.61

0.282597

0.373965

-0.8111

0.214471

0.442091

RBP5

cg24441911

0.609581

0.193144

0.416438

0.67

0.204222

0.40536

2.562149

0.162078

0.447504

FUT9

cg01837719

1.514984

1.10021

0.414775

0.23

1.290737

0.224247

-4.87768

1.064773

0.450211

ELOVL2

cg13562911

1.006106

0.576278

0.429828

0.3

0.691245

0.314861

-1.94761

0.55532

0.450786

MEP1A

cg20980592

0.691537

0.309015

0.382523

0.65

0.509764

0.181773

0.561969

0.239937

0.4516

GPA33

cg06665322

0.683287

0.276509

0.406778

0.47

0.290014

0.393273

2.688244

0.229175

0.454112

CCL15

cg23743114

0.572053

0.135469

0.436584

0.46

0.170003

0.402049

-0.16002

0.11699

0.455063

SPINK1

cg04577715

0.571031

0.259503

0.311528

0.65

0.175335

0.395696

2.964529

0.112849

0.458182

KRT20

cg25124433

0.597884

0.172336

0.425548

0.73

0.179377

0.418507

1.989879

0.13845

0.459434

LGALS4

cg06394229

0.71857

0.301996

0.416574

0.45

0.339338

0.379232

3.4325

0.258952

0.459618

GUCY2C

cg18754342

0.639586

0.17

0.469586

0.5

0.193055

0.446531

1.373467

0.162648

0.476939

RXFP4

cg08403419

0.978926

0.572869

0.406057

0.32

0.657796

0.32113

-2.15265

0.494636

0.48429

RIC3

cg08383315

1.306606

0.949637

0.356969

0.34

1.082187

0.22442

-2.97625

0.82194

0.484666

MYO1A

cg09541248

1.331314

0.910194

0.421119

0.38

0.975095

0.356219

0.692855

0.842628

0.488686
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FAM3D

cg02194211

0.703317

0.230127

0.47319

0.67

0.286637

0.41668

3.942016

0.202327

0.50099

EPS8L3

cg00491404

1.112369

0.662543

0.449826

0.51

0.692608

0.419762

2.764433

0.603092

0.509278

SOX11

cg08432727

1.557355

1.177898

0.379457

0.46

1.333619

0.223737

-2.77406

1.041207

0.516148

HNF1A

cg16175725

0.692391

0.152521

0.53987

0.63

0.172907

0.519485

0.840162

0.169552

0.522839

CDX1

cg15452204

0.852634

0.411413

0.441222

0.51

0.41054

0.442094

1.512887

0.328988

0.523647

CDH16

cg14221831

1.104623

0.658576

0.446046

0.62

0.684173

0.42045

1.071852

0.578087

0.526536

DQX1

cg02034222

0.784156

0.318513

0.465643

0.66

0.330438

0.453718

-0.31324

0.256062

0.528094

ARL14

cg24147596

0.999617

0.536725

0.462892

0.51

0.55707

0.442547

-0.89091

0.463837

0.535779

CLRN3

cg23817637

0.79768

0.346046

0.451633

0.47

0.366644

0.431036

1.132192

0.244632

0.553048

KCNQ5

cg15717808

1.032089

0.486842

0.545247

0.31

0.583496

0.448593

-2.60956

0.463127

0.568962

SLC39A5

cg00668685

0.961775

0.476375

0.4854

0.61

0.505763

0.456012

1.003672

0.391803

0.569973

ST6GALN
AC1

cg13015534

1.16578

0.660012

0.505768

0.39

0.6851

0.48068

-1.12498

0.582409

0.583371

PAX8

cg07403255

0.80501

0.221437

0.583574

0.54

0.222126

0.582885

1.642063

0.193171

0.611839

GPX2

cg09643186

1.091144

0.529561

0.561583

0.64

0.561502

0.529642

3.109897

0.472359

0.618785

CDH17

cg12038710

0.958454

0.432057

0.526397

0.59

0.43411

0.524344

2.838026

0.314921

0.643533
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Table S5.3 Gene set enrichment analysis (GSEA) on 128 identified “L-shaped” genes from MsigDB.
Top 50 significant gene set enrichments, with p-value < 0.05, are shown in three categories: curated
gene sets, GO gene set and oncogene signatures.

Curated gene sets
Gene Set Name

#
Genes
in Gene
Set (K)

DOANE_BREAST_CANCE
R_ESR1_UP

112

DODD_NASOPHARYNGE
AL_CARCINOMA_UP
SERVITJA_ISLET_HNF1A_
TARGETS_DN
TURASHVILI_BREAST_LO
BULAR_CARCINOMA_VS
_DUCTAL_NORMAL_DN
HUPER_BREAST_BASAL_
VS_LUMINAL_UP
JAEGER_METASTASIS_D
N
TURASHVILI_BREAST_DU
CTAL_CARCINOMA_VS_D
UCTAL_NORMAL_DN

1821
109
91
54
258
198

ONDER_CDH1_TARGETS
_2_DN

464

CERVERA_SDHB_TARGET
S_1_DN

38

HATADA_METHYLATED_I
N_LUNG_CANCER_UP
LEE_LIVER_CANCER_SUR
VIVAL_UP
GOZGIT_ESR1_TARGETS_
DN

390
185
781

SMID_BREAST_CANCER_
RELAPSE_IN_BRAIN_DN
VECCHI_GASTRIC_CANCE
R_ADVANCED_VS_EARLY
_DN
PID_A6B1_A6B4_INTEGR
IN_PATHWAY

138

MIKKELSEN_ES_LCP_WIT
H_H3K4ME3

142

SENGUPTA_NASOPHARY
NGEAL_CARCINOMA_DN
SMID_BREAST_CANCER_
RELAPSE_IN_BONE_UP
YOSHIMURA_MAPK8_TA
RGETS_UP

85

46

349

Description
Genes up-regulated in breast cancer samples positive
for ESR1 [GeneID=2099] compared to the ESR1 negative
tumors.
Genes up-regulated in nasopharyngeal carcinoma (NPC)
compared to the normal tissue.
Genes down-regulated in pancreatic islets upon
knockout of HNF1A [GeneID=6927].
Genes down-regulated in lobular carcinoma vs normal
ductal breast cells.
Genes up-regulated in basal mammary epithelial cells
compared to the luminal ones.
Genes down-regulated in metastases from malignant
melanoma compared to the primary tumors.
Genes down-regulated in ductal carcinoma vs normal
ductal breast cells.
Genes down-regulated in HMLE cells (immortalized
nontransformed mammary epithelium) after Ecadhedrin (CDH1) [GeneID=999] knockdown by RNAi.
Genes turned off in Hep3B cells (hepatocellular
carcinoma, HCC) upon knockdown of SDHB
[GeneID=6390] by RNAi.
Genes with hypermethylated DNA in lung cancer
samples.
Genes highly expressed in hepatocellular carcinoma
with good survival.
Genes down-regulated in TMX2-28 cells (breast cancer)
which do not express ESR1 [GeneID=2099]) compared
to the parental MCF7 cells which do.
Genes down-regulated in brain relapse of breast
cancer.
Down-regulated genes distinguishing between two
subtypes of gastric cancer: advanced (AGC) and early
(EGC).
a6b1 and a6b4 Integrin signaling
Genes with low-CpG-density promoters (LCP) bearing
histone H3 trimethylation mark at K4 (H3K4me3) in
embryonic stem cells (ES).
Genes down-regulated in nsopharyngeal carcinoma
relative to the normal tissue.

# Genes
in Overlap
(k)

k/K

p value

8

0.0714

2.11E-07

30

0.0154

5.55E-07

7

0.0642

2.56E-06

6

0.0659

1.18E-05

5

0.0926

1.24E-05

9

0.0349

1.42E-05

9

0.0404

1.51E-05

11

0.0237

5.65E-05

4

0.1053

5.79E-05

10

0.0256

6.53E-05

7

0.0378

7.95E-05

15

0.0179

1.12E-04

5

0.0588

1.12E-04

6

0.0435

1.23E-04

4

0.087

1.24E-04

7

0.0423

1.44E-04

9

0.0258

1.47E-04

97

Genes up-regulated in bone relapse of breast cancer.

5

0.0515

2.09E-04

1305

Genes up-regulated in vascular smooth muscle cells
(VSMC) by MAPK8 (JNK1) [GeneID=5599].

18

0.0138

3.10E-04

112

WAGNER_APO2_SENSITI
VITY
KEGG_GLYCOSPHINGOLI
PID_BIOSYNTHESIS_LACT
O_AND_NEOLACTO_SERI
ES
FEVR_CTNNB1_TARGETS
_UP
MIKKELSEN_IPS_LCP_WI
TH_H3K4ME3
LIEN_BREAST_CARCINO
MA_METAPLASTIC_VS_D
UCTAL_DN
HOEGERKORP_CD44_TA
RGETS_DIRECT_UP
LIM_MAMMARY_LUMIN
AL_MATURE_UP
FARMER_BREAST_CANCE
R_BASAL_VS_LULMINAL
CHARAFE_BREAST_CANC
ER_BASAL_VS_MESENCH
YMAL_UP
LI_PROSTATE_CANCER_E
PIGENETIC
CREIGHTON_ENDOCRINE
_THERAPY_RESISTANCE_
3

25

Genes whose expression most significantly correlated
with cancer cell line sensitivity to the proapoptotic
ligand APO2 [GeneID=8797].

3

0.12

3.52E-04

26

Glycosphingolipid biosynthesis - lacto and neolacto
series

3

0.1154

3.97E-04

12

0.0176

4.19E-04

7

0.0345

4.29E-04

5

0.0439

4.42E-04

3

0.1111

4.44E-04

5

0.0431

4.78E-04

8

0.0242

5.21E-04

5

0.0413

5.80E-04

3

0.1

6.09E-04

13

0.0167

6.76E-04

5

0.0388

7.75E-04

5

0.0373

9.20E-04

10

0.02

9.29E-04

11

0.017

9.81E-04

3

0.0833

1.05E-03

3

0.0833

1.05E-03

4

0.0494

1.09E-03

10

0.0177

1.21E-03

16

0.0134

1.35E-03

9

0.0185

1.61E-03

682
174
114
27
116

330

121
30
720

KIM_RESPONSE_TO_TSA
_AND_DECITABINE_UP

129

POOLA_INVASIVE_BREAS
T_CANCER_DN

134

CHARAFE_BREAST_CANC
ER_LUMINAL_VS_MESEN
CHYMAL_UP
SMID_BREAST_CANCER_
BASAL_UP

450
648

LIU_CDX2_TARGETS_UP

36

YANG_BREAST_CANCER_
ESR1_UP

36

WATANABE_COLON_CA
NCER_MSI_VS_MSS_DN

81

SMID_BREAST_CANCER_
LUMINAL_B_DN

564

BENPORATH_ES_WITH_
H3K27ME3

1118

SCHAEFFER_PROSTATE_
DEVELOPMENT_48HR_U

487

Genes up-regulated in intestinal crypt cells upon
deletion of CTNNB1 [GeneID=1499].
Table 2S. Genes in MEF, MCV6, MCV8.1 and ES cells by
epigenetic mark of their promoter
Genes down-regulated between two breast carcinoma
subtypes: metaplastic (MCB) and ductal (DCB).
Genes directly up-regulated by CD44 [GeneID=960]
stimulation of B lymphocytes.
Genes consistently up-regulated in mature mammary
luminal cells both in mouse and human species.
Genes which best discriminated between two groups of
breast cancer according to the status of ESR1 and AR
[GeneID=2099;367]: basal (ESR1- AR-) and luminal
(ESR1+ AR+).
Genes up-regulated in basal-like breast cancer cell lines
as compared to the mesenchymal-like ones.
Genes affected by epigenetic aberrations in prostate
cancer.
The 'group 3 set' of genes associated with acquired
endocrine therapy resistance in breast tumors
expressing ESR1 and ERBB2 [GeneID=2099;2064].
Genes up-regulated in glioma cell lines treated with
both decitabine [PubChem=451668] and TSA
[PubChem=5562].
Genes down-regulated in atypical ductal hyperplastic
tissues from patients with (ADHC) breast cancer vs
those without the cancer (ADH).
Genes up-regulated in luminal-like breast cancer cell
lines compared to the mesenchymal-like ones.
Genes up-regulated in basal subtype of breast cancer
samles.
Genes up-regulated in HET1A cells (esophagus
epithelium) engineered to stably express CDX2
[GeneID=1045].
Genes up-regulated in early primary breast tumors
expressing ESR1 [GeneID=2099] vs the ESR1 negative
ones.
Down-regulated genes discriminating between MSI
(microsatellite instability) and MSS (microsatellite
stability) colon cancers.
Genes down-regulated in the luminal B subtype of
breast cancer.
Set 'H3K27 bound': genes posessing the trimethylated
H3K27 (H3K27me3) mark in their promoters in human
embryonic stem cells, as identified by ChIP on chip.
Genes up-regulated in the urogenital sinus (UGS) of day
E16 females exposed to the androgen
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P

dihydrotestosterone [PubChem=10635] for 48 h.

ACEVEDO_FGFR1_TARGE
TS_IN_PROSTATE_CANCE
R_MODEL_DN

308

MIKKELSEN_MEF_HCP_
WITH_H3K27ME3

590

SMID_BREAST_CANCER_
BASAL_DN
PID_HNF3APATHWAY
TURASHVILI_BREAST_LO
BULAR_CARCINOMA_VS
_LOBULAR_NORMAL_UP

701
44
94

JI_CARCINOGENESIS_BY_
KRAS_AND_STK11_UP

12

MIKKELSEN_MCV6_LCP_
WITH_H3K4ME3

162

MADAN_DPPA4_TARGET
S
REACTOME_TRANSMEM
BRANE_TRANSPORT_OF_
SMALL_MOLECULES
RAY_ALZHEIMERS_DISEA
SE

46

Genes down-regulated during prostate cancer
progression in the JOCK1 model due to inducible
activation of FGFR1 [GeneID=2260] gene in prostate.
Genes with high-CpG-density promoters (HCP) bearing
histone H3 trimethylation mark at K27 (H3K27me3) in
MEF cells (embryonic fibroblast).
Genes down-regulated in basal subtype of breast
cancer samles.
FOXA1 transcription factor network

7

0.0227

1.69E-03

10

0.0169

1.69E-03

11

0.0157

1.83E-03

3

0.0682

1.88E-03

Genes up-regulated in lobular carcinoma vs normal
lobular breast cells.

4

0.0426

1.88E-03

2

0.1667

1.95E-03

6

0.0309

2.13E-03

3

0.0652

2.14E-03

Cluster A: genes up-regulated in primary lung tumors
driven by KRAS [GeneID=3845] activation and loss of
STK11 [GeneID=6794]; also up-regulated in human
squamous cell carcinoma (SCC) vs adenocarcinoma
subtype of NSCLC (non-small cell lung cancer).
Genes with low-CpG-density promoters (LCP) bearing
the tri-methylation mark at H3K4 (H3K4me3) in MCV6
cells (embryonic fibroblasts trapped in a differentiated
state).
Genes differentially expressed in ES cells with DPPA4
[GeneID=55211] knockout.

413

Genes involved in Transmembrane transport of small
molecules

8

0.0194

2.18E-03

13

A biomarker of plasma signaling proteins that predicts
clinical Alzheimer's diagnosis.

2

0.1538

2.30E-03

3

0.3

3.07E-04

2

0.2

8.28E-03

3

0.0833

1.40E-02

4

0.0563

1.78E-02

2

0.1176

2.35E-02

2

0.1176

2.35E-02

2

0.1111

2.61E-02

GO gene sets
FUCOSYLTRANSFERASE_
ACTIVITY

10

IONOTROPIC_GLUTAMAT
E_RECEPTOR_ACTIVITY

10

EXCRETION

36

EPIDERMIS_DEVELOPME
NT

71

APICAL_PART_OF_CELL

17

GLUTAMATE_SIGNALING
_PATHWAY

17

ACTIN_FILAMENT

18

Genes annotated by the GO term GO:0008417.
Catalysis of the transfer of a fucosyl group to an
acceptor molecule, typically another carbohydrate or a
lipid.
Genes annotated by the GO term GO:0004970.
Combining with glutamate to initiate a change in cell
activity through the regulation of ion channels.
Genes annotated by the GO term GO:0007588. The
elimination by an organism of the waste products that
arise as a result of metabolic activity. These products
include water, carbon dioxide (CO2), and nitrogenous
compounds.
Genes annotated by the GO term GO:0008544. The
process whose specific outcome is the progression of
the epidermis over time, from its formation to the
mature structure. The epidermis is the outer epithelial
layer of a plant or animal, it may be a single layer that
produces an extracellular material (e.g. the cuticle of
arthropods) or a complex stratified squamous
epithelium, as in the case of many vertebrate species.
Genes annotated by the GO term GO:0045177. The
apical region of a cell.
Genes annotated by the GO term GO:0007215. The
series of molecular signals generated as a consequence
of glutamate binding to a cell surface receptor.
Genes annotated by the GO term GO:0005884. A
filamentous structure formed of a two-stranded helical
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ECTODERM_DEVELOPME
NT

80

CHLORIDE_CHANNEL_AC
TIVITY

19

ANION_CHANNEL_ACTIVI
TY

20

GLUTAMATE_RECEPTOR
_ACTIVITY

20

NEGATIVE_REGULATION
_OF_TRANSPORT

20

CHANNEL_REGULATOR_
ACTIVITY

24

polymer of the protein actin and associated proteins.
Actin filaments are a major component of the
contractile apparatus of skeletal muscle and the
microfilaments of the cytoskeleton of eukaryotic cells.
The filaments, comprising polymerized globular actin
molecules, appear as flexible structures with a diameter
of 5-9 nm. They are organized into a variety of linear
bundles, two-dimensional networks, and three
dimensional gels. In the cytoskeleton they are most
highly concentrated in the cortex of the cell just
beneath the plasma membrane.
Genes annotated by the GO term GO:0007398. The
process whose specific outcome is the progression of
the ectoderm over time, from its formation to the
mature structure. In animal embryos, the ectoderm is
the outer germ layer of the embryo, formed during
gastrulation.
Genes annotated by the GO term GO:0005254.
Catalysis of facilitated diffusion of an chloride (by an
energy-independent process) involving passage through
a transmembrane aqueous pore or channel without
evidence for a carrier-mediated mechanism.
Genes annotated by the GO term GO:0005253.
Catalysis of the energy-independent passage of anions
across a lipid bilayer down a concentration gradient.
Genes annotated by the GO term GO:0008066.
Combining with glutamate to initiate a change in cell
activity.
Genes annotated by the GO term GO:0051051. Any
process that stops, prevents or reduces the frequency,
rate or extent of the directed movement of substances
(such as macromolecules, small molecules, ions) into,
out of, within or between cells.
Genes annotated by the GO term GO:0016247.

4

0.05

2.63E-02

2

0.1053

2.90E-02

2

0.1

3.19E-02

2

0.1

3.19E-02

2

0.1

3.19E-02

2

0.0833

4.47E-02

6

0.0316

1.43E-02

5

0.0355

1.58E-02

5

0.0262

4.90E-02

5

0.026

4.99E-02

Oncogene signatures
LEF1_UP.V1_DN

190

RELA_DN.V1_DN

141

ESC_J1_UP_LATE.V1_UP

191

P53_DN.V1_DN

192

Genes down-regulated in DLD1 cells (colon carcinoma)
over-expressing LEF1 [Gene ID=51176].
Genes down-regulated in HEK293 cells (kidney
fibroblasts) upon knockdown of RELA [Gene ID=5970]
gene by RNAi.
Genes up-regulated during late stages of differentiation
of embryoid bodies from J1 embryonic stem cells.
Genes down-regulated in NCI-60 panel of cell lines with
mutated TP53 [Gene ID=7157].
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Table S5.4 Associated network functions and biofunctions analysis on 128 identified “L-shaped”
genes by IPA.
Top Networks
Associated Network Functions
Gastrointestinal Disease, Hepatic System Disease, Liver Cholestasis
Endocrine System Disorders, Gastrointestinal Disease, Hereditary Disorder
Cellular Compromise, Neurological Disease, Organismal Injury and Abnormalities
Cell-To-Cell Signaling and Interaction, Hair and Skin Development and Function,
Tissue Development
5 Hereditary Disorder, Metabolic Disease, Renal and Urological Disease

ID
1
2
3
4

Name
Cancer
Gastrointestinal Disease
Inflammatory Response
Organismal Injury and
Abnormalities
Developmental Disorder

Name
Lipid Metabolism 4.62E-05
Molecular Transport 4.62E05
Small Molecule Biochemistry
Cell Death and Survival
Gene Expression

Diseases and Disorders
p-value
5.55E-08 - 1.36E-02
3.94E-05 - 1.36E-02
4.91E-05 - 1.36E-02

#Molecules
54
37
10

1.00E-04 - 1.36E-02
2.75E-04 - 1.36E-02

21
23

Molecular and Cellular Functions
p-value
4.62E-05 - 1.15E-02

#Molecules
12

4.62E-05 - 8.10E-03
4.62E-05 -1.26E-02
4.91E-05 - 1.36E-02
1.02E-04 - 1.06E-02

13
20
15
6
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Score
49
38
36
27
24

Table S5.5 Gene set enrichment analysis (GSEA) on 25 genes from MsigDB. These 25 genes were
identified to have the most differential methylation when comparing tumor samples with normal
samples. Top 50 significant gene set enrichments, with p-value < 0.05, are shown in three categories:
curated gene sets, GO gene set and oncogene signatures.

Curated gene sets
Gene Set Name
TURASHVILI_BREAST_DU
CTAL_CARCINOMA_VS_D
UCTAL_NORMAL_DN
SMID_BREAST_CANCER_
LUMINAL_B_DN
HOEGERKORP_CD44_TA
RGETS_DIRECT_UP
SMID_BREAST_CANCER_
NORMAL_LIKE_UP
PID_A6B1_A6B4_INTEGR
IN_PATHWAY
BIOCARTA_HSP27_PATH
WAY
CHARAFE_BREAST_CANC
ER_LUMINAL_VS_BASAL
_DN
TURASHVILI_BREAST_LO
BULAR_CARCINOMA_VS
_DUCTAL_NORMAL_DN
TURASHVILI_BREAST_LO
BULAR_CARCINOMA_VS
_LOBULAR_NORMAL_UP
SMID_BREAST_CANCER_
RELAPSE_IN_BONE_UP
LIM_MAMMARY_STEM_
CELL_UP
DOANE_BREAST_CANCE
R_ESR1_UP

FARMER_BREAST_CANCE
R_BASAL_VS_LULMINAL
SMID_BREAST_CANCER_
BASAL_UP
SMID_BREAST_CANCER_
RELAPSE_IN_BRAIN_UP

Description

k/K

p value

7

0.0303

7.51E-08

7

0.0124

2.23E-06

3

0.1111

3.74E-06

6

0.0126

1.23E-05

476

Genes down-regulated in ductal carcinoma vs normal
ductal breast cells.
Genes down-regulated in the luminal B subtype of
breast cancer.
Genes directly up-regulated by CD44 [GeneID=960]
stimulation of B lymphocytes.
Genes up-regulated in the normal-like subtype of breast
cancer.

46

a6b1 and a6b4 Integrin signaling

3

0.0652

1.92E-05

15

Stress Induction of HSP Regulation

2

0.1333

1.30E-04

455

Genes down-regulated in luminal-like breast cancer cell
lines compared to the basal-like ones.

5

0.011

1.40E-04

91

Genes down-regulated in lobular carcinoma vs normal
ductal breast cells.

3

0.033

1.48E-04

94

Genes up-regulated in lobular carcinoma vs normal
lobular breast cells.

3

0.0319

1.63E-04

Genes up-regulated in bone relapse of breast cancer.
Genes consistently up-regulated in mammary stem cells
both in mouse and human species.
Genes up-regulated in breast cancer samples positive
for ESR1 [GeneID=2099] compared to the ESR1 negative
tumors.
Genes which best discriminated between two groups of
breast cancer according to the status of ESR1 and AR
[GeneID=2099;367]: basal (ESR1- AR-) and luminal
(ESR1+ AR+).
Genes up-regulated in basal subtype of breast cancer
samles.

3

0.0309

1.79E-04

5

0.0102

1.96E-04

3

0.0268

2.74E-04

4

0.0121

4.92E-04

5

0.0077

7.12E-04

2

0.0513

9.00E-04

4

0.0101

9.64E-04

5

0.0071

1.01E-03

2

0.0465

1.09E-03

2

0.04

1.48E-03

198
564
27

97
489

112

330
648

COWLING_MYCN_TARGE
TS

43

Genes up-regulated in brain relapse of breast cancer.
Genes up-regulated in MDA-MB-231 cells (breast
cancer) after knockdown of SATB1 [GeneID=6304] by
RNAi.
Genes down-regulated in basal subtype of breast
cancer samles.
Genes down-regulated by MYCN [GeneID=4613] but
not by its transactivation-defficient, trunkated form NMyc-delta-73.

BECKER_TAMOXIFEN_RE

50

Genes up-regulated in a breast cancer cell line resistant

HAN_SATB1_TARGETS_U
P
SMID_BREAST_CANCER_
BASAL_DN

# Genes
in Overlap
(k)

39

395
701

117

SISTANCE_UP

HALMOS_CEBPA_TARGE
TS_UP

EBAUER_TARGETS_OF_P
AX3_FOXO1_FUSION_UP
HUPER_BREAST_BASAL_
VS_LUMINAL_UP

52

207
54

SU_PANCREAS

54

ONDER_CDH1_TARGETS
_2_DN

464

ISSAEVA_MLL2_TARGETS
PID_ERA_GENOMIC_PAT
HWAY
JAEGER_METASTASIS_D
N
REACTOME_CELL_JUNCTI
ON_ORGANIZATION
CHIANG_LIVER_CANCER_
SUBCLASS_POLYSOMY7_
UP
CROMER_METASTASIS_D
N
SMID_BREAST_CANCER_
RELAPSE_IN_BRAIN_DN
GHANDHI_BYSTANDER_I
RRADIATION_UP
BILANGES_SERUM_SENSI
TIVE_GENES
CADWELL_ATG16L1_TAR
GETS_UP
SMID_BREAST_CANCER_
RELAPSE_IN_BONE_DN

LEI_MYB_TARGETS
BENPORATH_EED_TARG
ETS
GHANDHI_DIRECT_IRRA
DIATION_UP
SENGUPTA_NASOPHARY
NGEAL_CARCINOMA_DN
LIEN_BREAST_CARCINO
MA_METAPLASTIC_VS_D
UCTAL_DN
LIM_MAMMARY_LUMIN
AL_MATURE_UP

62
65
258
78

79

81
85
86

90

93
315

318

1062
110
349

114
116

to tamoxifen [PubChem=5376] compared to the
parental line sensitive to the drug.
Genes up-regulated in H358 cells (lung cancer) by
inducible expression of CEBPA [GeneID=1050] off
plasmid vector.
Genes up-regulated in Rh4 cells (alveolar
rhabdomyosarcoma, ARMS) after knockdown of the
PAX3-FOXO1 [GeneiD=5077;2308] fusion protein by
RNAi for 72 hr.
Genes up-regulated in basal mammary epithelial cells
compared to the luminal ones.

2

0.0385

1.60E-03

3

0.0145

1.63E-03

2

0.037

1.72E-03

Genes up-regulated specifically in human pancreas.
Genes down-regulated in HMLE cells (immortalized
nontransformed mammary epithelium) after Ecadhedrin (CDH1) [GeneID=999] knockdown by RNAi.
Genes down-regulated in HeLa cells upon knockdown of
MLL2 [GeneID=8085] by RNAi.

2

0.037

1.72E-03

4

0.0086

1.75E-03

2

0.0323

2.26E-03

Validated nuclear estrogen receptor alpha network
Genes down-regulated in metastases from malignant
melanoma compared to the primary tumors.

2

0.0308

2.48E-03

3

0.0116

3.05E-03

Genes involved in Cell junction organization
Marker genes up-regulated in the 'chromosome 7
polysomy' subclass of hepatocellular carcinoma (HCC);
characterized by polysomy of chromosome 7 and by a
lack of gains of chromosome 8q.
Metastatic propensity markers of head and neck
squamous cell carcinoma (HNSCC): down-regulated in
metastatic vs non-metastatic tumors.
Genes down-regulated in brain relapse of breast
cancer.
Genes significantly (FDR < 10%) up-regulated in IMR-90
cells (fibroblast) in response to bystander irradiation.
Genes translationally regulated in MEF cells (embryonic
fibroblasts) in response to serum starvation but not by
rapamycin (sirolimus) [PubChemID=6610346].
Genes up-regulated in Paneth cell (part of intestiinal
epithelium) of mice with hypomorphic (reduced
function) form of ATG16L1 [GeneID=55054].

2

0.0256

3.55E-03

2

0.0253

3.64E-03

2

0.0247

3.82E-03

2

0.0235

4.20E-03

2

0.0233

4.30E-03

2

0.0222

4.70E-03

2

0.0215

5.00E-03

Genes down-regulated in bone relapse of breast cancer.
Myb-regulated genes in MCF7 (breast cancer) and lung
epithelial cell lines overexpressing MYBL2, MYBL1 or
MYB [GeneID=4605;4603;4602].
Set 'Eed targets': genes identified by ChIP on chip as
targets of the Polycomb protein EED [GeneID=8726] in
human embryonic stem cells.
Genes significantly (FDR < 10%) up-regulated in IMR-90
cells (fibroblast) in response to direct irradiation.
Genes down-regulated in nsopharyngeal carcinoma
relative to the normal tissue.

3

0.0095

5.32E-03

3

0.0094

5.47E-03

5

0.0047

6.17E-03

2

0.0182

6.93E-03

3

0.0086

7.07E-03

2

0.0175

7.43E-03

2

0.0172

7.68E-03

Genes down-regulated between two breast carcinoma
subtypes: metaplastic (MCB) and ductal (DCB).
Genes consistently up-regulated in mature mammary
luminal cells both in mouse and human species.

118

CERVERA_SDHB_TARGET
S_1_UP
REACTOME_CELL_CELL_C
OMMUNICATION
CHARAFE_BREAST_CANC
ER_LUMINAL_VS_BASAL
_UP
YEGNASUBRAMANIAN_P
ROSTATE_CANCER
SENESE_HDAC2_TARGET
S_DN
LIM_MAMMARY_STEM_
CELL_DN
RIGGI_EWING_SARCOM
A_PROGENITOR_UP
CHARAFE_BREAST_CANC
ER_LUMINAL_VS_MESEN
CHYMAL_UP
DODD_NASOPHARYNGE
AL_CARCINOMA_UP

118

Genes turned on in Hep3B cells (hepatocellular
carcinoma, HCC) upon knockdown of SDHB
[GeneID=6390] by RNAi.

2

0.0169

7.94E-03

120

Genes involved in Cell-Cell communication

2

0.0167

8.20E-03

3

0.0079

8.92E-03

2

0.0156

9.28E-03

2

0.015

9.99E-03

3

0.007

1.23E-02

3

0.007

1.25E-02

3

0.0067

1.41E-02

7

0.0033

1.44E-02

2

0.0556

4.78E-03

2

0.0455

7.08E-03

3

0.0192

9.94E-03

2

0.0345

1.21E-02

2

0.0282

1.77E-02

2

0.026

2.07E-02

3

0.0146

2.07E-02

2

0.025

2.22E-02

Genes up-regulated in luminal-like breast cancer cell
lines compared to the basal-like ones.
Genes expressed in at least one prostate cancer cell line
but not in normal prostate epithelial cells or stromal
cells
Genes down-regulated in U2OS cells (osteosarcoma)
upon knockdown of HDAC2 [GeneID=3066] by RNAi.
Genes consistently down-regulated in mammary stem
cells both in mouse and human species.
Genes up-regulated in mesenchymal stem cells (MSC)
engineered to express EWS-FLI1 [GeneID=2130;2321]
fusion protein.

380

128
133
428

430

Genes up-regulated in luminal-like breast cancer cell
lines compared to the mesenchymal-like ones.
Genes up-regulated in nasopharyngeal carcinoma (NPC)
compared to the normal tissue.

450
1821

GO gene sets

EXCRETION

36

DIGESTION
NEGATIVE_REGULATION
_OF_CELL_PROLIFERATIO
N

44

156

REGULATION_OF_GROW
TH

58

EPIDERMIS_DEVELOPME
NT

71

GROWTH

77

CYTOSOL

205

ECTODERM_DEVELOPME

80

Genes annotated by the GO term GO:0007588. The
elimination by an organism of the waste products that
arise as a result of metabolic activity. These products
include water, carbon dioxide (CO2), and nitrogenous
compounds.
Genes annotated by the GO term GO:0007586. The
whole of the physical, chemical, and biochemical
processes carried out by multicellular organisms to
break down ingested nutrients into components that
may be easily absorbed and directed into metabolism.
Genes annotated by the GO term GO:0008285. Any
process that stops, prevents or reduces the rate or
extent of cell proliferation.
Genes annotated by the GO term GO:0040008. Any
process that modulates the frequency, rate or extent of
the growth of all or part of an organism so that it occurs
at its proper speed, either globally or in a specific part
of the organism's development.
Genes annotated by the GO term GO:0008544. The
process whose specific outcome is the progression of
the epidermis over time, from its formation to the
mature structure. The epidermis is the outer epithelial
layer of a plant or animal, it may be a single layer that
produces an extracellular material (e.g. the cuticle of
arthropods) or a complex stratified squamous
epithelium, as in the case of many vertebrate species.
Genes annotated by the GO term GO:0040007. The
increase in size or mass of an entire organism, a part of
an organism or a cell.
Genes annotated by the GO term GO:0005829. That
part of the cytoplasm that does not contain
membranous or particulate subcellular components.
Genes annotated by the GO term GO:0007398. The

119

NT

ENDOPEPTIDASE_ACTIVI
TY

117

ANTI_APOPTOSIS

118

process whose specific outcome is the progression of
the ectoderm over time, from its formation to the
mature structure. In animal embryos, the ectoderm is
the outer germ layer of the embryo, formed during
gastrulation.
Genes annotated by the GO term GO:0004175.
Catalysis of the hydrolysis of nonterminal peptide
linkages in oligopeptides or polypeptides, and
comprising any enzyme of sub-subclasses EC:3.4.21-99.
They are classfied according to the presence of
essential catalytic residues or ions at their active sites.
Genes annotated by the GO term GO:0006916. A
process which directly inhibits any of the steps required
for cell death by apoptosis.

2

0.0171

4.47E-02

2

0.0169

4.53E-02

3

0.0158

7.39E-03

2

0.0138

3.78E-02

Oncogene signatures
LEF1_UP.V1_DN

190

BMI1_DN_MEL18_DN.V1
_UP

145

Genes down-regulated in DLD1 cells (colon carcinoma)
over-expressing LEF1 [Gene ID=51176].
Genes up-regulated in DAOY cells (medulloblastoma)
upon knockdown of BMI1 and PCGF2 [Gene ID=648,
7703] genes by RNAi.

120

Table S5.6 Associated network functions and biofunctions analysis on 25 genes from IPA. These 25
genes were identified to have the most differential methylation when comparing tumor samples with
normal samples.

ID
1
2
3

Top Networks
Associated Network Functions
Molecular Transport, Nucleic Acid Metabolism, Small Molecule Biochemistry
Cellular Movement, Reproductive System Development and Function, Cell
Morphology
Cell-To-Cell Signaling and Interaction, Cellular Assembly and Organization, Tissue
Development

Name
Cancer
Connective Tissue Disorders
Dermatological Diseases and
Conditions
Developmental Disorder
Hereditary Disorder

Name
Cell Cycle
Cellular Movement
Cell Death and Survival
Cellular Development
Cellular Growth and
Proliferation

Diseases and Disorders
p-value
6.29E-06 - 7.39E-03
2.09E-05 - 6.49E-03

#Molecules
14
9

2.09E-05 - 5.32E-03
2.09E-05 - 6.49E-03
2.09E-05 - 5.91E-03

4
7
5

Molecular and Cellular Functions
p-value
6.29E-06 - 7.39E-03
1.09E-05 - 5.91E-03
6.78E-05 - 7.39E-03
9.38E-05 - 7.39E-03

#Molecules
3
12
16
7

1.28E-04 - 7.39E-03

13

121

Score
29
23
3

Table S5.7 Gene set enrichment analysis (GSEA) on 128 identified “L-shaped” genes from MsigDB.
Significant gene set enrichments, with p-value < 0.05, are shown in three categories: curated gene
sets, GO gene set and oncogene signatures.
Curated gene sets
Gene Set Name
TURASHVILI_BREAST_LO
BULAR_CARCINOMA_VS
_DUCTAL_NORMAL_DN
TURASHVILI_BREAST_LO
BULAR_CARCINOMA_VS
_LOBULAR_NORMAL_UP
CHARAFE_BREAST_CANC
ER_LUMINAL_VS_BASAL
_DN
TURASHVILI_BREAST_DU
CTAL_CARCINOMA_VS_D
UCTAL_NORMAL_DN
PID_A6B1_A6B4_INTEGR
IN_PATHWAY
HUPER_BREAST_BASAL_
VS_LUMINAL_UP
ISSAEVA_MLL2_TARGETS
PID_ERA_GENOMIC_PAT
HWAY

FARMER_BREAST_CANCE
R_BASAL_VS_LULMINAL
GHANDHI_BYSTANDER_I
RRADIATION_UP
SMID_BREAST_CANCER_
RELAPSE_IN_BONE_UP
GHANDHI_DIRECT_IRRA
DIATION_UP
DOANE_BREAST_CANCE
R_ESR1_UP
ONDER_CDH1_TARGETS
_2_DN
LIU_PROSTATE_CANCER_
DN
LIM_MAMMARY_STEM_
CELL_UP
BENPORATH_EED_TARG
ETS
SMID_BREAST_CANCER_
LUMINAL_B_DN
MIKKELSEN_MEF_HCP_
WITH_H3K27ME3

#
Genes
in Gene
Set (K)

Description

# Genes
in Overlap
(k)

k/K

p value

91

Genes down-regulated in lobular carcinoma vs normal
ductal breast cells.

3

0.033

2.75E-05

94

Genes up-regulated in lobular carcinoma vs normal
lobular breast cells.

3

0.0319

3.03E-05

455

Genes down-regulated in luminal-like breast cancer cell
lines compared to the basal-like ones.

4

0.0088

1.82E-04

198

Genes down-regulated in ductal carcinoma vs normal
ductal breast cells.

3

0.0152

2.77E-04

a6b1 and a6b4 Integrin signaling
Genes up-regulated in basal mammary epithelial cells
compared to the luminal ones.
Genes down-regulated in HeLa cells upon knockdown of
MLL2 [GeneID=8085] by RNAi.

2

0.0435

4.18E-04

2

0.037

5.77E-04

2

0.0323

7.60E-04

Validated nuclear estrogen receptor alpha network
Genes which best discriminated between two groups of
breast cancer according to the status of ESR1 and AR
[GeneID=2099;367]: basal (ESR1- AR-) and luminal
(ESR1+ AR+).
Genes significantly (FDR < 10%) up-regulated in IMR-90
cells (fibroblast) in response to bystander irradiation.

2

0.0308

8.34E-04

3

0.0091

1.22E-03

2

0.0233

1.45E-03

Genes up-regulated in bone relapse of breast cancer.
Genes significantly (FDR < 10%) up-regulated in IMR-90
cells (fibroblast) in response to direct irradiation.
Genes up-regulated in breast cancer samples positive
for ESR1 [GeneID=2099] compared to the ESR1 negative
tumors.
Genes down-regulated in HMLE cells (immortalized
nontransformed mammary epithelium) after Ecadhedrin (CDH1) [GeneID=999] knockdown by RNAi.

2

0.0206

1.85E-03

2

0.0182

2.36E-03

2

0.0179

2.45E-03

3

0.0065

3.23E-03

Genes down-regulated in prostate cancer samples.
Genes consistently up-regulated in mammary stem cells
both in mouse and human species.
Set 'Eed targets': genes identified by ChIP on chip as
targets of the Polycomb protein EED [GeneID=8726] in
human embryonic stem cells.
Genes down-regulated in the luminal B subtype of
breast cancer.
Genes with high-CpG-density promoters (HCP) bearing
histone H3 trimethylation mark at K27 (H3K27me3) in
MEF cells (embryonic fibroblast).

3

0.0062

3.58E-03

3

0.0061

3.75E-03

4

0.0038

4.30E-03

3

0.0053

5.59E-03

3

0.0051

6.33E-03

46
54
62
65

330
86
97
110

112

464
481
489

1062
564

590

122

WU_CELL_MIGRATION
SMID_BREAST_CANCER_
BASAL_UP

BENPORATH_PRC2_TAR
GETS
ZHANG_RESPONSE_TO_I
KK_INHIBITOR_AND_TNF
_UP
OSWALD_HEMATOPOIET
IC_STEM_CELL_IN_COLL
AGEN_GEL_UP
SMID_BREAST_CANCER_
BASAL_DN
JAEGER_METASTASIS_D
N
KEGG_CYTOKINE_CYTOKI
NE_RECEPTOR_INTERAC
TION
HADDAD_B_LYMPHOCYT
E_PROGENITOR
ZHANG_TLX_TARGETS_6
0HR_UP
MARTENS_TRETINOIN_R
ESPONSE_UP
SMID_BREAST_CANCER_
RELAPSE_IN_BONE_DN

LEI_MYB_TARGETS
SENGUPTA_NASOPHARY
NGEAL_CARCINOMA_DN
GRUETZMANN_PANCREA
TIC_CANCER_UP
CHARAFE_BREAST_CANC
ER_LUMINAL_VS_BASAL
_UP
CHEMNITZ_RESPONSE_T
O_PROSTAGLANDIN_E2_
DN

184
648

652

223

233
701
258

267

293
293

857
315

318
349

358

Genes associated with migration rate of 40 human
bladder cancer cells.
Genes up-regulated in basal subtype of breast cancer
samles.
Set 'PRC2 targets': Polycomb Repression Complex 2
(PRC) targets; identified by ChIP on chip on human
embryonic stem cells as genes that: posess the
trimethylated H3K27 mark in their promoters and are
bound by SUZ12 [GeneID=23512] and EED
[GeneID=8726] Polycomb proteins.
Genes up-regulated in BxPC3 cells (pancreatic cancer)
after treatment with TNF [GeneID=7124] or IKI-1, an
inhibitor of IkappaB kinase (IKK).
Genes up-regulated in hematopoietic stem cells (HSC,
CD34+ [GeneID=947]) cultured in a three-dimentional
collagen gel compared to the cells grown in suspension.
Genes down-regulated in basal subtype of breast
cancer samles.
Genes down-regulated in metastases from malignant
melanoma compared to the primary tumors.

2

0.0109

6.46E-03

3

0.0046

8.21E-03

3

0.0046

8.35E-03

2

0.009

9.35E-03

2

0.0086

1.02E-02

3

0.0043

1.02E-02

2

0.0078

1.24E-02

Cytokine-cytokine receptor interaction
Genes up-regulated in hematopoietic progenitor cells
(HPC) of B lymphocyte lineage CD34+CD45RA+CD10+
[GeneID=947;5788;4311].
Genes up-regulated in neural stem cells (NSC) at 60 h
after cre-lox knockout of TLX (NR2E1) [GeneID=7101].
Genes up-regulated in NB4 cells (acute promyelocytic
leukemia, APL) in response to tretinoin
[PubChem=5538]; based on Chip-seq data.

2

0.0075

1.32E-02

2

0.0068

1.57E-02

2

0.0068

1.57E-02

3

0.0035

1.75E-02

Genes down-regulated in bone relapse of breast cancer.
Myb-regulated genes in MCF7 (breast cancer) and lung
epithelial cell lines overexpressing MYBL2, MYBL1 or
MYB [GeneID=4605;4603;4602].
Genes down-regulated in nsopharyngeal carcinoma
relative to the normal tissue.
Genes up-regulated in pancreatic ductal
adenocarcinoma (PDAC) identified in a meta analysis
across four independent studies.

2

0.0063

1.80E-02

2

0.0063

1.84E-02

2

0.0057

2.19E-02

2

0.0056

2.29E-02

2

0.0053

2.56E-02

2

0.0051

2.70E-02

2

0.0051

2.75E-02

3

0.0029

2.90E-02

2

0.0047

3.22E-02

2

0.0046

3.29E-02

HAN_SATB1_TARGETS_U
P

395

BENPORATH_SUZ12_TAR
GETS

1038

RIGGI_EWING_SARCOM
A_PROGENITOR_UP

430

Genes up-regulated in luminal-like breast cancer cell
lines compared to the basal-like ones.
Genes down-regulated in CD4+ [GeneID=920] T
lymphocytes after stimulation with prostaglandin E2
[PubChem=5280360].
Genes up-regulated in MDA-MB-231 cells (breast
cancer) after knockdown of SATB1 [GeneID=6304] by
RNAi.
Set 'Suz12 targets': genes identified by ChIP on chip as
targets of the Polycomb protein SUZ12 [GeneID=23512]
in human embryonic stem cells.
Genes up-regulated in mesenchymal stem cells (MSC)
engineered to express EWS-FLI1 [GeneID=2130;2321]
fusion protein.

MIKKELSEN_MCV6_HCP_

435

Genes with high-CpG-density promoters (HCP) bearing

380

391

123

WITH_H3K27ME3

DELYS_THYROID_CANCE
R_UP
BENPORATH_ES_WITH_
H3K27ME3
SENESE_HDAC1_TARGET
S_UP
ZHOU_INFLAMMATORY_
RESPONSE_LIVE_UP
ENK_UV_RESPONSE_KER
ATINOCYTE_UP

443

1118
457
485
530

the tri-methylation mark at H3K27 (H3K27me3) in
MCV6 cells (embryonic fibroblasts trapped in a
differentiated state).
Genes up-regulated in papillary thyroid carcinoma (PTC)
compared to normal tissue.
Set 'H3K27 bound': genes posessing the trimethylated
H3K27 (H3K27me3) mark in their promoters in human
embryonic stem cells, as identified by ChIP on chip.
Genes up-regulated in U2OS cells (osteosarcoma) upon
knockdown of HDAC1 [GeneID=3065] by RNAi.
Genes up-regulated in macrophage by live P.gingivalis.
Genes up-regulated in NHEK cells (normal epidermal
keratinocytes) after UVB irradiation.

2

0.0045

3.40E-02

3

0.0027

3.51E-02

2

0.0044

3.60E-02

2

0.0041

4.02E-02

2

0.0038

4.72E-02

2

0.0455

2.41E-03

2

0.0169

1.64E-02

3

0.0085

1.99E-02

2

0.0133

2.57E-02

2

0.0132

2.61E-02

2

0.0102

4.25E-02

3

0.0158

1.50E-03

2

0.0138

1.36E-02

GO gene sets

DIGESTION

44

ANTI_APOPTOSIS

118

TRANSCRIPTION_FACTOR
_ACTIVITY

354

NEGATIVE_REGULATION
_OF_APOPTOSIS

150

NEGATIVE_REGULATION
_OF_PROGRAMMED_CEL
L_DEATH

151

NEGATIVE_REGULATION
_OF_DEVELOPMENTAL_P
ROCESS

197

Genes annotated by the GO term GO:0007586. The
whole of the physical, chemical, and biochemical
processes carried out by multicellular organisms to
break down ingested nutrients into components that
may be easily absorbed and directed into metabolism.
Genes annotated by the GO term GO:0006916. A
process which directly inhibits any of the steps required
for cell death by apoptosis.
Genes annotated by the GO term GO:0003700. The
function of binding to a specific DNA sequence in order
to modulate transcription. The transcription factor may
or may not also interact selectively with a protein or
macromolecular complex.
Genes annotated by the GO term GO:0043066. Any
process that stops, prevents or reduces the frequency,
rate or extent of cell death by apoptosis.
Genes annotated by the GO term GO:0043069. Any
process that stops, prevents or reduces the frequency,
rate or extent of programmed cell death, cell death
resulting from activation of endogenous cellular
processes.
Genes annotated by the GO term GO:0051093. Any
process that stops, prevents or reduces the rate or
extent of development, the biological process whose
specific outcome is the progression of an organism over
time from an initial condition (e.g. a zygote, or a young
adult) to a later condition (e.g. a multicellular animal or
an aged adult).

Oncogene signatures
LEF1_UP.V1_DN

190

BMI1_DN_MEL18_DN.V1
_UP

145

Genes down-regulated in DLD1 cells (colon carcinoma)
over-expressing LEF1 [Gene ID=51176].
Genes up-regulated in DAOY cells (medulloblastoma)
upon knockdown of BMI1 and PCGF2 [Gene ID=648,
7703] genes by RNAi.
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Table S5.8 Significance of biomarkers in term of methylation status in survival analysis by
GENESURV tools in bioprofiling.de. The methylation status determined by our method is shown in
columns under the headings of Methylation_CIMP+ and Methylation_CIMP-.

gene

Methylat
ion_CIMP
+

methylati
on_CIMP
-

GENESURV
_survival
longer_exp
ression

GENESUR
V_pvalue

SLC44A4

hypo

hyper

high

9.77E-05

IL20RA

hypo

hyper

high

7.83E-05

TFF1

hypo

hyper

high

0.00154

C1orf64

hypo

hyper

high

0.00637

MEP1A

hypo

hyper

low

0.0257

POU4F1

hyper

hypo

low

1.99E-05
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GENESURV_link
http://www.bioprofiling.de/cgibin/GEO/GENESURV/display_survival_details.GENE.pl?I
D=GSE30682&affy=ILMN_1730977&ncbi=80736&gene
A=SLC44A4&tmp_dir=dir_10084_1355434594
http://www.bioprofiling.de/cgibin/GEO/GENESURV/display_survival_details.GENE.pl?I
D=GSE22220&affy=3390504&ncbi=53832&geneA=IL20
RA&tmp_dir=dir_10084_1355434594
http://www.bioprofiling.de/cgibin/GEO/GENESURV/display_survival_details.GENE.pl?I
D=GSE30682&affy=ILMN_1722489&ncbi=7031&geneA
=TFF1&tmp_dir=dir_10084_1355434594
http://www.bioprofiling.de/cgibin/GEO/GENESURV/display_survival_details.GENE.pl?I
D=GSE22226&affy=39434&ncbi=149563&geneA=C1OR
F64&tmp_dir=dir_10084_1355434594
http://www.bioprofiling.de/cgibin/GEO/GENESURV/display_survival_details.GENE.pl?I
D=GSE30682&affy=ILMN_1659984&ncbi=4224&geneA
=MEP1A&tmp_dir=dir_10084_1355434594
http://www.bioprofiling.de/cgibin/GEO/GENESURV/display_survival_details.GENE.pl?I
D=GSE30682&affy=ILMN_1738691&ncbi=5457&geneA
=POU4F1&tmp_dir=dir_10084_1355434594
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